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Abstract: 
Bmi-1 is a member of the Polycomb group (PcG) family of transcriptional repressors, 
which are implicated in the maintenance of embryonic and adult stem cells. Previous 
reports indicate that Bmi-1 plays a key role in repressing the Ink4a/Arf tumour 
suppressor locus.  Overexpression of Bmi-1 in putative liver stem/progenitor cells 
leads to increased self-renewal in vitro and tumourigenesis following transplantation 
into immunocompromised mice.  However, the in vivo functional requirement for Bmi-
1 in liver development, homeostasis and regeneration has not been investigated. For 
this thesis, the consequences of Bmi-1 deletion for the post-natal murine liver were 
assessed using a knockout mouse model. Immunohistochemical techniques were first 
used to examine Bmi-1 expression in normal murine and human liver, and in human 
liver pathologies. Bmi-1 was highly expressed in biliary cells of both mouse and 
human liver, and at lower levels in some murine hepatocytes. Strong expression of 
Bmi-1 was observed in cytokeratin 19-positive oval cells in regenerating murine liver. 
Bmi-1 knockout mice exhibited structural abnormalities in the liver parenchyma, most 
strikingly the abnormal development of polyploidy in hepatocytes. Bmi-1 deletion did 
not result in impaired proliferation in mice, despite increased expression levels of cell 
cycle inhibitors p16Ink4a, p19Arf and p21. In contrast, an increase in hepatocyte 
proliferation was observed in 8 week old Bmi-1 deficient mice, which was correlated 
with upregulation of cyclin D1. Mel-18, a structural homologue of Bmi-1, was also 
expressed in murine cholangiocytes and was upregulated in the livers of Bmi-1 
deficient mice during ageing, suggesting it may have been exerting a compensatory 
effect. Adult Bmi-1 knockout mice also exhibited excessive iron loading and 
abnormalities in the expression of key regulators of hepatic iron homeostasis. 
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1. Introduction: 
During my PhD studies, I have addressed the role of the Polycomb group protein Bmi-
1 in regulating hepatic growth and function. In particular, I have investigated 
alterations in hepatocellular ploidy, proliferation and iron accumulation following global 
deletion of Bmi-1 in mice. In addition, I have generated preliminary data suggesting 
that Bmi-1 is highly expressed during tissue regeneration in both murine oval cells and 
some human cirrhotic nodules, which will underpin future studies to investigate the 
role of Bmi-1 during hepatic repair. 
The following introduction section will review the literature relevant to this work, with 
particular regard to the following topics: 
1. The structure, regenerative capacity, and pathologies of the liver 
2. Hepatocyte polyploidisation in the postnatal liver 
3. The role of the liver in iron homeostasis 
4. Bmi-1 and the Polycomb group family 
5. Regulation of the cell cycle by Bmi-1 
6. The Bmi-1 homologue, Mel-18 
7. The function of Bmi-1 in hepatic cell populations 
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1.1. Liver anatomy and physiology: 
The liver is the largest internal organ in the body and carries out a diverse array of 
functions, including detoxification of blood, production of bile and plasma proteins, 
carbohydrate storage and metabolism of lipids and amino acids (Wright & Alison, 
1984). The bulk of the liver is formed from hepatocytes, which are arranged in plates 
separated by vascular sinusoids. The hepatocyte plates radiate out from the central 
vein to form the classical hexagonal liver lobule, which is the structural unit of the liver 
(Figure 1). At the vertices of the lobule are portal triads, consisting of terminal 
branches of the hepatic artery and portal vein, and the bile duct, formed from 
cholangiocytes. The endothelium lining liver sinusoids is fenestrated, permitting blood 
from the hepatic artery and portal vein to wash over the exposed apical surfaces of 
the hepatocytes before draining into the central vein. The space between the 
endothelium and hepatocytes is known as the space of Disse. This contains stellate 
cells, which are involved in liver fibrosis and vitamin A storage, and liver macrophages 
called Kupffer cells. The basal faces of the hepatocytes form bile canaliculi, which 
carry secreted bile to the main bile duct in the portal triad. 
19 
 
 
Figure 1: Liver structure. 
a) The classical liver lobule. b) Haematoxylin & eosin stained paraffin-embedded 
mouse liver section, image at 100x magnification. 
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1.2. Hepatocyte-mediated liver regeneration: 
The many essential functions carried out by the liver have led to the evolution of a 
great capacity for regeneration (Michalopoulos, 2007; Taub, 2004). Under resting 
conditions, the liver is a largely quiescent organ with a cell turnover of a year or more. 
A regenerative response mediated by hepatocyte proliferation can be initiated in 
rodents by using one of several available models to induce liver injury. The most 
commonly used is the two-thirds partial hepatectomy (PHx), which involves surgically 
removing two lobes (median and left lateral) of the liver while leaving the other lobes 
completely intact. This procedure can also be used in humans for tumour resection or 
repair following trauma. Alternatively, a hepatotoxic chemical such as carbon 
tetrachloride (CCl4) can be used to cause necrosis of centrilobular cells. Following 
injury, the remaining liver cells enter the cell cycle and restore the complete liver mass 
within 5-7 days (in rodents). This process requires 90-95% of hepatocytes to undergo 
approximately two doublings, with a semi-synchronous peak in DNA synthesis 
observed at approximately 24h in rats (Grisham, 1962). Induction of DNA synthesis 
occurs later in non-parenchymal cells.  
1.3. Stem cell-mediated liver regeneration: 
1.3.1. Induction of the oval cell response: 
There is strong evidence for the existence of a resident liver stem/progenitor cell 
compartment from experimental models for oval cell (or progenitor cell) activation in 
rodent livers (Duncan et al, 2009a; Santoni-Rugiu et al, 2005). Oval cells are small, 
transient, non-parenchymal cells with an ovoid shaped nucleus and high nuclear to 
cytoplasmic ratio. They are able to repopulate the liver in the absence of hepatocyte 
mediated regeneration. Models for oval cell activation tend to involve a combination of 
liver injury (usually two-thirds partial hepatectomy) and exposure to chemicals which 
prevent hepatocytes from proliferating in response to the damage, thus compromising 
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hepatocyte mediated regeneration processes. In the rat, the mitoinhibitory agent 2-
acetylaminofluorene (2-AAF) is the most commonly used (Evarts et al, 1989; 
Tatematsu et al, 1984), although this does not induce a strong oval cell response in 
mice (Jelnes et al, 2007). Mouse models include partial hepatectomy in combination 
with the DNA alkylating agent dipin (Faktor et al, 1980). Alternatively, administration of 
carcinogenic choline-deficient, ethionine-supplemented (CDE) (Shinozuka et al, 1978) 
or diethoxycarbonyl-1,4-dihydrocollidine (DDC) (Preisegger et al, 1999) diets can 
induce an oval cell response without the requirement for partial hepatectomy. The 
models used to activate oval cells in rodents are not suitable for humans, although 
ductular reactions of progenitor cells are found in several human liver diseases (Bird 
et al, 2008), including alcoholic and non-alcoholic fatty liver disease (Roskams et al, 
2003). The cells appear in chronic and acute liver diseases, and are commonly 
referred to as hepatic progenitor cells (HPCs) instead of oval cells. 
1.3.2. Proposed site of origin: 
The precise origin of oval/progenitor cells has not been conclusively established. 
Based on histological observations, they appear to arise from areas close to the 
canals of Hering (terminal biliary ducts of the liver, lined partly by cholangiocytes and 
hepatocytes) in rodents (Paku et al, 2001) and humans (Theise et al, 1999). However, 
it is unclear whether they originate from pre-existing liver stem/progenitor cells, or 
develop from other cell types following injury. A small cluster of cells has been 
identified within the portal region (two to four cells out of a total of 50,000) that 
express the embryonic stem cell markers Oct4, Nanog and Stat3, suggesting the 
presence a resident stem/progenitor cell pool (Tang et al, 2008). Label retaining 
assays in murine liver have identified putative stem cell compartments proximal to the 
portal areas: in the canals of Hering, intraductal cholangiocytes and peribiliary 
hepatocytes (Kuwahara et al, 2008), although it is possible that slower cycling stem 
cell populations are not initially labelled using this technique. Destruction of the biliary 
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epithelium by 4,4’-methylene dianiline (4,4’-diaminodiphenylmethane, DAPM) results 
in a complete absence of oval cell proliferation in 2-AAF/PHx treated rats (Petersen et 
al, 1997), suggesting a close relationship between oval cells and biliary epithelial 
cells. In support of this, a 3-dimensional reconstruction of human cirrhotic livers has 
also shown hepatocyte regenerative nodules linked directly to intralobular bile ducts 
by ductular reactions (Falkowski et al, 2003). However, there have not been any 
lineage tracing experiments which specifically demonstrate that mature 
cholangiocytes themselves can act as progenitor cells, although they do share several 
markers with oval cells (see section 1.3.4). Bone marrow cells have previously been 
reported as a potential source of oval cells (Petersen et al, 1999), however it has 
since been demonstrated that this is due to cell fusion and is not significant in liver 
regeneration (Wang et al, 2003b). There is also a body of evidence suggesting that 
glial fibrillary acidic protein (GFAP) positive quiescent hepatic stellate cells may be a 
type of epithelial progenitor. Following liver injury, green fluorescent protein (GFP) 
marked stellate cells from GFAP-Cre/GFP double transgenic mice become highly 
proliferative and express several oval cell markers, before repopulating areas of the 
parenchyma (Yang et al, 2008). Rats treated with the pyrrolizidine alkaloid retrorsine 
undergo liver regeneration mediated by small hepatocyte progenitor cells (SHPCs), 
which share characteristics of oval cells but are phenotypically distinct (Gordon et al, 
2000). It therefore seems there is may be a multi-tiered progenitor cell system within 
the liver. 
1.3.3. Bilineage differentiation of oval cells: 
Following induction by the models described previously, oval cells proliferate in the 
periportal region of the liver and proceed to infiltrate the parenchyma (Alison et al, 
1996) (Figure 2). This process is known as a ductular reaction. Oval cells are not 
observed in normal uninjured liver, or following the completion of regeneration in 
response to liver injury. It is therefore believed that they are transitional cells in a 
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lineage which can give rise to mature hepatocytes and biliary cells following injury. In 
vivo evidence for oval cell bipotentiality comes from studies using a Forkhead Box l1 
(Foxl1)-Cre transgenic mouse crossed with a reporter line (Sackett et al, 2009). Foxl1 
is a transcription factor which shows increased expression in DDC diet treated mice. 
Foxl1-Cre expressing cells are found in the periportal region following injury, and can 
give rise to progeny expressing either a hepatocyte marker (hepatocyte nuclear factor 
4 alpha) or cholangiocyte marker (CK19). This suggests that Foxl1 expressing cells 
are bipotent progenitors, although it has not been demonstrated that an individual cell 
can give rise to both types of progeny. In humans, immunohistochemical analysis of 
cirrhotic livers has identified individual ductular reactions containing hepatocytes and 
cholangiocytes separated by transitional cells (Zhou et al, 2007). 
 
Figure 2: The murine oval cell response. 
Paraffin-embedded liver section from mouse treated with the DNA alkylating agent 
dipin. Section labelled with antibody against cytokeratin 19 (CK19). Labelled are CK19 
positive oval cells (OC) and bile duct (BD). Scale bar 100 µm. 
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1.3.4. Oval cell markers 
A number of markers have been used to identify oval cells in rodents (Bird et al, 
2008)(Santoni-Rugiu et al, 2005), however these are often also expressed on some 
other cell populations within the liver. Briefly, these include markers for biliary cells 
(e.g. cytokeratins 7, 8, 18 & 19, OV-6, muscle pyruvate kinase, A6), hepatocytes (e.g. 
albumin), foetal hepatoblasts (e.g. alpha fetoprotein (AFP), delta-like protein (Dlk). 
Oval cells have also been reported to express proteins common to non-liver cell 
populations, including haematopoietic cell markers c-kit, CD34 and thymus cell 
antigen 1 (Thy-1). Oval cells are difficult to study due to this phenotypic heterogeneity 
exhibited within the activated progenitor cell population. This heterogeneity is likely to 
be due in part the different degrees of differentiation along hepatocyte and biliary 
lineages (Zhou et al, 2007), and the emergence of other populations, potentially 
including Thy-1 positive myofibroblasts (Dezso et al, 2007), in regenerative 
responses. It seems that the oval cell response represents a heterogeneous 
population of liver cells that emerge in livers undergoing oval cell activation, including 
progenitor cells, biliary cells, stellate cells and fibroblasts. Hence the term ‘oval cell’ is 
not well defined as it does not represent a single cell type, and may not necessarily 
describe only cells with repopulating ability. It is also important to consider oval cell 
heterogeneity in different models and species. For example, oval cell reactions 
induced in the rat 2-AAF/PHx protocol express alpha-fetoprotein (AFP), whereas 
mouse oval cells from the DDC or CDE diet models do not (Jelnes et al, 2007).  
1.3.5. Contribution of stem/progenitor cells to normal liver turnover: 
Although the liver is primarily a quiescent organ, there is a gradual turnover of 
hepatocytes, with each cell having a lifespan of about 200-300 days (Duncan et al, 
2009a). An early model for this was proposed by Zajicek et al, who observed 
migration of hepatocytes labelled with tritiated thymidine from the portal region to 
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central vein in rat livers (Zajicek et al, 1985). This led to the formulation of the 
‘streaming liver’ hypothesis, whereby young hepatocytes originate near the portal 
region and then migrate through the liver, undergoing a differentiation process as they 
move. This is consistent with the idea of a stem/progenitor cell within the portal region, 
and would also explain the difference in gene expression patterns seen in periportal 
and pericentral hepatocytes. However, studies using tritiated thymidine are often 
criticised due to loss and subsequent re-utilisation of thymidine from nuclei, and low 
labelling indices (Bralet et al, 1994). The widespread belief has been that existing 
hepatocytes and cholangiocytes alone are responsible for liver turnover, and that 
there is little contribution from a stem/progenitor cell population (Duncan et al, 2009a). 
This is due in part to a study which retrovirally labelled proliferating hepatocytes 
following partial hepatectomy, and demonstrated that the labelled hepatocytes divide 
in isolated clusters with no evidence of migration (Bralet et al, 1994). This method only 
labelled approximately 1-5% of hepatocytes, and does not appear to rule out 
contribution of a stem/progenitor cell as this would not have been labelled in the first 
place. Another study has also reported similar results, by labelling a small proportion 
of hepatocytes which express human α1-antitrypsin (Kennedy et al, 1995). Over time, 
randomly scattered clusters of labelled hepatocytes were observed, again with no 
evidence of migration. The gene expression pattern in hepatocytes is also dependent 
on blood flow, as reversing the direction of the flow inverts the gene expression 
pattern in periportal and pericentral hepatocytes (Thurman & Kauffman, 1985). These 
studies all suggest that hepatocyte streaming does not occur in normal liver. 
However, recent lineage tracing data has provided support for the involvement of 
stem cell populations in normal liver turnover. Fellous et al used histochemical 
techniques to identify patches of cells within normal tumour-adjacent human livers, 
which all have naturally occurring mutations in the mitochondrially encoded 
cytochrome c oxidase gene (Fellous et al, 2009a). Sequence analysis revealed that 
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cells within the same patch have identical mutations, suggesting that the patches are 
clonally derived. The patches also always originate from portal regions of the liver and 
extend out into the parenchyma, which suggests that they may be derived from a 
long-lived portal stem/progenitor cell which is able to accumulate the mutations. 
These data support a hypothesis that a portally-derived liver stem/progenitor cell is 
able to contribute to hepatocyte turnover in normal liver. Further support for this 
hypothesis has come from analysis of progenitors expressing sex determining region 
Y-box 9 (Sox9), a protein important in embryonic formation of several tissues, in 
murine models (Furuyama et al, 2011). The authors found Sox9 expression in all 
cholangiocytes in the liver, and then carried out tamoxifen induced lineage tracing to 
mark Sox9 expressing cells and their progeny with lacZ. Following tamoxifen injection, 
the majority of labelled cells are initially found in bile duct structures. Over time, the 
number of labelled hepatocytes gradually increases, and they appear to migrate 
slowly from the periportal region to the central vein. The biliary structures also 
maintain a population of Sox9 positive cells after 12 months, suggesting the cells are 
able to self-renew. The Sox9 positive cells also contribute to liver regeneration in 
some liver injury models. The number of lineage labelled hepatocytes increases 
following CCl4 treatment, bile duct ligation and CDE diet administration. Interestingly, 
Sox9 expressing precursors appear to have limited ability to contribute to hepatocyte 
regeneration following a DDC supplemented diet, suggesting that other cell types are 
more important for the regeneration observed in this model. These data provide solid 
evidence that stem/progenitor cells located in the biliary tree contribute to hepatocyte 
turnover under resting conditions, in addition to replication of existing hepatocytes.  
 
 
 
27 
 
1.4. Liver cancer and disease: 
1.4.1. Liver cancers: 
There are two major cancers of the liver – hepatocellular carcinoma (HCC) and 
cholangiocarcinoma (CC) (Alison & Lovell, 2005). HCC is a malignant tumour which is 
composed of cells that resemble hepatocytes, but exhibit abnormalities in 
appearance. The majority arise in livers where hepatocyte damage and chronic 
inflammation leads to fibrosis. Infection with either hepatitis B or C virus is a major risk 
factor, along with alcohol abuse, metabolic liver disease and other conditions which 
lead to cirrhosis. CC is much less common, and is believed to arise from intrahepatic 
or extrahepatic biliary epithelium. Risk factors include chronic inflammation leading to 
biliary epithelial injuries, and impediment of bile flow. 
1.4.2. Contribution of oval cells to liver tumours: 
Progenitor cells and progenitor cell markers have also been identified in human liver 
cancers, leading to the suggestion that they may be involved in carcinogenesis. Many 
human liver tumours contain a mixture of mature cells and cells more phenotypically 
similar to HPCs, including cells that express progenitor cell markers such as OV-6 
(Libbrecht & Roskams, 2002). A subset of tumours containing areas of both HCC and 
CC has also been observed, supporting the notion that a bipotent progenitor may be 
the tumour initiating cell (Theise et al, 2003). In rats fed with 2-AAF, hepatocytes 
labelled with β-galactosidase contribute to the formation of preneoplastic foci, 
demonstrating direct involvement of hepatocytes in carcinogenesis (Gournay et al, 
2002). However, oval cells isolated from p53 null mice are able to produce HCCs in 
athymic nude mice (Dumble et al, 2002), suggesting there may be multiple potential 
tumour initiating cells. 
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1.4.3. Liver cirrhosis: 
Liver cirrhosis occurs as a consequence of chronic liver injuries, including alcoholism, 
hepatitis B and C viruses and fatty liver diseases (Schuppan & Afdhal, 2008). It is 
characterised by advanced liver fibrosis, where there is replacement of injured liver 
tissue by fibrous connective tissue and scarring, leading to disruption of hepatic 
vasculature and end stage liver disease. The fibrosis is thought to be caused by 
activated myofibroblasts which arise from resident hepatic stellate cells (Brenner, 
2009). There is some functional in vivo evidence that stellate cell and myofibroblast 
populations can be derived from the bone marrow in cirrhotic livers, based on 
transplantation of male bone marrow into lethally irradiated female mice (Russo et al, 
2006). Cirrhotic tissue also contains regenerative nodules of hepatic parenchyma 
which are enclosed by areas of fibrosis, with proliferative biliary cells and ductular 
reactions within the fibrotic tissue. Recent lineage tracing using naturally occurring 
mitochondrial mutations suggests that regenerative nodules are clonally derived from 
hepatic progenitor cells within ductular reactions, as cells within both ductular 
reactions and the nodules all share identical mutations (Lin et al, 2010). 
Reconstruction of cirrhotic livers using serial sections has also demonstrated that 
regenerating hepatocyte buds are structurally associated with ductular reactions and 
the biliary tree (Falkowski et al, 2003). 
1.5. Liver polyploidisation: 
1.5.1. Introduction to polyploidisation: 
The adult mammalian liver parenchyma consists of a heterogeneous mix of 
hepatocytes of varying ploidy, both mononuclear and binuclear. The process of 
polyploidisation begins at weaning (Margall-Ducos et al, 2007) and has been best 
characterised in the rat. The livers of newborn rats consist almost exclusively of 
diploid hepatocytes, which contain two copies of the genome (2n) (Guidotti et al, 
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2003). Upon weaning, a population of diploid cells with two nuclei (binuclear) 
emerges, followed by the mononuclear tetraploid (4n) cells which form the bulk of the 
adult rat liver. This sequential process can continue further to generate binuclear 4n 
and mononuclear octaploid (8n) cells (Figure 3). The number of polyploid cells 
appears to increase with age in both rats (Enesco et al, 1991) and mice (Funk-
Keenan et al, 2008). Polyploidy is correlated with cell size (Rajvanshi et al, 1998), and 
its onset occurs at a similar time to a shift from hyperplastic liver growth (increase in 
cell number) to hypertrophic growth (increase in cell size) (Funk-Keenan et al, 2008). 
The polyploidisation process is conserved in all mammalian species, however the 
degree to which it occurs varies dramatically. In mice, an estimated 80% of 
hepatocytes are binuclear, and cells with ploidy classes of 16n and beyond have been 
observed (Wright & Alison, 1984). In humans, the process is less extensive, with the 
proportion of mononuclear, diploid cells in the adult liver estimated at approximately 
75% (Toyoda et al, 2005). 
 
Figure 3: Polyploidisation in mammalian liver. 
Schematic showing development of hepatocyte polyploidy from 2n mononuclear cells. 
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1.5.2. Mechanisms of polyploidisation: 
The mechanism by which polyploid hepatocytes emerge in rat livers has been 
extensively studied (Guidotti et al, 2003). A proportion of 2n mononuclear hepatocytes 
undergo a process of incomplete cytokinesis, which leads to the formation of 2n 
binuclear cells. This occurs through the incomplete formation of a functional 
contractile actomyosin ring due to disorganised microtubule networks, leading to the 
abortion of cytokinesis in telophase (Margall-Ducos et al, 2007). The number of 
incomplete cytokinesis events increases dramatically following weaning, however this 
is not due to changes in carbohydrate intake due to an altered diet (Celton-Morizur et 
al, 2009). The binuclear cells formed have a critical role in the subsequent emergence 
of tetraploid cells (Guidotti et al, 2003). Both nuclei proceed through mitosis normally 
until metaphase, where a bipolar spindle is formed. This causes all the chromosomes 
to line up and segregate equally, leading to the formation of two 4n mononuclear cells 
following normal cytokinesis. 
1.5.3. Regulation of polyploidisation: 
The incomplete cytokinesis program is a feature of normal hepatocytes, but the 
signalling pathways which control it have not been well defined. Celton-Morizur et al 
demonstrated that the livers of rats treated with streptozotocin to destroy pancreatic β-
cells, and hence reduce insulin levels, have reduced content of binuclear tetraploid 
hepatocytes and fewer incomplete cytokinesis events (Celton-Morizur et al, 2009). 
This also occurs in ob/ob mice, which have impaired insulin signalling. In contrast, 
injection of insulin into rats at the weaning stage leads to an increase in levels of 
tetraploid cells, suggesting insulin is involved in regulating liver tetraploidisation. This 
may be via the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, an important 
downstream mediator of insulin signalling. The authors discovered that direct 
inhibition of Akt phosphorylation in primary rat hepatocytes leads to a decrease in the 
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number of cytokinesis failure events, suggesting Akt may have a direct or indirect role 
in the generation of binuclear tetraploid hepatocytes. Akt upregulation also causes 
increased polyploidy in cultured vascular smooth muscle cells (Hixon et al, 2000). A 
potential role for the pro-proliferative transcription factor c-myc in the polyploidisation 
process has been established from observations that liver specific c-myc inactivation 
in mice leads to reduced cell ploidy (Baena et al, 2005). This supports earlier findings 
that the livers of mice overexpressing c-myc show a shift towards 4n and 8n nuclei 
(Kao et al, 1996).  
1.5.4. Ploidy reduction: 
It has recently been demonstrated that hepatocytes can undergo reductions in ploidy 
as well as increases. Fumarylacetoacetate hydrolase (Fah) is an enzyme involved in 
tyrosine catabolism, and its deficiency leads to the disease hereditary tyrosinaemia 
type I, which causes progressive liver failure (Overturf et al, 1996). Fah-/- mice 
provide an important model for hepatocyte transplantation and repopulation studies, 
as transplanted hepatocytes have a strong selective growth advantage. 
Transplantation of wild type bone marrow into fah-/- mice leads to the fusion of bone 
marrow cells with host hepatocytes (Wang et al, 2003b). These fusion derived 
hepatocytes are tetraploid, and are able to undergo ploidy reductions to form diploid 
cells (Duncan et al, 2009b). It has since been demonstrated that this also occurs with 
normal polyploid hepatocytes (Duncan et al, 2010). Fluorescence activated cell 
sorting (FACS) purified octaploid hepatocytes transplanted into an fah-/- mouse can 
reconstitute the liver with the same overall ploidy distribution as found in a normal 
mouse, suggesting the transplanted cells have undergone ploidy reversal. This also 
occurs in cultured hepatocytes, and is due to either multipolar or double mitoses 
(Duncan et al, 2010). It has not been established whether this process occurs in the 
liver under normal physiological conditions. 
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1.5.5. Functional purpose of polyploidisation: 
Little is known about the functional purpose of hepatocyte polyploidisation. Polyploid 
rat hepatocytes have a greater degree of cytoplasmic complexity than diploid cells, 
with increased numbers of vacuoles, lysosomes and inclusions (Rajvanshi et al, 
1998). They also exhibit increased cytochrome P450 activity compared to diploid 
cells, although diploid cells have higher levels of albumin synthesis. This suggests 
there may be some functional differences between diploid and polyploid hepatocytes. 
There have been suggestions that binucleate hepatocytes have increased protein 
synthesis capacity, based on the fact that they are more frequently immunopositive for 
retinol binding protein, a protein synthesised but not recycled in hepatocytes (Grizzi & 
Chiriva-Internati, 2007). The authors therefore interpret its expression as a marker for 
total protein synthesis, however this is not convincing as there is no evidence that 
protein synthesis is increased other than for retinol binding protein. Increased ploidy 
has been associated with increased mRNA synthesis of three key genes in 
megakaryocytes, which also undergo polyploidisation (Hancock et al, 1993). In 
another study, Anatskaya & Vinogradov tried to examine functional differences in 
polyploid cells by comparing gene expression microarray data from predominantly 
diploid tissue (human liver, mouse heart) with mainly polyploid tissue (mouse liver, 
human heart) (Anatskaya & Vinogradov, 2010). The polyploid (mouse) livers have 
increased expression of genes involved in key liver functions, including immunity, 
nitrogenous metabolism, redox state maintenance and metabolic adaptations to long 
term energy depletion. There is also an increase in gene expression related to cell 
survival pathways, reserve adenosine-5’-triphosphate (ATP) production and the 
switching of tissue specific functions to an energy saving mode. The authors suggest 
that polyploid cells have evolved to improve adaptation to stress and promote the 
performing of tissue specific functions in severe conditions. It appears uncertain 
whether the differences observed are merely due to variations between the species 
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studied. The authors’ method of normalising a particular gene to its average 
expression across other tissues from that species should eliminate general species-
specific upregulation of that gene. However, it is unclear if changes are specifically 
due to differences in ploidy between the tissues, or to other undefined differences in 
hepatic function between species. As such, these results do not provide conclusive 
evidence for improved function in polyploid cells. 
1.5.6. Proliferative potential of polyploid hepatocytes: 
Following partial hepatectomy, regenerating rat livers exhibit a large increase in the 
numbers of tetraploid and octaploid mononuclear cells, coupled with a dramatic 
decrease in the population of binuclear cells (Melchiorri et al, 1993). This is due to the 
replication of pre-existing binuclear cells to form mononuclear daughters (Gerlyng et 
al, 1993). In contrast, treatment with the mitogen lead nitrate results in increased 
polyploidisation via the induction of large numbers of binucleate cells, leading to liver 
growth (Melchiorri et al, 1993). The polyploid cells that emerge following partial 
hepatectomy remain in the liver for a prolonged period. These livers exhibit some 
senescence-like changes, including an increase in expression of senescence 
associated β-galactosidase and the cyclin dependent kinase (Cdk) inhibitor p21 (Sigal 
et al, 1999). Hepatocytes isolated from these livers following partial hepatectomy 
induced regeneration also have decreased proliferative capacity in vitro. Adult rat liver 
contains a minor population of small hepatocytes, which are mononuclear, diploid 
cells with a higher replicative potential than normal hepatocytes in culture (Asahina et 
al, 2006). Diploid rat hepatocytes also show increased DNA synthesis in response to 
hepatocyte growth factor, compared to polyploid cells (Rajvanshi et al, 1998). These 
results appear to support the general theory that advanced polyploidy represents a 
shift towards terminal differentiation, senescence and reduced proliferative capacity 
(Gupta, 2000). However, hepatocytes in all ploidy classes participate equally in 
repopulating mouse livers with hepatocellular damage following transplantation 
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(Overturf et al, 1999; Weglarz et al, 2000). Hepatocytes formed by fusion with bone 
marrow cells, which are tetraploid by definition, can also fully repopulate the liver, and 
maintain proliferative ability following serial transplantation (Wang et al, 2003a). These 
data suggest that hepatocytes still retain proliferative capacity with increasing ploidy.  
1.5.7. Ploidy changes in liver disease and damage: 
Alterations in hepatocyte ploidy have been observed in a variety of liver diseases. 
Chronic viral hepatitis with fibrosis results in an increase in polyploid hepatocyte 
numbers, which correlates with the severity of the illness (Toyoda et al, 2005). The 
livers of carcinogen treated rats contain approximately 70% small diploid hepatocytes 
after 8 weeks, compared to only 10% in normal wild type animals (Schwarze et al, 
1984). Carcinogenesis is characterised by the appearance of hyperplastic nodules, 
which are believed to represent neoplastic precursor lesions. These consist almost 
exclusively of diploid cells (Schwarze et al, 1984), suggesting that diploid hepatocytes 
are tumour precursor cells. This is in keeping with the theory that higher proliferative 
potential resides in diploid cells. However, the protocol used involves administering 
diethylnitrosamine (DEN) followed by partial hepatectomy and 2-AAF, which will 
induce oval cell proliferation, so it is possible that these are the tumour precursor cells 
rather than existing hepatocytes. Mice treated with DEN alone (Danielsen et al, 1988), 
or with N-methyl-N-nitrosourea and phenobarbital feeding (Sarafoff et al, 1986) both 
show a general increase in diploid cells and decrease in binuclearity in most tumour 
foci, although polyploid lesions were also observed, suggesting that diploid foci are 
not essential for tumour development. There is also a link between DNA damage and 
increased polyploidy. Excision repair cross complementing 1 (Ercc1) is part of a 
complex required for incision of damaged DNA during nucleotide excision repair. Mice 
with liver specific deletion of the Ercc1 gene have dramatically increased polyploidy 
(Kirschner et al, 2007), suggesting that accumulated DNA damage may be a 
characteristic of increased polyploid cells observed in older mammals. However, the 
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fact that the polyploidisation process occurs following weaning in all normal animals 
suggests that it is not simply a consequence of disease or age related damage to the 
liver. 
1.5.8. Aneuploidy in hepatocytes: 
As described earlier, octaploid hepatocytes transplanted into damaged mouse liver 
will reconstitute the liver with a normal ploidy distribution (Duncan et al, 2010). The 
authors note that the majority of the donor cells are aneuploid following repopulation. 
This was also observed in the karyotypes of wild type mice. In yeast cells, aneuploidy 
can provide a selective advantage in response to environmental stress, and polyploidy 
and aneuploidy are common features of the best evolved yeast strains (Rancati et al, 
2008). This has led to the theory that hepatocyte polyploidisation evolved as a 
mechanism to create aneuploidy via ploidy reversal (Duncan et al, 2010). This would 
create a genetically diverse pool of hepatocytes with variations in gene expression, 
from which the fittest strains would be selected following any liver injury. It could 
potentially allow selection of particular karyotypes with a degree of genetic resistance 
to specific liver diseases, or resistance to the harsh microenvironment which 
hepatocytes are exposed to. 
In summary, the importance of hepatocyte polyploidisation is not well understood. The 
fact that it is a conserved process in mammals suggests its importance, and the need 
to learn more about the molecular regulators and functional consequences.  
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1.6. Iron homeostasis: 
1.6.1. Introduction and iron absorption: 
The liver plays a central role in the metabolism, storage and homeostasis of bodily 
iron (Graham et al, 2007; Papanikolaou & Pantopoulos, 2005). Iron is an essential 
trace element in all living cells, however is highly toxic when present in excess due to 
its ability to catalyse the formation of free radicals. It is therefore essential that iron 
homeostasis is tightly controlled. This is achieved at the level of iron absorption, as 
mammals do not have a mechanism for active iron secretion. Dietary iron is absorbed 
across the apical membrane of duodenal enterocytes through the broad specificity 
divalent metal transporter 1 (DMT1) (Gunshin et al, 1997). The absorbed iron is then 
exported into the plasma across the basolateral membrane, via the iron export protein 
ferroportin (Abboud & Haile, 2000). Excess intracellular iron is stored as ferritin, an 
iron storage protein which renders it non-toxic. The liver is the major site for the 
storage of iron, which occurs in hepatocytes (predominantly periportal) and Kupffer 
cells. Plasma iron is transported almost exclusively in complex with the glycoprotein 
transferrin, which maintains it in a soluble, non-toxic state.  
1.6.2. Iron uptake from plasma: 
Transferrin receptor 1: 
Entry of plasma transferrin (diferric transferrin) into cells occurs via one of two 
transferrin receptors, with the predominant uptake in most cells being via transferrin 
receptor 1 (TfR1). Diferric transferrin binds to TfR1, which is then endocytosed 
(Dautry-Varsat et al, 1983). The iron now dissociates from transferrin in the more 
acidic environment of the endosome, and enters the cytoplasm via DMT1. Once 
internalised, iron is incorporated into iron-containing compounds such as haem, or 
stored as ferritin (Young et al, 1985).  
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Regulation of TfR1 expression by iron response elements: 
The expression of TfR1 is post-transcriptionally regulated by iron levels, via iron 
response elements (IREs) in the 3’ untranslated region (UTR) (Casey et al, 1988). In 
iron depleted cells, iron regulatory proteins (IRPs) bind to the IRE and increase the 
stability of the mRNA, and hence expression of TfR1 (Pantopoulos, 2004). In cells 
where iron is abundant the reverse occurs; IRPs are inactivated to increase Tfr1 
mRNA degradation. The 5’ UTR of ferritin mRNA also contains IREs which can be 
bound by IRPs, however in this case IRP binding blocks ferritin translation when iron 
levels are low. There are two IRPs, IRP1 and IRP2, both of which are only present in 
forms which will bind IREs in the absence of iron (Pantopoulos, 2004). Briefly, IRP1 is 
usually assembled as an iron-sulphate cluster, which degrades in iron starved cells to 
allow IRE binding. IRP2 is synthesised de novo following iron depletion, and then 
proteasomally degraded as iron levels increase. This regulatory system promotes 
increased transferrin bound iron uptake coupled with decreased iron storage when 
iron levels are low and the reverse when iron is plentiful. There are also other 
methods of regulating TfR1 expression, including increases in hypoxia, in response to 
cytokines, and in proliferating cells in response to increased cellular demand for iron 
during growth (Graham et al, 2007). 
Transferrin receptor 2: 
Transferrin receptor 2 (TfR2) is a homologue of TfR1, but has much more restricted 
tissue distribution with predominant expression in hepatocytes and haematopoietic 
cells (Kawabata et al, 1999). Its function has not been studied to the degree of TfR1, 
but it is believed to be involved in an alternative, low affinity method of iron uptake. 
The method of iron uptake by TfR2 is the same as TfR1, however the affinity of TfR2 
for transferrin is 25-30 times lower than TfR1 (Kawabata et al, 2000). It is thought that 
the primary role of TfR2 is not actually iron uptake, as Tfr2 mutant mice still 
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accumulate hepatic iron (Fleming et al, 2002). Instead its key role may be in sensing 
iron levels and controlling iron metabolism through regulation of hepcidin expression 
(see section 1.6.4). Unlike Tfr1, Tfr2 mRNA expression is not believed to be regulated 
by intracellular iron levels, and has instead been shown to be altered during the cell 
cycle, with an increase found in proliferating cells (Kawabata et al, 2000). 
Non-transferrin-bound iron uptake: 
Small quantities of non-transferrin-bound iron (NTBI) can also exist in the plasma as a 
low molecular weight pool of chelates. Hepatocytes are the primary cells involved in 
uptake of these species (Craven et al, 1987). This is believed to be via DMT1, as 
NTBI uptake increases following overexpression of DMT1 protein, and membrane 
expression of DMT1 increases in iron depleted cultured cells (Shindo et al, 2006). 
1.6.3. Iron export: 
The ferrous iron transporter ferroportin (FPN) is the only known mediator of iron 
release from cells, and its inactivation in mice leads to iron accumulation in 
hepatocytes, macrophages and enterocytes (Donovan et al, 2005). Like ferritin, Fpn 
mRNA contains an IRE in the 5’UTR, so translation should be increased when iron is 
abundant. This is the case in iron overloaded hepatic, intestinal and monocytic cell 
lines, based on the use of a luciferase reporter gene flanked by the 5’ region 
(Lymboussaki et al, 2003). However, increased FPN mRNA levels are found in 
duodenal biopsies from patients with iron deficiency (Zoller et al, 2001), suggesting 
cell specific regulation of FPN expression. Mouse in vivo immunohistochemical data 
supports this, as iron deficiency leads to increased FPN expression in the duodenum, 
but decreased expression in liver Kupffer cells (Abboud & Haile, 2000). It is likely that 
other mechanisms of FPN regulation, including its degradation by hepcidin (see 
section 1.6.4), are more important in FPN regulation than the IRE. 
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1.6.4. Control of iron homeostasis by hepcidin: 
Hepcidin, encoded by the HAMP (hepcidin antimicrobial peptide) gene, is a small 
circulating peptide produced in hepatocytes and is a key regulator of body iron 
homeostasis (Pigeon et al, 2001). Hepcidin is synthesised when iron levels are high, 
and hence reflects the level of iron sufficiency in the body (Papanikolaou & 
Pantopoulos, 2005). Increased hepcidin expression leads to a decrease in iron 
absorption in the duodenum, and retention of cellular iron stores. Correspondingly, 
mice with liver specific overexpression of hepcidin display severe symptoms of iron 
deficiency and anaemia (Nicolas et al, 2002a). When iron stores are depleted, or large 
amounts of iron are required for processes such as erythropoiesis, hepcidin 
expression drops. This causes an increase in iron absorption in the duodenum and 
release of iron from hepatocyte and macrophage stores. The mechanism for hepcidin 
action is thought to be via degradation of the iron export transporter ferroportin (FPN) 
(Figure 4a). Hepcidin has been shown to bind and internalise FPN in vitro, leading to 
ubiquitin mediated degradation (Nemeth et al, 2004b). This leads to a reduction in 
cellular iron export during iron sufficiency. 
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Figure 4: Regulation of iron homeostasis by hepcidin. 
a) Hepcidin acts to degrade the iron exporter, ferroportin (FPN), preventing iron export 
from duodenal enterocytes and hepatocyte/macrophage stores. b) Proposed 
mechanism for sensing of bodily iron levels by TfR1, TfR2 and HFE. Under low iron 
conditions, HFE is able to bind to TfR1. Increased levels of diferric transferrin (labelled 
Fe in diagram) stabilise Tfr2 and bind to TfR1, displacing HFE. TfR2 and HFE now 
facilitate the production of hepcidin. 
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1.6.5. Control of hepcidin expression: 
Hepcidin expression is regulated at the transcriptional level both by hepatic and 
plasma iron concentrations. The precise pathway is not completely understood, 
however both transferrin receptors and the HFE protein are believed to be involved in 
sensing extracellular iron levels (Figure 4b). HFE is a major histocompatibility-type 
protein and is often mutated in iron overload disorders. HFE is able to complex with 
TfR1 and lower its affinity for transferrin (Feder et al, 1998), due to the fact that HFE 
and transferrin have overlapping binding sites on TfR1 (West et al, 2001). Mice with 
mutations in Tfr1 leading to a constitutive interaction of TfR1 with HFE suffer iron 
overload due to low hepcidin expression, while mice with a mutation preventing the 
HFE-TfR1 interaction express high hepcidin (Schmidt et al, 2008). This suggests that 
HFE is able to induce hepcidin expression when not in complex with TfR1. Given that 
the affinity of TfR1 for HFE is lower than for transferrin (West et al, 2001), it is likely 
that increased concentrations of diferric transferrin displace HFE from TfR1 and lead 
to induction of hepcidin expression.  
Mutations in Tfr2 in mice lead to reduced hepcidin expression, inferring that TfR2 is an 
upstream regulator of the hepcidin pathway (Kawabata et al, 2005). The exposure of 
cell lines to diferric transferrin leads an increase in both numbers and cell surface 
localisation of TfR2 (Deaglio et al, 2002). This means that increased transferrin levels 
act to stabilise TfR2, effectively allowing it to act as an iron sensor, and to facilitate 
hepcidin production in response to increased iron levels. HFE is able to form a 
complex with TfR2, suggesting that TfR2 and HFE could be involved in the same 
hepcidin regulatory pathway (Goswami & Andrews, 2006). This is supported by work 
in HepG2 cells stably expressing HFE, which usually increase hepcidin production in 
response to diferric transferrin (Gao et al, 2009). Depletion of TFR2 in these cells 
abolishes the increase in hepcidin production following treatment with diferric 
transferrin, supporting the notion that the TfR2-HFE complex is required for increasing 
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hepcidin synthesis. However, mice deficient for both Hfe and Tfr2 exhibit more severe 
iron loading and greater reductions in hepcidin expression than mice deficient for only 
one of the proteins (Wallace et al, 2009). This suggests that the TfR2-HFE interaction 
may not be as critical in vivo, and that the two proteins can also regulate hepcidin 
production through independent pathways. The signals which regulate hepcidin 
expression downstream of the TfR1/TfR2/HFE pathway outlined above are not well 
understood. It is also not clear how intracellular iron levels are able to regulate 
hepcidin synthesis.  
Another pathway which may play an important role in hepcidin regulation is the bone 
morphogenetic protein (BMP) signalling pathway. Increased BMP signalling 
upregulates hepcidin expression in hepatocytes, this is enhanced by haemojuvelin 
(HJV), a co-receptor for BMP ligands that is sometimes mutated in iron overload 
disorders (Babitt et al, 2006). In particular, expression of Bmp6 is regulated by iron at 
the mRNA level, and Bmp6-/- mice exhibit a dramatic accumulation of iron in the liver 
and other tissues (Andriopoulos et al, 2009; Meynard et al, 2009). The mice also show 
decreased hepcidin expression, despite the iron overload, suggesting a specific role 
for BMP6 in regulating hepcidin expression. Both mRNA and protein levels of BMP6 
also correlate with iron loading in mouse models, in a similar manner to hepcidin 
(Kautz et al, 2010). 
Hepcidin production can also be regulated by signals other than iron levels. 
Erythropoiesis requires a large increase in the release of iron, both from stores and 
through iron absorption. Administration of the erythropoiesis stimulating agent 
erythropoietin (EPO) in mouse models leads to suppression of hepcidin expression, 
while the addition of erythropoiesis inhibitors results in increased hepcidin expression, 
despite anaemia induced by phlebotomy (Pak et al, 2006). It is therefore likely that 
regulators released during erythropoiesis signal to repress hepcidin expression and 
increase iron supply, although it is currently unclear what these are. Hepcidin is also 
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suppressed during hypoxia and anaemia (Nicolas et al, 2002b), precipitating the 
increase of iron absorption and release from stores. In contrast, hepcidin expression 
is upregulated during inflammation, this is likely to be mediated through cytokines 
including interleukin-6 (Nemeth et al, 2004a).  
1.6.6. Kupffer cells and iron metabolism: 
In addition to hepatocytes, the resident liver macrophages, Kupffer cells, have an 
important role in iron metabolism. Their major role is in the breakdown of haem, and 
subsequent iron release, from old erythrocytes which have been phagocytosed. The 
waste products of this are excreted in bile. Some excess iron can be stored in Kupffer 
cells as ferritin, although a large proportion appears to be exported back into the 
bloodstream (Kondo et al, 1988), supported by the fact that Kupffer cells express high 
levels of FPN (Delaby et al, 2005). FPN in Kupffer cells is mainly found in intracellular 
vesicles, which localise to the cell surface following erythrophagocytosis to allow for 
release of the recycled iron (Delaby et al, 2005). Kupffer cells can also obtain iron 
from transferrin when required (van Berkel et al, 1987). 
1.6.7. Iron overload: 
Primary iron overload 
Haemochromatosis is a disorder characterised by high absorption of dietary iron, 
which leads to iron accumulation in tissues and long term organ damage. In the liver 
this can lead to fibrosis and cirrhosis, which in turn increases the risk of hepatocellular 
carcinoma. The iron overload tends to occur predominantly in the liver parenchyma, 
where it is more toxic, with Kupffer cells not exhibiting as severe a phenotype in the 
early stages of the disease (Papanikolaou & Pantopoulos, 2005). Iron deposits in 
overloaded tissues tend to occur as haemosiderin, a heterogeneous, insoluble iron 
storage compound thought to contain haem and degraded ferritin (Iancu, 2011). In 
most cases, haemochromatosis is hereditary and is commonly caused by mutations in 
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the HFE gene (Feder et al, 1996). Hfe knockout mice display the same iron overload 
phenotype as haemochromatosis patients (Zhou et al, 1998). Haemochromatosis 
patients and Hfe knockout mice both also exhibit low hepcidin mRNA expression 
levels, which are unexpected in cases of iron overload (Bridle et al, 2003). These 
results support a key role for HFE in the hepcidin regulation pathway. There are 
numerous other results which also imply that dysregulation of hepcidin expression is a 
key factor in haemochromatosis. The majority of mutations found in cases of juvenile 
haemochromatosis, in which severe iron overload is observed early in life, are in HJV 
(sometimes known as HFE2), which is also believed to regulate hepcidin levels. Hjv 
knockout mice exhibit increased liver iron loading and decreased hepcidin expression, 
possibly due to reductions in BMP signalling, as HJV is a co-receptor for BMP ligands 
(Babitt et al, 2006). Mutations in TFR2, which is thought to be an upstream regulator 
of hepcidin, ferroportin, which is targeted by hepcidin for degradation, and the HAMP 
gene itself are also observed in cases of haemochromatosis (Darshan et al, 2010). 
Together, these observations all suggest that inappropriate reductions in hepcidin 
expression, and consequent increases in membrane ferroportin levels, are a common 
factor in haemochromatosis. This resulting rise in iron export through FPN causes 
increased plasma iron concentrations, and hence transferrin becomes saturated. This 
in turn increases the amount of NTBI in the plasma, which is quickly taken up by a 
variety of tissues, in particular hepatocytes in the liver through DMT1 (Chua et al, 
2004). The excessive uptake of NTBI and transferrin is higher than the rate of iron 
loss due to increased FPN expression, so the liver will overload with iron.  
Secondary iron overload: 
Secondary iron overload is used to describe range of disorders where the primary iron 
regulatory pathways remain intact, but iron builds up for alternative reasons (Darshan 
et al, 2010). It can result from a number of factors, including excessive dietary iron, 
haemolysis or repeated blood transfusions applied to treat anaemia. Following 
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multiple transfusions, iron tends to localise primarily to Kupffer cells, although may 
gradually distribute to hepatocytes as well (Batts, 2007). This overload is more severe 
when combined with anaemias, such as β-thalassaemia, which also involve defective 
erythropoiesis and hence have increased production of erythroid regulators such as 
EPO (Ganz & Nemeth, 2011). As described earlier, erythropoiesis regulators have a 
suppressive effect on hepcidin expression, so patients with β-thalassaemia will have 
excessive iron absorption leading to iron overload. 
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1.7. Polycomb Group Genes: 
1.7.1. Introduction – the Polycomb family: 
Bmi-1 is a member of the Polycomb group (PcG) family of transcriptional repressors. 
PcG genes were first discovered in Drosophila melanogaster as epigenetic silencers 
of the Hox gene family, preserving cell fate and body patterning decisions in 
embryogenesis (Ringrose & Paro, 2004). Accumulation of PcG proteins has since 
been observed at many other chromosomal sites (Simon & Kingston, 2009), indicating 
that the PcG family represses many other genes in addition to the Hox family. 
Conserved homologues have since been found in vertebrates, with roles in 
maintaining stable transcriptional repression of a large number of target genes. The 
PcG proteins in mammals can be broadly classified into 2 primary complexes – 
Polycomb Repressor Complex (PRC) 1 and PRC2 (Table 1). 
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Drosophila melanogaster Mouse Human 
PRC2   
Esc (Extra sex combs) Eed (4 isoforms) EED (4 isoforms) 
E(z) (Enhancer of zeste) Ezh1 EZH1 
 Ezh2 EZH2 
Su(z)12 (Suppressor of 
zeste) 12) 
Suz12 SUZ12 
 Rbbp4/RbAp48 RBBP4/RBAP48 
 Rbbp7/RbAp46 RBBP7/RBAP46 
 Aebp2 AEBP2 
   
PRC1   
Pc (Polycomb) Cbx2/M33 CBX2/HPC1 
 Cbx4/Mpc2 CBX4/HPC2 
 Cbx8/Pc3 CBX8/HPC3 
 Cbx6 CBX6 
 Cbx7 CBX7 
Ph (Polyhomeotic) Edr1/Mph1/Rae28/Phc1 EDR1/HPH1/PHC1 
 Edr2/Mph2/Phc2 EDR2/HPH2/PHC2 
 Edr3/Mph3/Phc3 EDR3/HPH3/PHC3 
Ring Ring1/Ring1A RING1/RNF1/RING1A 
 Ring1B/Rnf2 RING1B/RNF2 
Psc (Posterior sex combs) Bmi-1 BMI-1 
 Mel-18/Rnf110/Pcgf2 MEL-18/RNF110/PCGF2 
 MBLR/Pcgf6 MBLR /PCGF6 
 Nspc1/Pcgf1 NSPC1/PCGF1 
 Pcgf3 PCGF3 
 Pcgf5 PCGF5 
Other PcG Genes   
Pho (Pleiohomeotic) Yy1 YY1 
Pho-like Yy2 YY2 
Scm (Sex combs on midleg) Scmh1/Scml1 SCMH1 
 Scml2 SCML2 
 Scml4 SCML4 
Pcl (Polycomb like) Phf1/Pcl1 PHF1 
dSfmbt Sfmbt1 SFMBT1 
 Sfmbt2 SFMBT2 
L(3)Mbt L3Mbtl1 L3MBTL1 
 
Table 1: Polycomb Repressor Complexes.          
Table of Drosophila Melanogaster, Mouse and Human Polycomb family members 
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1.7.2. PRC complexes: 
PRC2 
PRC2 in mammals consists of 3 core components: Eed, Suz12 and either Ezh1 or 
Ezh2. These are all essential for embryonic development, as mouse embryos which 
lack Eed, Ezh2 or Suz12 have gastrulation defects at 7-9 days postcoitus (Faust et al, 
1995; O'Carroll et al, 2001; Pasini et al, 2004), and embryonic stem cells which lack 
Eed or Suz12 are unable to maintain pluripotency in vitro. Ezh2 is a histone 
methyltransferase (HMTase) which functions as the catalytic subunit of PRC2 (Muller 
et al, 2002). Ezh1, a homologue of Ezh2, also has HMTase activity (albeit less than 
Ezh2) and in some contexts can substitute for Ezh2 to form an alternative PRC2 
complex, which can repress transcription in vitro and in vivo (Margueron et al, 2008). 
There may be some mechanistic differences between the complexes, as the Ezh1-
PRC2 complex is able to compact polynucleosomes, while the Ezh2 complex cannot. 
It has been suggested that the Ezh2 containing PRC2 is associated strongly with 
proliferation, as it is strongly expressed in proliferative cell lines and is associated with 
markers of DNA replication, such as proliferating cell nuclear antigen (PCNA). 
Expression of the Ezh1-PRC2 complex is more predominant than Ezh2 in the adult 
mouse kidney, due to a decline in Ezh2 levels after birth, leading to the suggestion 
that Ezh1-PRC2 complex is associated more with non-proliferative adult tissues 
(Margueron et al, 2008). However, this is likely to be tissue specific, as expressed 
sequence tag based profiling shows large variations in the Ezh1/Ezh2 ratio between 
different adult tissues (Shen et al, 2008). The Ezh1-PRC2 complex also appears able 
to partially compensate for the loss of Ezh2 mediated methylation in Ezh2 null 
embryonic stem cells, as concurrent Ezh1 knockdown leads to the abolition of residual 
methylation (Shen et al, 2008). 
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Eed is a scaffold protein which physically links Ezh2 and the histone H3 substrate (Tie 
et al, 2007). There are four different isoforms of Eed; the largest of which, Eed1, is the 
predominant component of PRC2 (Kuzmichev et al, 2004). Incorporation of other 
isoforms leads to the formation of different PRC complexes, which the authors have 
designated PRC3 and PRC4. These appear to have different histone substrate 
specificities, which may help contribute to the diversity of polycomb targets 
(Kuzmichev et al, 2005). Suz12 is required for the HMTase activity of Ezh2 (Cao & 
Zhang, 2004), and is also involved in the recruitment of two other components, 
RbAp48/Rbbp4, and Aebp2, which can optimise enzymatic activity in vitro (Pasini et 
al, 2004). 
PRC1 
In Drosophila, PRC1 is formed from four components: Pc (Polycomb), Ph 
(Polyhomeotic), dRing and Psc (Posterior Sex Combs). In mammals, each of these 
proteins has two or more homologues (see Table 1), and these associate in various 
combinations to form a variety of PRC1 complexes. PRC1 is therefore not actually a 
single defined entity, but a broad term for a number of closely related complexes. The 
core component of PRC1 is an E3 ubiquitin ligase, Ring1b (also known as Rnf2), 
which is essential for survival as deletion causes embryonic lethality in mice (Voncken 
et al, 2003). PRC1 also contains homologues to Pc, Ph and Psc. The exact roles of 
each of these individual PRC complex members have not been fully elucidated. It has 
been demonstrated by tandem affinity purification that human PRC1 complexes 
contain only a single representative of the Psc and Pc homologues (Maertens et al, 
2009). 
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1.7.3. Repression by PcG proteins: 
The precise mechanism by which polycomb group proteins repress transcription in 
mammals is not particularly well understood. The canonical sequential model 
(Rajasekhar & Begemann, 2007) (Figure 5) contends that PRC2 is recruited to DNA, 
whereby it initiates transcriptional repression by trimethylating lysine 27 on histone H3 
(H3K27me3). In Drosophila, PcG proteins are recruited to collections of binding sites 
known as Polycomb Repressive Elements (PRE) (Schuettengruber & Cavalli, 2009). 
These have not been defined in mammals despite numerous mapping studies, which 
appears to suggest that other molecules, such as transcription factors, may be more 
important for recruitment. None of the mammalian PRC2 members has a DNA binding 
sequence, so a PRC2 recruiter molecule must exist. In Drosophila, the Pleiohomeotic 
(Pho) protein can mediate interactions between PcG proteins and nucleosomes 
(Klymenko et al, 2006). The mammalian Pho homologue Yy1 is a candidate PRC2 
recruiter, as Yy1 knockdown leads to the dislodging of Ezh2 in mouse myoblasts 
(Caretti et al, 2004). However, the overlap between Yy1 and PRC2 on chromatin in 
mouse embryonic stem cells is limited, suggesting this is not universal (Squazzo et al, 
2006). Other molecules implicated as PcG protein recruiters include the transcription 
factors Oct4 and Nanog, long non-coding RNAs, and CpG binding proteins, as many 
PRC2 targets correspond to CpG islands or other CG rich regions (Simon & Kingston, 
2009). It is possible that there is not a genome wide method of PcG recruitment, and 
that the mechanism varies at different targets. 
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Figure 5: Sequential model of PcG mediated gene silencing. 
PRC2 is recruited to active chromatin, and the HMTase Ezh2 trimethylates histone H3 
on lysine 27. This mark serves as a recruitment factor for PRC1, which ubiquitinates 
histone H2A on lysine 119 through the activity of the Ring1 E3 ubiquitin ligase. These 
modifications result in the long term maintenance of chromatin in a repressed state. 
 
The H3K27me3 mark formed by PRC2 is believed to act in part as a recruitment mark 
for PRC1 (Simon & Kingston, 2009), which is needed for long term maintenance of 
repressive conditions. Knockdown of the PRC2 component Suz12 affects the 
chromatin binding and activity of PRC1 (Cao et al, 2005). There are however some 
examples of PRC1 accumulation without PRC2, for example recruitment by Xist non-
coding RNA in X-inactivation (Schoeftner et al, 2006), demonstrating that independent 
methods of recruitment also exist. PRC1 is thought to act via monoubiquitination of 
histone H2A on K119, a modification associated with transcriptional repression (Wang 
et al, 2004). This is due to the ubiquitin ligase activity of Ring1b, removal of which 
leads to a large decrease in H2A ubiquitination in HeLa cells (Wang et al, 2004). It is 
not clear mechanistically how the action of PRC1 leads to long term transcriptional 
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silencing; theories include DNA polymerase pausing via ubiquitinated H2A, or 
chromatin compaction (Simon & Kingston, 2009). 
The sequential model is likely to be an oversimplification of the actual mechanisms by 
which Polycomb proteins repress transcription, and more work is required to fully 
understand the complexities of PcG mediated silencing. This is in part due to the 
diversity of different PRC1 and PRC2 complexes that can form (Schuettengruber & 
Cavalli, 2009), which will have both distinct and overlapping functions in the 
repressive mechanism. One example involves recent Drosophila studies which have 
identified a distinct complex, known as dRAF, which contains dRing and Psc along 
with a histone lysine demethylase, Kdm2 (Lagarou et al, 2008). The addition of Kdm2 
stimulates the H2A ubiquitination activity of dRing and Psc while the addition of Ph 
and Pc does not, suggesting that dRAF and not PRC1 may be the major ubiquitinating 
complex in Drosophila. dRAF has similarities to the Bcl-6 co-repressor (BCOR) 
complex found in mammals, which contains PcG proteins Ring1, Ring1b and the Psc 
homologue Nspc1, as well as another protein, the Kdm2 homologue Fbxl10, which 
contains a Jumonji C demethylase domain (Gearhart et al, 2006). This suggests there 
may also be two central members of the PRC1 family in mammals, although the 
specific functions and targeting of these have not been well defined. Recent work has 
also implicated the Jumonji C demethylase Jarid2 in the recruitment of PRC2 and 
modulation of its activity (Pasini et al, 2010; Peng et al, 2009). Another H3K4 
demethylase, Rbp2/Jarid1a, can be recruited to PcG targets by PRC2 (Pasini et al, 
2008), suggesting that tightly balanced, coordinated methylation and demethylation is 
important for PcG functions. 
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1.8. Bmi-1: 
Bmi-1, a member of PRC1, was initially identified as an oncogene that cooperates 
with c-myc in the generation of mouse B cell lymphomas in Eµ-myc transgenic mice 
(van Lohuizen et al, 1991b). C-myc is a transcription factor that is commonly 
overexpressed in tumours and has a key role in the development of many human 
cancers. C-myc has a large collection of target genes and a range of different 
functions, a few of which include the ability to drive unrestricted cell proliferation, 
promote cell growth, reduce cell adhesion and, counter-intuitively given its proto-
oncogene status, stimulating apoptosis (Adhikary & Eilers, 2005; Zeller et al, 2003). 
Eµ-myc transgenic mice highly express the c-myc gene specifically in B cells, leading 
to the development of pre-B cell lymphomas within 12 months (Verbeek et al, 1991). 
The infection of these mice with Moloney murine leukaemia virus (Mo-MLV) 
accelerates tumourigenesis, due to integration of the virus into specific sites and the 
activation of cooperating oncogenes. One of the sites most commonly occupied by the 
virus was a gene labelled B-cell specific Mo-MLV integration site 1, or Bmi-1 (van 
Lohuizen et al, 1991b). It was later discovered that Bmi-1 enhances tumourigenesis 
through inhibition of c-myc induced apoptosis, which represents a fail-safe following 
aberrant mitogenic signalling (Jacobs et al, 1999b). This is achieved through Bmi-1 
mediated repression of the Ink4a/Arf locus (see section 1.9.2), as the presence of the 
Arf product p19Arf is required for c-myc induced apoptosis. 
1.8.1. Function of Bmi-1 within PRC1: 
Initial structural analysis of the Bmi-1 protein revealed the presence of motifs 
characteristic of transcription factors, including an N-terminal zinc finger and helix-
turn-helix domain (van Lohuizen et al, 1991a). The protein was classified into the 
polycomb family of epigenetic repressors due to its sequence similarity with the 
Drosophila Psc protein. The precise function of Bmi-1 within mammalian polycomb 
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complexes has not been clearly defined. Bmi-1 is able to make multiple interactions 
with other PRC1 members, suggesting it may be important for PRC1 complex integrity 
(Cao et al, 2005). In vitro reconstitution of PRC1 complexes has demonstrated that 
the addition of Bmi-1 stimulates the E3 ubiquitin ligase activity of Ring1b, which is 
further enhanced by addition of other PRC1 members Ring1a and Cbx8 (Cao et al, 
2005). Moreover, knockdown of Bmi-1 reduces H2A ubiquitination in mouse 
fibroblasts, suggesting that Bmi-1 is an important contributory factor in PRC1 
mediated ubiquitination.  
1.8.2. Bmi-1 knockout mice: 
Many of the insights into Bmi-1 function have come from knockout mouse studies, first 
characterised by Van der Lugt et al (van der Lugt et al, 1994). Bmi-1 knockout mice 
appear relatively normal at birth, although an estimated 50% are selectively 
cannibalised by the mothers. The mice that survive show stunted growth compared to 
wild type littermates, and survive for a maximum of 3-5 months. Their growth is 
characterised by the development of severe neurological, haematopoietic and skeletal 
defects. Neurological abnormalities include an ataxic gait which increases in severity 
with age, and abnormalities in the cerebellum including massive loss of neurons in the 
molecular layer. The mice suffer from haematopoietic abnormalities, including an 
involuted thymus caused by defective thymocyte maturation, smaller spleen and 
hypoplasia in regions of haematopoiesis, leading to a reduced haematopoietic cell 
count. These immunological defects lead to functional abnormalities, including a lack 
of response to interleukin-7, which usually induces pre-B-cell colonies. Bmi-1 
knockout mice exhibit defects in lymphopoiesis and myelopoiesis, but not 
erythropoiesis, suggesting Bmi-1 is only required within certain lineages of the 
haematopoietic system. Finally, the mice have skeletal abnormalities and posterior 
transformations along the anteroposterior axis, similar to those observed in Hox 
mutant mice. This is consistent with a function for Bmi-1 in regulating Hox genes, as 
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the Drosophila homologue Psc functions in a similar way. Following on from this initial 
characterisation, subsequent studies have revealed other defects in mice following 
Bmi-1 knockdown. Bmi-1 deficient mice have inhibited postnatal mammary gland 
development; in particular they usually lack terminal end buds, which contain stem 
cells and their progeny, leading to failure of the ductal epithelium to invade the fat pad 
(Pietersen et al, 2008a). However, these defects can be rescued by pregnancy when 
Bmi-1 deficient tissue is transplanted into wild type mice, suggesting that hormones 
associated with pregnancy are able to overcome the effect of Bmi-1 deletion. Retinas 
from Bmi-1 knockout mice have smaller diameters than wild type littermates despite 
similar overall eye size, and this is associated with a reduction in progenitor cell 
number (Chatoo et al, 2010). Bmi-1 knockout mice also suffer from cataracts and a 
premature ageing-like ocular phenotype (Chatoo et al, 2009). Examination of Bmi-1 
knockout pancreatic islets revealed a reduction in β-cell proliferation, which is 
associated with an increase in expression of the cell cycle inhibitor and Bmi-1 target 
p16Ink4a (see section 1.9.2) (Dhawan et al, 2009). This leads to a decrease in overall 
islet size as Bmi-1 knockout mice age, with the β-cell mass similar to the wild type 
mice at birth, but dramatically reduced by 10 weeks of age. This is also associated 
with abnormal glucose homeostasis; Bmi-1 knockout mice fail to reduce glucose 
levels to a baseline following glucose tolerance tests, and do not increase insulin 
levels in response to glucose injection. The loss of Bmi-1 also affects the regenerative 
capacity of pancreatic β-cells, as Bmi-1 knockout mice do not show any increase in β-
cell proliferation or islet regeneration following exposure to streptozotocin, which 
induces β-cell destruction. Overall, the data from Bmi-1 knockout mice demonstrates 
an important role for Bmi-1 in the postnatal development of several adult tissues. 
1.8.3. Regulation of somatic stem cells by Bmi-1: 
The neurological and haematopoietic abnormalities of Bmi-1 knockout mice are 
thought to be due to the essential function of Bmi-1 in the self-renewal of stem cells. 
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Bmi-1 knockout mice are born with normal numbers of foetal liver haematopoietic 
stem cells (HSCs), however the numbers are dramatically reduced in adult mice due 
to the absence of self-renewal (Park et al, 2003). Forced overexpression of Bmi-1 in 
HSCs leads to the promotion of HSC self-renewal and expansion (Iwama et al, 2004) 
and HSCs from 5 week old Bmi-1 knockout mice are not able to significantly 
contribute to haematopoiesis following transplantation into an irradiated recipient 
(Park et al, 2003). Bmi-1 deficiency impairs the self-renewal of stem cells from foetal 
central nervous system telencephalon and peripheral neural crest stem cells in culture 
(Molofsky et al, 2003). Furthermore, Bmi-1 deficient mice have reduced frequencies of 
subventricular zone cells capable of forming neurospheres in culture, with their 
numbers becoming more depleted with age. Bmi-1 deletion does not significantly 
affect the colony forming potential of more restricted neural progenitors from the 
forebrain and gut, suggesting that Bmi-1 is specifically required for stem cell 
maintenance in these contexts (Molofsky et al, 2003). In contrast, Bmi-1 knockout 
mice have reduced numbers and expansion of immature granule cell precursors in 
vivo, leading to reduced cerebellar size (Leung et al, 2004). Immature granule cell 
precursors are more committed cerebellar precursor cells, so this work demonstrates 
that the function of Bmi-1 is not always limited to undifferentiated stem cells. 
Roles for Bmi-1 in the regulation of stem cells from other tissues have also been 
elucidated. In the lung, bronchioalveolar stem cells isolated from Bmi-1 knockout mice 
show defects in proliferation and self-renewal in culture (Dovey et al, 2008), although, 
the mice themselves do not have obvious abnormalities in lung development. Lineage 
tracing using a Bmi-1-Cre-ER transgenic mouse, which expresses Cre from the Bmi-1 
locus upon addition of tamoxifen, crossed to a strain with a conditional reporter, has 
identified Bmi-1 expressing stem cells near the bottom of crypts in the small intestine 
(Sangiorgi & Capecchi, 2008). These cells expand over time and can give rise to all 
the cell lineages in the intestinal epithelium. The authors then ablated the Bmi-1 
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positive cells by crossing the Bmi-1-Cre-ER mice to mice with a conditional diphtheria 
toxin allele expressed by the ubiquitous Rosa26 locus. The result of this was cell 
death and the loss of crypts, demonstrating that the Bmi-1 expressing cells are 
essential for crypt maintenance. A similar technique was used to label Bmi-1 
expressing cells in the pancreas, with the most abundant labelled population being a 
subpopulation of acinar cells (Sangiorgi & Capecchi, 2009). Interestingly, the Bmi-1 
positive cells do not express markers for undifferentiated pancreatic progenitor cells, 
and instead co-localise with markers for differentiated acinar, endothelial and 
glucagon positive cells. This appears in contrast to the previously defined role of Bmi-
1 in the maintenance of undifferentiated adult stem cells. However, analysis of the 
Bmi-1 expressing acinar cells revealed that the lineage persists for at least one year, 
and is characterised by an expansion and then contraction of the population of 
labelled cells. The Bmi-1 positive cells also show co-localisation for proliferation 
markers, in support of previous work showing acinar cells can proliferate despite their 
differentiated state. They also retain a 5’-bromo-2-deoxyuridine (BrdU) label for long 
periods, demonstrating that the Bmi-1 expressing cells are not continuously 
replicating, but are maintained until required. Ablation of the Bmi-1 lineage using 
diphtheria toxin leads to an increase in mitosis among the acinar cell population, 
demonstrating that the Bmi-1 expressing cells are not required for acinar cell 
proliferation. These data all suggest that Bmi-1 may have a function in a 
subpopulation of more differentiated cells, as well as in undifferentiated stem cells.  
This is supported by data showing that Bmi-1 is expressed at varying levels in all cells 
in wild type mouse mammary glands, as opposed to just a minority of stem cells 
(Pietersen et al, 2008a). Injection of Bmi-1 knockout mammary epithelial cell (MEC) 
populations, which include multiple cell types, into wild type mice does not result in 
any growth. This led the authors to propose that the proliferation of more committed 
progenitor cells within the MEC population is also impaired by Bmi-1 loss, in addition 
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to mammary stem cells. This would be in contrast to the neural forebrain, where 
restricted progenitors are unaffected by Bmi-1 depletion (Molofsky et al, 2003), 
although the authors did not specifically show that this is the case in an isolated 
population of mammary progenitor cells. 
Overall, these data show that Bmi-1 is important for maintenance of self-renewal and 
proliferation in stem cells in a number of adult tissues, and that the requirement of 
Bmi-1 in more differentiated progenitor cells varies between different tissue types. 
1.8.4. Bmi-1 in tumourigenesis: 
Bmi-1 also has an important role in the regulation of cancer stem cells and 
tumourigenesis, as determined by a number of functional studies. Amongst these, 
Bmi-1 knockout leukaemic stem cells undergo proliferation arrest and differentiation in 
vitro, and are unable to repopulate secondary hosts, suggesting a key role for Bmi-1 
in regulating proliferation of cancer stem cells as well as somatic stem cells (Lessard 
& Sauvageau, 2003). Bmi-1 deficient neural stem cells also give rise to lower grade 
gliomas when grafted into mice (Bruggeman et al, 2007). Bmi-1 is also overexpressed 
in medulloblastomas (Leung et al, 2004), and a crucial role for Bmi-1 in hedgehog-
driven medulloblastoma expansion has been suggested due to the failure of 
medulloblastomas to develop in Bmi-1 knockout mice expressing the oncogenic 
hedgehog effecter, SmoA1 (Michael et al, 2008). Bmi-1 knockout mice also exhibit 
decreases in lung tumour frequency, when crossed with mice carrying an oncogenic 
K-ras allele to provide an oncogenic stimulus. This is accompanied by decreased 
expansion of bronchioalveolar stem cells, which are thought to be the tumour initiating 
cells in K-ras induced lung tumours (Dovey et al, 2008). Consistent with these studies, 
Bmi-1 overexpression has been reported in tissue microarrays from several different 
types of human tumours (Sanchez-Beato et al, 2006). There are also a number of 
studies showing that high Bmi-1 expression is associated with more aggressive 
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tumour subtypes and poor long term survival, for example in oligodendroglial tumours 
(Hayry et al, 2008), non-small cell lung cancers (Vrzalikova et al, 2008) and metastatic 
melanomas (Mihic-Probst et al, 2007). There is also some work detailing improved 
survival and less aggressive phenotypes in Bmi-1 overexpressing tumours, including 
in breast cancers (Pietersen et al, 2008b), squamous cell carcinomas (Hayry et al, 
2010) and endometrial carcinomas (Engelsen et al, 2008). These results appear to 
contradict the functional studies, and suggest that the role of Bmi-1 in tumour 
progression may be dependent on the context and tissue type of the tumours, 
although there are doubts over the reliability of anti-Bmi-1 antibodies that are used in 
many immunohistochemical studies (Sangiorgi & Capecchi, 2009). 
1.9. Regulation of the cell cycle by Bmi-1: 
The downstream effects of Bmi-1 containing PRC1 complexes are due to 
transcriptional repression of a variety of targets, in particular cell cycle inhibitors such 
as p21 and the Ink4a/Arf locus, which encodes p16Ink4a and p19Arf. This section will 
introduce these proteins and their functions, and describe the evidence implicating 
Bmi-1 as a regulator of their expression. 
1.9.1. Introduction to the cell cycle: 
Proliferating cells proceed through the cell cycle in a highly regulated manner 
(Schafer, 1998; Yu et al, 2007) (Figure 6). Cells which are not actively cycling but 
have the potential to enter the cell cycle, such as the majority of hepatocytes, are 
termed as being in G0 phase. Cells that are cycling will proceed through G1 phase, S 
phase (DNA synthesis), G2 phase and M phase (mitosis). Cell cycle progression is 
tightly regulated, and is catalysed by complexes containing cyclin dependent kinases 
(Cdk) and their regulatory subunits, cyclins. The formation of Cdk-cyclin complexes is 
a requirement for Cdk activation and nuclear targeting. Cdks control cell cycle 
progression by phosphorylating and inactivating target substrates, such as 
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retinoblastoma (Rb), which controls entry into S-phase via the release of E2F 
transcription factors. Initial Rb phosphorylation occurs in mid G1 by cyclin D family 
dependent kinases, this is enhanced later in G1 by the Cdk2/cyclin E complex and 
maintained later in the cell cycle by cyclin A and B dependent Cdks. Numerous other 
molecules are also involved in cell cycle regulation, including the tumour suppressor 
gene p53 and the INK4 and WAF1/CIP/KIP families of Cdk inhibitors. The roles of p53 
include the arrest of cells at the G1/S and G2M checkpoints following DNA damage, 
achieved by activating a number of downstream targets, including the Cdk inhibitor 
p21Cip1/Waf1 (henceforth referred to as p21). 
 
 
Figure 6: The mammalian cell cycle. 
Simplified schematic showing the stages of the mammalian cell cycle and selected 
key cell cycle regulatory proteins. 
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1.9.2. The Ink4a/Arf locus 
The Ink4a/Arf locus (also known as Cdkn2a locus) encodes the tumour suppressor 
proteins p16Ink4a and p19Arf (p14Arf in humans). The two proteins have distinct first 
exons spliced to a common second, however this is translated in an alternative 
reading frame so there is no sequence similarity between the two proteins (Gil & 
Peters, 2006; Kim & Sharpless, 2006) (Figure 7). An adjacent gene, Cdkn2b, encodes 
another tumour suppressor, p15Ink4b. Both p15Ink4b and p16Ink4a are members of the 
INK4 family of Cdk inhibitors, which also includes p18Ink4c and p19Ink4d (a distinct 
protein from p19Arf). All the INK4 proteins are highly conserved at the amino acid level 
and there appears to be very little biochemical difference between them (Sharpless, 
2005). It is likely that functional differences in the proteins occur through differences in 
their expression patterns. For example, p18Ink4c and p19Ink4d appear to have a role in 
development, as they are widely expressed during mouse embryogenesis, while 
p16Ink4a and p15Ink4b are not (Zindy et al, 1997). p16Ink4a is associated with tumour 
suppression and senescence, as p16Ink4a knockout mice (which will also delete p19Arf) 
develop normally, but many spontaneously generate tumours by 29 weeks of age 
(Serrano et al, 1996). The INK4 members all act by blocking progression through the 
G1 phase of the cell cycle, specifically by inhibiting the activity of kinases that bind 
cyclin D (Cdk4 or Cdk6), but do not affect the functions of other Cdk/cyclin complexes 
(Serrano et al, 1993) (Hirai et al, 1995). INK4 proteins bind directly to Cdk4 or Cdk6 
and induce a structural change, prevent the binding of the Cdks to cyclin D proteins 
(Russo et al, 1998). This is turn prevents Cdk4/6 mediated phosphorylation of Rb, 
leading to binding of E2Fs to hypophosphorylated Rb, and G1 arrest (Kim & 
Sharpless, 2006).  
The Arf product does not share any homology with p16Ink4a as the proteins are 
encoded by alternative reading frames, and hence it exerts its tumour suppressor 
function via a different mechanism involving regulation of the murine double minute 2 
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(Mdm2) - p53 pathway. Mdm2 is an oncogenic protein which binds to p53 and 
controls its function primarily through promoting p53 polyubiquitination and 
proteasomal degradation (Michael & Oren, 2003). Arf proteins are able to interact with 
Mdm2 and inhibit its activity, thus preventing degradation of p53 (Pomerantz et al, 
1998). 
 
 
Figure 7: The murine Ink4a/Arf locus. 
Schematic showing the Ink4a/Arf (Cdkn2a) and adjacent Ink4b (Cdkn2b) loci, gene 
products and downstream targets. 
 
Functions of p16Ink4a and p19Arf 
p16Ink4a and p19Arf have both been implicated as biomarkers of ageing in rodents, as 
expression of Ink4a/Arf is dramatically increased in most tissues in older mice (26 
months compared to 2.5 months), while other cell cycle inhibitors do not exhibit 
significant changes (Krishnamurthy et al, 2004). Levels of p16Ink4a in haematopoietic 
stem cells increase as mice age, leading to decreased proliferation and more limited 
repopulating ability following bone marrow transplants (Janzen et al, 2006). These 
defects are rescued in p16Ink4a null cells, suggesting a role for p16Ink4a in stem cell 
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ageing. Age related increases in p16Ink4a expression linked to decreased 
stem/progenitor cell function are also found in other cell types, including pancreatic 
islet cells, which have decreased regenerative potential (Krishnamurthy et al, 2006), 
and neural forebrain progenitors (Molofsky et al, 2006). Fibroblasts from Ink4a/Arf 
knockout mice do not senesce when explanted into culture, unlike normal cells, 
revealing a role for p16Ink4a and p19Arf in senescence (Serrano et al, 1996). Mice with 
individual deletions of p16Ink4a or p19Arf both have increased susceptibility to tumour 
formation, suggesting that both proteins are involved in mediating the tumour 
suppressive function of the Ink4a/Arf locus, although mice doubly deficient for p16Ink4a 
and p19Arf show more dramatic tumour formation than the individual knockouts 
(Sharpless et al, 2004). In human tumours, mutations in INK4A/ARF are found 
frequently. Mutations of p16INK4A appear to be particularly important and have been 
observed in a large number of tumours (Forbes et al, 2006), including a number of 
cases that do not also mutate p14ARF or the adjacent INK4B locus (Kim & Sharpless, 
2006). Although loss of p19Arf alone is oncogenic in mice, mutations in the p14ARF 
gene in human tumours that do not also affect p16Ink4a are quite rare. This appears to 
suggest that p16Ink4a is a more important tumour suppressor than p14Arf in humans, 
although some have pointed out that only a small portion of the N-terminus of p14Arf is 
actually required for the interaction with Mdm2, so mutations that actually disable 
p14Arf function would be less likely (Kim & Sharpless, 2006). 
The Ink4a/Arf locus as a Bmi-1 target: 
Some of the effects of Bmi-1 are thought to be mediated through repression of the 
Ink4a/Arf locus, as p16Ink4a and p19Arf are upregulated in Bmi-1 null fibroblasts and 
lymphocytes, and removal of Ink4a/Arf partially rescues some of the haematopoietic 
and neural defects in Bmi-1 knockout mice. In particular, the Bmi-1-/-Ink4a-/- mice have 
normal cerebellar size and cell numbers, normal marker profiles on splenocytes and 
thymocytes (Jacobs et al, 1999a), and restored HSC self-renewal capacity (Oguro et 
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al, 2006). Ink4a/Arf deletion also rescues the mammary epithelial growth defects 
found in Bmi-1 knockout mice (Pietersen et al, 2008a). Chromatin 
immunoprecipitation (ChIP) analysis has revealed that Bmi-1 binds directly throughout 
the Ink4a/Arf locus in human and mouse cells (Bracken et al, 2007). The presence of 
PRC2 is required for the repressive effect, and Bmi-1 is displaced from the Ink4a/Arf 
locus in senescent cells following Ezh2 downregulation. Recent ChIP studies have 
demonstrated the existence of a particular region of the p16Ink4a promoter, labelled a 
Bmi-1 responding element (BRE), to which Bmi-1 directly binds (Meng et al, 2010). 
Interestingly, the authors found that Ring1b/Rnf2 is not recruited to this site in the 
p16Ink4a promoter, and that Ring1b overexpression does not affect the activity of a 
luciferase reporter linked to the p16Ink4a promoter sequence. This suggests that Bmi-1 
mediated repression of p16Ink4a may be independent of the canonical Ring1b-
containing PRC1. 
There appears to be some species and cell-type specificity in Bmi-1 repression of the 
Ink4a/Arf promoter, with variability in binding of Bmi-1 to the p14ARF promoter 
observed in human cells. Repression of Arf following Bmi-1 overexpression is found in 
cultured mouse embryonic fibroblasts, but not in human embryonic fibroblasts 
(Bracken et al, 2007). In contrast, increases in polycomb associated methylation of 
histone H3 are found throughout INK4A/ARF in human CD34+ bone marrow cells, 
with an associated loss of both p16Ink4a and p14Arf expression (Bracken et al, 2007). 
The effects of cell culture on expression of p16Ink4a and p14/19Arf has to be taken into 
account when analysing in vitro studies, backed up by the fact that the previous 
authors observed loss of Bmi-1 and the H3K27me3 mark from the Ink4a/Arf locus in 
mouse embryonic fibroblasts after three passages. However, in vivo data also 
demonstrates different effects following deletion of p16Ink4a versus p19Arf in Bmi-1 
knockout mice (Bruggeman et al, 2005). The p19Arf/p53 pathway appears to be a 
general target of Bmi-1 repression in mice, as deletion of p19Arf leads to partial rescue 
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of a number of Bmi-1 knockout phenotypes in lymphoid cells and neural 
stem/progenitor cells. Loss of p16Ink4a alone does not rescue the phenotypes of some 
types of Bmi-1 deficient cells, including splenocytes, mouse embryonic fibroblasts and 
cerebellar granule neuron progenitors (Bruggeman et al, 2005). However, p16Ink4a 
deletion is required to completely alleviate defects in self-renewal and/or proliferation 
in Bmi-1 knockout neural stem cells, other neural progenitors and thymocytes, 
suggesting Bmi-1 mediated p16Ink4a repression is required in some cell types in mice. 
These data suggest that the contributions of p16Ink4a and p19Arf repression in relaying 
Bmi-1 functions vary according to the cellular context. 
1.9.3. p21: 
p21, encoded by the Cdkn1a gene, is a member of the WAF1/Cip/Kip family of cell 
cycle inhibitors, which also includes p27Kip1 and p57Kip2. It was initially discovered by 
multiple laboratories due to its interaction with Cdk2/cyclin E complexes, and was 
identified as a Cdk2 inhibitor (Weinberg & Denning, 2002). Further research revealed 
that p21 is induced in response to p53 expression, and can suppress the growth of 
tumour cells in culture (el-Deiry et al, 1993). p21 is an essential mediator of p53 
dependent cell cycle arrest, as mice deficient for p21 show defects in p53 mediated 
G1 arrest in response to γ-radiation (Deng et al, 1995). It is not required for all aspects 
of p53 function and is also activated by several p53 independent mechanisms (Jung 
et al, 2010). The early research all marked p21 as purely a cell cycle inhibitor, 
however subsequent findings have shown that it is actually involved in multiple levels 
of cell cycle control, and can have both oncogenic and tumour suppressive effects.  
Function of p21 in cell cycle progression: 
An increase in p21 expression has generally been associated with growth arrest and 
terminal differentiation (Jung et al, 2010). Mice with a complete knockout of p21 
develop normally, suggesting p21 is not required for normal differentiation (Deng et al, 
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1995), although it is possible that other family members may be able to compensate. 
However, p21 null embryonic fibroblasts isolated from these mice have deficiencies in 
G1 arrest, supporting a role for p21 in regulating the G1 checkpoint. p21 is able to 
inhibit the activity of different Cdk/cyclin complexes in in vitro reconstitution assays, 
and its overexpression inhibits the proliferation of mammalian cells (Xiong et al, 1993). 
It appears that the inhibitory effects of p21 are mediated in particular through inhibition 
of complexes containing cdk2 and cyclin E or cyclin A. Cdk2/cyclin E complexes 
which contain p21 have been shown to be catalytically active when p21 is 
subsaturating, but become inactive as the levels of p21 are increased (Zhang et al, 
1994). However, p21 also appears to have positive as well as negative effects on G1 
progression. Concurrent transfection of p21 or p27 with cyclin D1 and Cdk4 into 
cultured cells actually promotes formation of the Cdk4/cyclin D1 complexes, as 
determined by an immunoprecipitation-western assay (LaBaer et al, 1997). The 
authors observed very little complex assembly without p21 or p27 present. The 
complexes also have increased kinase activity at basal p21 levels, although this 
decreases when p21 is expressed at much higher levels. Moreover, another study has 
shown that mouse embryonic fibroblasts lacking p21 and p27 fail to assemble 
detectable Cdk/cyclin D complexes, and cannot direct cyclin D proteins to the nucleus 
(Cheng et al, 1999). Transient transfection of moderate levels of p21 into smooth 
muscle cells also causes an increase in proliferation (Kavurma & Khachigian, 2003). 
Taken together, these results demonstrate a dual role for p21 in both promoting 
assembly of active Cdk4/cyclin D complexes, but inhibiting their activity at higher 
stoichiometries. The sequestering of p21 and p27 into Cdk4/cyclin D complexes is 
also thought to help to relieve their inhibition of Cdk2/cyclin E complexes, thus 
facilitating cell cycle progression (Sherr & Roberts, 1999). In addition to its role as a 
cell cycle regulator, p21 has been reported to have both pro- and anti-apoptotic 
functions, which are likely to depend on the cellular context (Jung et al, 2010). 
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p21 in tumourigenesis: 
p21 was originally considered a tumour suppressor, due to its anti-proliferative effects 
and regulation by p53. In the liver, loss of p21 accelerates hepatocarcinogenesis in 
the fah-/- mouse model (Willenbring et al, 2008), suggesting a tumour suppressor 
function for p21 in hepatic cells in this context. However, unlike p53 knockout mice, 
mice deficient in p21 have low levels of spontaneous tumour formation in the short 
term (Deng et al, 1995), although increased tumour incidence has been reported over 
a 2 year time frame (Martin-Caballero et al, 2001). Mutations in p21 are also 
uncommon in most human cancers (Weinberg & Denning, 2002), suggesting that p21 
is not a general mediator of tumour suppression, in contrast to p53. Given the 
reported status of p21 as a cell cycle inhibitor, the preliminary expectation is that p21 
levels would be decreased rather than overexpressed in tumours. However, this is not 
always the case. Overexpression of p21 has been noted in various squamous cell 
carcinomas, including in head and neck cancers (Erber et al, 1997; van Oijen et al, 
1998) and also in breast cancers (Rey et al, 1998). The expression appears 
independent of functional p53, and in many cases correlates with expression of Ki67, 
leading to the conclusion that p21 overexpression is found in actively proliferating 
cells as well as differentiated cells (Erber et al, 1997). This suggests that the growth 
inhibitory function of p21 may be bypassed in some tumour cells. Van Oijen et al 
found that nuclear p21 expression in proliferating tumour cells usually occurs 
concurrently with overexpression of cyclin D1 in the same region (van Oijen et al, 
1998), although this was not specifically demonstrated in a single cell. A correlation 
between expression of p21, cyclin D1 and the percentage of cells in S-phase is also 
found in breast cancers (Rey et al, 1998). These findings led van Oijen et al to 
suggest that cyclin D1 expression could overcome the anti-proliferative effects of 
excess p21 expression, which could possibly be due to the sequestering of excess 
p21 by cyclin D1 containing complexes. This theory has support from other studies 
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showing a sequestering effect of cyclin D family members on p21. Russell et al 
demonstrated that elevated levels of cyclin D3 can sequester overexpressed p21 
away from Cdk4/cyclin D1 and Cdk2 containing complexes in MCF-7 breast cancer 
cells, hence increasing the Cdk activity (Russell et al, 1999). They also found elevated 
p21 levels in cyclin D1 and cyclin D3 positive breast cancer samples. In addition to 
this, c-myc activation in cell lines leads to an increase in protein synthesis of cyclins 
D1 and D2, which in turn leads to increased binding of the cyclins to p27 and p21 
(Perez-Roger et al, 1999). This proliferative effect of c-myc activation does not occur 
in cells from cyclin D1 or D2 null mouse embryos, showing that the sequestering 
function of cyclin D proteins is essential for c-myc induced cell cycle progression. 
Functions of p21 - summary: 
In summary, a major role of p21 appears to be as a negative regulator of the cell cycle 
through inhibition of Cdk/cyclin complexes. However, it can also have pro-growth 
functions, including its role as an assembly factor for Cdk4/cyclin D1 complexes, and 
as an inhibitor of apoptosis. It also seems to have both tumour-suppressive and 
oncogenic capabilities in different contexts. Which of these contradictory functions 
occurs seems to depend on a variety of factors, including the stoichiometry of the p21 
protein in relation to other cell cycle regulatory molecules, the subcellular localisation 
of p21, and the cell system used in the study. 
p21 as a Bmi-1 target: 
The requirement of Bmi-1 for adult stem cell maintenance may be in part related to 
repression of the effects of activated Ink4a/Arf, however Bmi-1 must also regulate 
other genes, as deletion of Ink4a/Arf does not completely abrogate the phenotype of 
the Bmi-1 knockout mouse. For example, these double knockout mice still exhibit 
defects in the bone marrow microenvironment (Oguro et al, 2006), have only partial 
rescue of splenocyte and thymocyte numbers (Jacobs et al, 1999a), and do not show 
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improved growth or survival compared to Bmi-1 knockout mice (Molofsky et al, 2005). 
One other potential Bmi-1 target is p21. The knockdown of Bmi-1 in neural progenitor 
cells in vitro and in vivo causes rapid upregulation of p21, while p16Ink4a and p19Arf 
remain relatively unaffected (Fasano et al, 2007). The anti-proliferative effect 
observed in the Bmi-1 depleted cells is rescued by co-transfection of a small hairpin 
RNA (shRNA) against p21, confirming that p21 is an important target in this system. It 
is possible in some cases that alterations in p21 expression following Bmi-1 
knockdown are mediated through p19Arf activation, as increased p19Arf protein leads 
to the inhibition of Mdm2 activity and the stabilisation of p53, which in turn will cause 
increased transcription of p21. However the fact that transfection of shRNAs against 
Ink4a/Arf does not rescue the phenotype of Bmi-1 depleted neural progenitor cells 
(Fasano et al, 2007) suggests that p21 is a Bmi-1 target independent of repression of 
the Cdkn2a locus. This has since been demonstrated by ChIP studies showing that 
Bmi-1 directly binds the p21 promoter in cells isolated from wild type mouse 
cerebellum (Subkhankulova et al, 2010). 
1.9.4. Other Bmi-1 targets: 
In addition to the previously described role of Bmi-1 in repressing the expression of 
cell cycle inhibitors and Hox genes, there have been other reported targets for Bmi-1. 
Overexpression of BMI-1 in human mammary epithelial cells leads to immortalisation 
and an increase in telomerase activity; reporter assays confirmed that this is due to 
transcriptional activation of human telomerase reverse transcriptase (hTERT) (Dimri 
et al, 2002). hTERT is the catalytic subunit of telomerase, which also contains a 
telomerase RNA component (TERC). Telomerase is required particularly in germ cells 
and stem cells to prevent senescence by maintaining the length of telomeres, which 
are short repetitive sequences at the ends of chromosomes which shorten with each 
cell cycle. Telomerase activation is also therefore a common occurrence in tumour 
cells. The finding of a potential role for Bmi-1 in telomerase activation would be 
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consistent with the established Bmi-1 functions in promoting stem cell self-renewal 
and preventing senescence, and with its frequent upregulation in tumours. However, 
the authors also found that Bmi-1 does not induce telomerase in human fibroblasts, 
suggesting the function is cell type specific. 
Bracken et al performed expression array analysis of human embryonic fibroblasts 
depleted for either of three PRC2 members or BMI-1, and identified over 300 potential 
polycomb targets based on expression changes (Bracken et al, 2006). Subsequently, 
ChIP-on-chip analysis using antibodies against PRC2 and PRC1 proteins, or the 
H3K27me3 mark validated many of these, and genome wide promoter array studies 
extended the number of potential Polycomb target genes to over 1000. These include 
genes involved in several key pathways in development and differentiation, including 
the Wnt, Notch, Hedgehog, transforming growth factor, and fibroblast growth factor 
signalling pathways, amongst others, although it has not specifically been 
demonstrated that Bmi-1-containing complexes regulate all these genes. Meng et al 
have since performed analysis of the total precipitated DNA content from a ChIP 
experiment using an anti-Bmi-1 antibody in HeLa cells (Meng et al, 2010). This 
revealed over 1500 genes potentially regulated by Bmi-1, including genes involved in 
the cell cycle, apoptosis and tissue specific development. These results are 
suggestive of a broader and more complex role for Bmi-1 in regulating a much more 
diverse array of cellular processes than simply progression of the cell cycle. 
1.9.5. Bmi-1 in mitochondrial function and the DNA damage response 
Recent work has also implicated Bmi-1 in the DNA damage response. Bone 
thymocytes isolated from Bmi-1 knockout mice have increased levels of reactive 
oxygen species (ROS), which are linked to impaired mitochondrial function (Liu et al, 
2009). This is coupled with upregulation of components of the DNA damage response 
(DDR), including the protein kinase Chk2 which is involved in cell cycle arrest. Both 
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ROS-scavenging antioxidants and Chk2 deletion can partially rescue many of the 
defects in thymus and spleen found in Bmi-1 knockout mice, as well improve the 
colony forming ability of Bmi-1 null haematopoietic stem cells. The authors note that 
activation of the DDR has been implicated in stem/progenitor cell ageing and 
senescence, so the observation that Bmi-1 may have a role in regulating the DDR is 
consistent with the established role for Bmi-1 in stem cell maintenance. Bmi-1 is also 
recruited to DNA damage foci in HeLa cells, and Bmi-1 depleted cell lines have 
impaired homologous recombination-mediated repair of double strand breaks (Ginjala 
et al, 2011). Furthermore, both cell lines and primary primitive haematopoietic cells 
depleted for Bmi-1 show increased sensitivity to clastogenic agents, leading to 
spontaneous chromosome breakage and instability (Chagraoui et al, 2011). Bmi-1 
knockout mice also die within 3 weeks of whole body irradiation, suggesting increased 
in vivo susceptibility to DNA damage. This is independent of increased ROS levels, as 
antioxidant treatment does not rescue the phenotype. Together, these studies suggest 
a new role for Bmi-1 in the maintenance of chromosome integrity. 
1.10. Mel-18: 
The Mel-18 gene product is structurally very similar to Bmi-1, sharing 93% homology 
in the N-terminal RING-finger and helix-turn-helix domains, and overall amino acid 
identity of 58% (Ishida et al, 1993), suggesting possible redundancy between the two 
proteins. Individual Mel-18 knockout mice show stunted growth, severe 
immunodeficiency and posterior transformations virtually identical to the Bmi-1 
knockout mouse (Akasaka et al, 1996). They also exhibit reductions in both lymphoid 
progenitor numbers and their mitotic response to interleukin-7 (Akasaka et al, 1997) 
and reduced expansion of immature T progenitor cells (Miyazaki et al, 2005). These 
observations would appear to suggest that Bmi-1 and Mel-18 act in synergy in some 
cases. However, Mel-18 null mice do not show any of the cerebellar abnormalities 
seen in the Bmi-1 knockout, and have additional defects in the smooth muscle of the 
72 
 
colon. These unique phenotypes suggest some differences in the functions of Bmi-1 
and Mel-18, despite their strong homology. Mice doubly deficient for Mel-18 and Bmi-
1 die at embryonic day 9.5 with severe morphological abnormalities, including more 
severe skeletal transformations than in single knockout mice (Akasaka et al, 2001). 
Tandem affinity purification of Bmi-1 and Mel-18 shows they are found in nearly 
identical core complexes, interacting with other known PRC1 members, but never with 
each other (Wiederschain et al, 2007). In addition to this, simultaneous binding of both 
Mel-18-PRC1 and Bmi-1-PRC1 complexes has been observed at the INK4A/ARF 
locus in human fibroblasts (Maertens et al, 2009). Furthermore, shRNA mediated 
knockdown of either BMI-1 or MEL-18 leads to a reduction in the binding of the other 
protein at the INK4A/ARF locus. This suggests that binding of both complexes may be 
interdependent, and supports the idea that the complexes act synergistically in some 
cases. There do appear to be functional differences between the two complexes, as 
addition of Mel-18 is able to stabilise PRC1, but does not increase the E3 ubiquitin 
ligase activity of Ring1b, unlike Bmi-1 (Cao et al, 2005). 
1.10.1. Functions of Mel-18: 
Mel-18 as a tumour suppressor: 
The exact role of Mel-18 in cell cycle regulation and tumour progression is a matter of 
debate. There is a body of evidence suggesting that Mel-18 functions as a tumour 
suppressor, in contrast to Bmi-1. Mel-18 was initially identified as a transcriptional 
negative regulator, with the recombinant protein able to directly bind to a specific DNA 
motif (Kanno et al, 1995). NIH 3T3 cells transfected with antisense MEL-18 RNA 
acquire tumourigenicity, suggesting Mel-18 has tumour suppressive activity. Bmi-1 
and Mel-18 expression are inversely correlated in breast cancer cell lines and breast 
tumours, with the majority of samples having high Bmi-1 and low Mel-18, suggesting 
that the proteins have opposing roles (Guo et al, 2007b). This inverse correlation has 
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been noted in gastric cancers (Zhang et al, 2010), with increased Bmi-1 and low Mel-
18 again associated with tumour progression (Lu et al, 2010). Low Mel-18 expression 
also correlates with poor survival in breast cancers (Guo et al, 2010) and prostate 
cancer (Wang et al, 2009). Primitive murine haematopoietic cells and human bone 
marrow cells express either Mel-18 or Bmi-1, but rarely both (Kajiume et al, 2009), 
again suggesting different functions within this context. This is supported by small 
interfering RNA (siRNA) knockdown experiments showing that the colony forming 
ability of putative murine haematopoietic stem cells is reduced by loss of Bmi-1, but 
increased by knockdown of Mel-18 (Kajiume et al, 2009). Isolated B cells from 
transgenic mice overexpressing Mel-18 exhibit suppressed proliferation combined 
with cell cycle arrest between G1 and S phase, suggesting that Mel-18 is a cell cycle 
inhibitor (Tetsu et al, 1998). This phenotype is accompanied by the downregulation of 
various proteins involved in the cell cycle, including c-myc, cyclins G2 and E, and the 
activities of Cdk 4&6. The B cell proliferation defects in the Mel-18 overexpressing 
mice are rescued by crossing the mice to c-myc overexpressing transgenic mice, 
identifying c-myc as an important mediator of Mel-18 cell cycle repression. Co-
transfection of a Mel-18 plasmid with a reporter plasmid containing the upstream 
promoter of c-myc leads to a decrease in expression of the reporter, further 
supporting the view that c-myc is a downstream target of Mel-18. This repression 
does not occur when deletion mutants of the c-myc reporter are used, suggesting that 
Mel-18 directly binds the c-myc promoter in mice.  
These results are supported by a thorough analysis of MEL-18 overexpression in 
human cells (Guo et al, 2007a). The authors found that overexpression of MEL-18 in 
human fibroblasts leads to inhibition of proliferation and cellular senescence, the 
opposite of the phenotype following Bmi-1 overexpression. The MEL-18 
overexpressing cells exhibit downregulation of c-myc expression, but strikingly also a 
decrease in Bmi-1 protein and mRNA expression, and upregulation of p16Ink4a. 
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Conversely, shRNA mediated MEL-18 knockdown results in upregulation of Bmi-1. 
Further analysis revealed that the BMI-1 promoter contains a binding site for c-myc, 
but not Mel-18, and use of ChIP showed binding of c-myc to this region. Reporter 
assays for BMI-1 promoter activity demonstrate that c-myc can positively regulate 
BMI-1 expression, and that Mel-18 negatively regulates BMI-1 via repression of c-
myc. However, addition of siRNAs against Mel-18 to murine bone marrow cells does 
not affect expression of Bmi-1 (Kajiume et al, 2009), suggesting that this effect is not 
universal.  
Further work in human breast cancer cells has demonstrated that the repression of 
BMI-1 by Mel-18 is accompanied by a reduction in Akt activity, as measured by levels 
of phosphorylated Akt, and also downregulation of cyclin D1, which can be activated 
by the Akt pathway (Guo et al, 2007b). Work by Lee et al, also in human breast 
cancer cells, has shown that Mel-18 mediated proliferation arrest occurs through 
downregulation of Cdk2 and Cdk4 activities (Lee et al, 2008). This is due to reductions 
in cyclin D1 expression and a phosphorylation mediated shift in the binding of p27 
from Cdk4 to Cdk2, where it acts to inhibit cell cycle expression. These changes are 
mediated through Akt signalling without alterations in expression of INK4A/ARF, 
demonstrating that Mel-18 can also regulate the cell cycle independently of 
INK4A/ARF. The results obtained using the breast cancer model were supported by 
work in gastric cancer cell lines, which again show that Mel-18 can decrease Bmi-1 
expression, leading to increased p16Ink4a levels, a reduction in phosphorylated Akt, 
and a reduced transformation phenotype (Zhang et al, 2010). There is also evidence 
from a yeast two hybrid screen that Mel-18 can bind directly to cyclin D2, and may 
block its activity, as Mel-18 knockdown causes increased proliferation in hamster 
ovarian cells (Chun et al, 2005). Overall, these studies suggest that Bmi-1 and Mel-18 
have opposing functions, with senescent cells showing high Mel-18 expression and 
proliferating cells high Bmi-1 expression. 
75 
 
Mel-18 as an oncogene 
Contrary to these results, a study by Wiederschain et al reports that overexpression of 
Bmi-1 or Mel-18 in Rat1 fibroblasts increases proliferation, with an enhanced 
phenotype observed when both are overexpressed together (Wiederschain et al, 
2007). Different human cancer cell lines show varying sensitivities to shRNA mediated 
knockdown of BMI-1 or MEL-18. Some lines, such as U2OS human osteosarcoma, 
show decreased proliferation and colony formation only when both proteins are 
knocked down in combination. Others, including DAOY medulloblastoma and MCF7 
breast cancer cells, are sensitive to individual knockdown of either BMI-1 or MEL-18, 
with a stronger phenotype observed when both are concurrently eliminated. 
Furthermore, downregulation of either BMI-1 or MEL-18 suppresses growth of human 
medulloblastoma xenografts in vivo, suggesting both have oncogenic functions. 
Transcriptional profiling also shows a significant overlap in genes regulated by Bmi-1 
and Mel-18 in medulloblastoma, supporting the idea of complementary functions for 
the two proteins in this context. It appears that Mel-18 can also repress transcription 
of p16Ink4a, as mouse embryonic fibroblasts overexpress p16Ink4a mRNA following Mel-
18 knockdown (Jacobs et al, 1999a). p16INK4A derepression without changes in BMI-1 
expression is seen following MEL-18 knockdown in human fibroblasts (Maertens et al, 
2009), with the authors also showing that Mel-18 binds to the INK4A/ARF locus with a 
similar pattern to Bmi-1. There is also evidence from tissue microarray 
immunolabelling that Mel-18 is upregulated in some types of human tumour samples 
compared to normal tissue, including in hepatocellular carcinoma (Sanchez-Beato et 
al, 2006). 
Summary of Mel-18/Bmi-1 relationship: 
In summary, the work described above suggests that the oncogenic capacity of Mel-
18 and functional redundancy with Bmi-1 can differ in different cellular contexts. The 
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high levels of homology between Bmi-1 and Mel-18 would appear to suggest similar 
functions, and this appears to be the case in some contexts, supported by the fact that 
the knockout mice display many overlapping phenotypes. However, other work has 
clearly demonstrated that Mel-18 can act as an inhibitor of proliferation in a variety of 
tumour cell types. It is possible that the Mel-18 and Bmi-1 function similarly in normal 
development, but contribute to cancer growth and survival differently. It seems there 
may be multiple methods by which Mel-18 can regulate the cell cycle and tumour 
progression; including by acting to repress transcription of genes such as Ink4a/Arf as 
part of a polycomb complex analogous to Bmi-1, and by downregulating Bmi-1 
expression via repression of c-myc. It is not clear which signalling pathways or cellular 
contexts causes these seemingly contradictory functions of Mel-18 to occur, although 
they may be dependent on the level of c-myc expression. Given that the tumour 
suppressor function of Mel-18 seems in part to be due repression of Bmi-1 via c-myc, 
it is possible that Mel-18 will be unable to perform this role in tumour cells with 
overexpressed c-myc. 
1.11. Other Bmi-1 homologues: 
In addition to Mel-18, two other Bmi-1 homologues have been characterised in 
mammals: Mel-18-and-Bmi-1-like Ring finger protein (MBLR) and Nervous System 
Polycomb 1 (Nspc1). MBLR acts a transcriptional repressor when transfected into 
cultured cells and can directly interact with Ring1b/Rnf2 (Akasaka et al, 2002). Nspc1 
expression was initially discovered in neural crest structures in mouse embryos 
(Nunes et al, 2001) and also has transcriptional repressive activity (Gong et al, 2005). 
It is able to repress p21 transcription in vivo (Gong et al, 2006) and can cooperate 
with Ezh2 and DNA methyltransferase 1 in repressing Hox genes via H2A 
ubiquitination (Wu et al, 2008). It is also part of the mammalian BCOR ubiquitinating 
complex (discussed in section 1.7.3), which may be an important source of PcG 
mediated ubiquitination. Any functional relationship or redundancy between these 
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proteins and Bmi-1 has not yet been established. At least two other proteins 
homologous to Bmi-1 exist; Pcgf3 and Pcgf5 (Sauvageau & Sauvageau, 2010), 
however these have not been characterised.  
1.12. Polycomb genes and the liver: 
1.12.1 Polycomb genes and liver stem cells: 
There has not been a large amount of investigation into the role of Bmi-1 and other 
polycomb genes in the liver, with functional studies limited primarily to in vitro work. A 
key study was carried out by Chiba et al, who examined the role of Bmi-1 in a putative 
stem/progenitor cell fraction derived from foetal murine liver (Chiba et al, 2007). These 
cells were sorted based on expression of five markers (c-kit-, CD29+, CD49f+, CD45-, 
Ter-119-), and previously showed increased enrichment of hepatic colony forming 
units in culture (H-CFU-C) (Suzuki et al, 2000). Overexpression of Bmi-1 in these cells 
results in larger colonies, and an increased number of albumin and CK7 double-
positive cells, which suggests bilineage potential. Conversely, shRNA mediated Bmi-1 
knockdown causes a four-fold decrease in the number of colonies. These effects do 
not occur in fractions which lack H-CFU-C capacity, suggesting a specific role for Bmi-
1 in liver stem cells. Putative stem cells transduced with Bmi-1 demonstrate increased 
colony growth in soft agar and form tumour nodules with combined CC-HCC 
characteristics in immunodeficient mice, suggesting that enhanced self-renewal due to 
Bmi-1 overexpression drives transformation. 
Later studies examined the role of Bmi-1 in hepatic stem cells using foetal liver cells 
positive for delta like protein (Dlk), a marker of early hepatic stem/progenitor cells. 
Chiba et al found a higher expression of Bmi-1 in Dlk+ cells than in Dlk- fractions, 
however were still able to isolate comparable numbers of Dlk+ cells from the foetal 
livers of Bmi-1 knockout mice, indicating that Bmi-1 is not required for development of 
the hepatic components of foetal liver (Chiba et al, 2010). In culture, loss of Bmi-1 has 
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a small effect on the size but not number of colonies formed from Dlk+ cells, with the 
effect significant after 14 days in culture. This effect appears to be smaller than in the 
authors’ previous work on shRNA mediated knockdown for Bmi-1 in a hepatic 
stem/progenitor cell fraction (Chiba et al, 2007). More dramatic is the reduction in the 
number of albumin/cytokeratin 7 (CK7) double positive cells in colonies obtained from 
Bmi-1 null Dlk+ cells. These double positive cells are thought to represent hepatic 
progenitor cells due to their ability to give rise to hepatocyte and cholangiocyte 
lineages. The proportion of Dlk+ cells in Bmi-1 deficient colonies also declines at a 
greater rate than in wild type colonies, suggesting a progressive loss of stem cells. 
The Bmi-1 null Dlk+ cells do however maintain some ability to give rise to albumin 
positive (hepatocyte) and CK7 positive (cholangiocyte) lineages, which suggests that 
Bmi-1 does play a role in the maintenance of stem cells in foetal liver, but is not 
critical. It is important to underline that these studies were carried out in cells from 
foetal liver. Bmi-1 knockout mice appear relatively normal at birth, and only exhibit 
stronger phenotypes in other organs postnatally (van der Lugt et al, 1994). It is 
possible that more dramatic effects may be observed in adult liver cells, in line with 
what is observed in the haematopoietic system (Park et al, 2003). However, Chiba et 
al also found that Bmi-1 knockout mice treated with a DDC diet show a reduction in 
oval cell numbers, but not a complete loss, suggesting Bmi-1 may not be critical in 
adult liver stem cells either.  
Bmi-1 knockout Dlk+ cells have increased expression of p16Ink4a and p19Arf, and ChIP 
assays in wild type cells have demonstrated that Bmi-1 directly binds the Ink4a/Arf 
locus in liver progenitor cells (Chiba et al, 2010). Ink4a/Arf null Dlk+ cells have both 
increased colony forming ability and increased numbers of bipotent albumin and CK7 
double positive cells compared to wild types. Dlk+ cells with concurrent knockdown of 
both Bmi-1 and Ink4a/Arf show small but significant decreases in colony sizes and 
numbers of bipotent cells compared to cells deficient in Ink4a/Arf alone. The colony 
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sizes and bipotent cell numbers appear much larger than in Bmi-1-/- cells, suggesting 
that deletion of Ink4a/Arf largely, but not completely, rescues the defects found in Bmi-
1 knockout Dlk+ cells. This suggests that the Ink4a/Arf locus is a major Bmi-1 target in 
liver progenitor cells. However, overexpression of Bmi-1 in Ink4a/Arf null Dlk+ cells 
increases colony size, but not number nor the frequency of bipotent cells. These Bmi-
1 overexpressing cells are also able to form tumours when transplanted into non-
obese diabetic/severe combined immunodeficiency (NOD/SCID) mice, unlike 
Ink4a/Arf null cells without transduction of Bmi-1. These results indicate that while 
Ink4a/Arf is a Bmi-1 target in liver progenitor cells, it is not the only one, and its 
derepression is not responsible for the tumourigenic potential of Bmi-1. The authors 
then performed gene expression analysis on Bmi-1 transduced Ink4a/Arf null cells to 
identify a number of other targets. Gene ontology analysis revealed that many 
downregulated genes are involved in metabolism or transport, and include genes 
involved in hepatocyte maturation, suggesting Bmi-1 suppresses hepatocyte 
maturation and differentiation. Many upregulated genes are associated with the 
maintenance of stemness features, migration and development. In particular, the 
authors found that Bmi-1 binds directly to the promoter of Sox17 (sex determining 
region Y-box 17), suggesting a novel target for Bmi-1 in hepatic stem cells. In support 
of this, overexpression of Sox17 impairs the colony forming ability of wild type Dlk+ 
cells, and transduction of Sox17 suppresses the tumourigenic capacity of Bmi-1 
overexpressing Ink4a/Arf null Dlk+ cells. Sox17 is a Wnt antagonist expressed in the 
early endoderm, suggesting activation of the Wnt pathway may mediate some effects 
of Bmi-1.  
Another paper from the same group looked at the effect of the PRC2 member Ezh2 
on Dlk+ hepatic stem/progenitor cells (Aoki et al, 2010). Ezh2 knockdown in Dlk+ cells 
causes a slight decrease in total colony numbers and a more pronounced drop in the 
number of large colonies. This phenotype is similar to that found in Bmi-1 knockdown 
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cells, but more dramatic. Ezh2 depletion also appears to induce a shift towards 
hepatocyte differentiation, as indicated by an increase in the number of albumin 
positive cells. As with Bmi-1, ChIP studies demonstrated that Ezh2 binds directly to 
the Ink4a/Arf locus. Knockdown of Ezh2 in Ink4a/Arf null Dlk+ cells partially abrogates 
the colony forming defects found in Ezh2 depleted cells, however this is smaller than 
for Bmi-1 knockdown. This suggests that other targets exist for Ezh2 in hepatic 
stem/progenitor cells. 
Overall, these data indicate that Bmi-1, along with Ezh2, has a role in regulating liver 
stem cells and tumourigenesis, similar to its function in several other tissues. This is 
achieved in part through repression of the Ink4a/Arf locus, however other targets also 
exist. The effect of Bmi-1 knockdown on hepatic stem/progenitor cells appears 
generally to be less dramatic than that found in other tissues, such as the 
haematopoietic system. 
1.12.2. Polycomb genes in HCC and hepatocytes: 
Bmi-1 overexpression was initially reported in HCC using cDNA microarray analysis to 
identify suitable markers for HCC diagnosis (Neo et al, 2004). Wang et al have since 
found high expression of Bmi-1 in 29.9% of HCC specimens examined using 
immunohistochemistry, with more positive staining in well differentiated tumours 
(Wang et al, 2008). They also observed that high Bmi-1 expression is a prognostic 
factor for poor overall survival. This seems unexpected, given that well differentiated 
tumours are generally thought to be less aggressive. However, they report 
cytoplasmic Bmi-1 staining, whereas the expectation based on other studies and the 
role of Bmi-1 as an epigenetic regulator is for nuclear localisation. Some of the data 
are backed up by western blotting, but it is not specified how many samples this was 
performed on. Nuclear Bmi-1 expression has been observed in several HCC cell lines 
(Effendi et al, 2010), and the authors also found overexpression in HCC clinical 
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samples, in particular in well differentiated and early HCC. This is correlated with 
overexpression of ATP binding cassette transporter B1 (ABCB1), a protein reported to 
be expressed on stem cells and cells displaying resistance to anti-cancer drugs, 
although this would appear to suggest a worse prognosis. Another study reports 
nuclear expression of both Bmi-1 and the PRC2 member Ezh2 in HCC and combined 
hepatocellular-cholangiocellular carcinoma (HC-CC) (Sasaki et al, 2008a). The 
authors found Bmi-1 staining in most cells within the CC component of HC-CC, and 
heterogeneous staining within HCC samples. The expression pattern of Ezh2 is 
similar, but appears in a smaller number of cells to Bmi-1. Both proteins show higher 
expression in poorly differentiated tumours, in contrast to the results of Effendi et al 
and Wang et al described previously. Expression of Bmi-1, and in particular Ezh2, is 
associated with both increased proliferation, as indicated by cyclin A expression, and 
vascular invasion. siRNA mediated knockdown of BMI-1 and EZH2 also leads to a 
decrease in proliferation of the HCC cell lines HepG2 and Huh7. A correlation 
between high Bmi-1 and high Ezh2 expression has also been reported independently 
(Yonemitsu et al, 2009). In this case, no correlation between expression of Bmi-1 or 
Ezh2 and survival or Ki67 expression was found. Another study has also found 
increased Ezh2 mRNA expression in HCC samples, correlating with increased portal 
vein invasion but not survival rate (Sudo et al, 2005). 
It has also been observed that Bmi-1 is preferentially expressed in side population 
(SP) cells from the HCC cell lines Huh7 and PLC/PRF/5 (Chiba et al, 2008). SP cells 
are characterised by the ability to efflux Hoechst 33342 dye, which is thought to 
represent stem cell behaviour, so are believed to represent minor populations with 
cancer stem cell ability. BMI-1 knockdown in both HCC cell lines decreases the 
number of SP cells, while stable overexpression of BMI-1 in Huh7 leads to an 
increased SP. BMI-1 transduced SP cells show increased tumourigenicity when 
xenografted into NOD/SCID mice, while BMI-1 knockdown has the opposite effect. 
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This appears to be via INK4A/ARF, as mRNA levels of the gene products increase in 
BMI-1 depleted PLC/PRF/5 cells. Another study has also implicated Bmi-1 as an 
oncogene in HCC independent of INK4A/ARF (Xu et al, 2009). The authors again 
found upregulation of BMI-1 mRNA in HCC samples, but did not see expression 
changes in INK4A/ARF. They also found that BMI-1 knockdown leads to growth 
inhibition of three human HCC cell lines (SK-Hep1, Huh7, Hep3B), with INK4A/ARF 
expression again unaffected in any of these lines. This result is not relevant in Huh7 
and SK-Hep1, which have either a deletion (SK-Hep1) or strong promoter methylation 
(Huh7) of INK4A/ARF, but appears to suggest Bmi-1 acts independently of 
INK4A/ARF in Hep3B. The authors then established a mouse model to examine the 
role of Bmi-1 in hepatocarcinogenesis in vivo. Transgenic mice stably overexpressing 
either Bmi-1 or RasV12 (an activated form of N-Ras) alone in hepatocytes did not 
show enhanced tumour development, however co-expression of both induced 
tumours in the majority of animals. This demonstrates that Bmi-1 and RasV12 can 
cooperate to form liver tumours in vivo. Surprisingly, mRNA expression of p16Ink4a and 
p19Arf was also increased in the tumours. This seems inconsistent with the 
established role of Bmi-1 in repressing the Ink4a/Arf locus and with the proliferative 
phenotype of the tumours. It is unclear why this would be the case, as there is no 
previous literature suggesting that Bmi-1 overexpression can lead to increased 
expression of Ink4a/Arf. The increase in Ink4a/Arf is not due to RasV12, as 
adenovirus mediated expression of RasV12 in hepatocytes has little effect on 
Ink4a/Arf levels. Examination of the effects of V5 tagged Bmi-1 overexpression in 
primary hepatocytes also revealed little effect on cell senescence, levels of p16Ink4a 
protein or p19Arf mRNA, although p16Ink4a mRNA was upregulated. The reasons for 
this were not established, although the expression level of V5 tagged Bmi-1 appears 
very low compared to endogenous Bmi-1, so it is unclear how much effect it would 
really have. In summary, this study suggests that the function of Bmi-1 in hepatocytes 
and liver tumourigenesis is independent of Ink4a/Arf repression. This does not appear 
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universal to all hepatic tumour cells, as Chiba et al report increased mRNA levels of 
p16INK4A and p14ARF in PLC/PRF/5 cells depleted of Bmi-1 (Chiba et al, 2008). 
1.12.3. Polycomb genes in CC and biliary diseases: 
Bmi-1 expression has been reported within normal cholangiocytes in both mouse and 
human livers. Examination of liver tissue from a Bmi-1-GFP-knock-in mouse showed 
strong GFP tagged Bmi-1 expression in the portal region, and possible weaker 
expression within the parenchyma (Hosen et al, 2007). Sasaki et al observed Bmi-1 
expression in biliary cells in human livers (Sasaki et al, 2006). They also noted that 
decreased Bmi-1 expression is associated with damaged bile ducts in human livers 
with primary biliary cirrhosis (PBC), an autoimmune disease leading to bile duct loss, 
cholestasis and liver failure. This appears to be related to oxidative stress, a 
candidate cause of senescence in PBC cells, as oxidative stress causes a decrease 
in Bmi-1 expression in mouse biliary epithelial cells (mBECs). Loss of Bmi-1 was also 
associated with an increase in expression of p16Ink4a in PBC cells in vivo, suggesting 
that Bmi-1 regulates p16Ink4a expression in cholangiocytes, in contrast to what has 
been reported in hepatocytes. In agreement with this, Bmi-1 knockdown in mBECs 
results in decreased proliferation, increased senescence and increased p16Ink4a 
expression. In contrast, knockdown of Ezh2 in mBECs slightly reduces nuclear Bmi-1 
expression, but has no effect on proliferation or senescence. 
Constant Bmi-1 expression has been noted in biliary epithelia of both non-neoplastic 
and neoplastic tissue, and invasive CC (Sasaki et al, 2008b). However, similar to 
HCCs, increasing Ezh2 expression characterises more invasive tumours, with 
expression progressively increasing from low grade biliary dysplasias up to invasive 
carcinomas. This correlates with a decrease in p16Ink4a protein levels and increase in 
promoter methylation, suggesting that the overexpression of Ezh2 contributes to a 
drop in p16Ink4a in multi-step carcinogenesis. This was supported by in vitro data 
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demonstrating that knockdown of EZH2 in CC cell lines decreases both p16INK4A 
promoter methylation and Ezh2 binding. The same group has later reported that BMI-
1 mRNA is upregulated in intrahepatic cholangiocarcinoma compared to non-tumour 
liver samples (Sasaki et al, 2009). This comparison seems unlikely to be particularly 
meaningful, as the non-tumour samples will consist mainly of hepatocytes, while CC is 
thought to be derived from biliary cells. There does not appear to be any conclusive 
data on whether Bmi-1 is overexpressed in CC cells when compared to normal 
cholangiocytes. The authors also observed that BMI-1 knockdown in CC cell lines 
leads to decreased colony formation, decreased proliferation and increased 
senescence, suggesting that Bmi-1 may have a function in CC progression. However, 
there are no data on whether the loss of Bmi-1 would also affect these parameters in 
normal cholangiocytes. Given that Bmi-1 is expressed in normal cholangiocytes, it 
seems logical that it would also be found in CC samples, and hence may not be 
specifically relevant to the progression of the disease. 
1.12.4. Summary - Bmi-1 in liver tumours: 
In conclusion, the data seem to suggest roles for Bmi-1 and Ezh2 in malignant 
progression of both HCC and CC, as their overexpression has been found in several 
liver cancers, and both tumour cell lines and putative stem cell fractions transfected 
with Bmi-1 have increased tumourigenicity when transplanted into mice. Bmi-1 
overexpression has been associated with poorly differentiated tumour cells, increased 
proliferation and invasion; although other work has marked Bmi-1 overexpression as a 
factor in well differentiated cells and the early stages of hepatocarcinogenesis, which 
appears contradictory. A general problem with many studies is that they are based 
almost entirely on immunohistochemical analysis. Inconsistencies in the staining 
pattern observed using commercially available anti-Bmi-1 antibodies have been 
reported in pancreatic tissue (Sangiorgi & Capecchi, 2009), making it difficult to 
assess how robust many of these studies are. The validity of Bmi-1 and Ezh2 
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overexpression as prognostic factors for long term survival is therefore not clear. 
Functional data in mice suggests overexpressed Bmi-1 alone cannot induce tumours 
in vivo, but that the presence of an activated form of Ras is also required. 
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1.13. Aims:  
There is growing acknowledgement of the importance of understanding the role of 
epigenetic regulators, as they can impact on multiple signalling pathways. From the 
evidence summarised in the introduction, it can be concluded that Bmi-1 has an 
important role in adult stem cell maintenance in vitro. Following on from this, defects 
of varying severity have been reported in virtually all murine Bmi-1 knockout tissues 
examined. Hepatic cell populations appear to exhibit impairments in proliferation and 
self-renewal in vitro following Bmi-1 depletion, along the same lines as those 
observed in cells derived from other organs. Despite this fact, there has been no 
detailed assessment of the function of Bmi-1 in hepatic tissue in vivo. Only in vivo 
models permit assessment of tissue development, disease progression and wound 
healing. The work detailed in this thesis aims to address this issue with regard to the 
following objectives: 
Objectives: To investigate the role of Bmi-1 in hepatic growth and function in vivo. 
1. To examine the evidence for Bmi-1 expression in rodent and human hepatic tissue, 
under homeostatic conditions and during perturbed tissue growth. 
2. To assess the effect of Bmi-1 deletion on postnatal murine liver structure, function 
and development in vivo. 
The results section of the thesis is presented in four chapters which address the 
above objectives as follows: 
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Objective 1: 
Chapter 3: Expression of Bmi-1 in normal liver and regenerating tissue 
As a precursor to functional in vivo studies, it was first considered important to 
ascertain the precise expression pattern of Bmi-1 in murine liver, as 
immunohistochemical studies thus far have predominantly examined Bmi-1 
expression in human hepatic tissue. Bmi-1 expression was also assessed in murine 
oval cells and human cirrhotic liver tissue, to investigate whether Bmi-1 is likely to 
have a function in hepatic repair, and in human tumour samples. 
Objective 2: 
Chapter 4: Liver structure and function in Bmi-1 knockout mice 
Bmi-1 deletion in mice leads to structural and functional defects in a variety of adult 
organs, including in neural tissue, the haematopoietic system, mammary glands and 
pancreatic islets. However, there has been no investigation into abnormalities in the 
livers of Bmi-1 knockout mice. This chapter examines liver structure and function in 
both newborn and adult Bmi-1 knockout mice. In particular, abnormalities in 
hepatocyte size in Bmi-1 knockout mice were indicative of impairment in the postnatal 
developmental process of polyploidisation. The expression of other Polycomb group 
genes in Bmi-1 knockout livers was also examined to determine whether functional 
redundancy could be a contributory or compensatory factor impacting the phenotype. 
Chapter 5: The effect of Bmi-1 deletion on the cell cycle in murine liver 
Bmi-1 depletion leads to proliferative defects in putative hepatic stem/progenitor cells 
populations and liver tumour cells in vitro. Impaired proliferation is also observed in 
other tissues from Bmi-1 knockout mice. This is due in part to the fact that the most 
well characterised targets of Bmi-1 are cell cycle inhibitors, in particular those 
encoded by the Ink4a/Arf locus. This chapter attempts to investigate the proliferative 
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ability of hepatocytes and cholangiocytes following Bmi-1 deletion in vivo, and to 
correlate this phenotype with expression changes of key cell cycle regulators.  
Chapter 6: Iron overload in Bmi-1 knockout mice 
Observations in hepatic tissue from Bmi-1 knockout mice suggested the possibility 
that the mice were suffering from iron overload, a phenotype which has not previously 
been described in any other Bmi-1 deficient cell populations in vitro or in vivo. This 
chapter provides preliminary analysis of this phenotype, and assesses expression 
changes in key members of iron regulatory pathways. 
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Chapter 2 
 
Materials and 
Methods 
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2. Materials and Methods: 
2.1. Mice and animal procedures: 
2.1.1. Generation of Bmi-1 knockout mice: 
Bmi-1 +/- mice generated on a FVB/N background (van der Lugt et al, 1994) (mice 
provided by Professor Silvia Marino) were intercrossed to generate knockout offspring 
(Bmi-1 -/-) together with wild type control littermates (Bmi-1 +/+). 
2.1.2. Animal husbandry and Home Office compliance: 
All mice were bred, maintained and experimentally treated in accordance with the 
Animal (Scientific Procedures Act) 1986. Mice were housed in pathogen free facilities 
located at Queen Mary, University of London that have been licensed by the Home 
Office. 
I have completed modules 1-4 of the Home Office training course and hold a personal 
license (PIL 70/24337). All animal procedures were performed under project licenses 
PPL 70/7166 and PPL 70/6452. 
2.1.3. BrdU injections: 
To be able to detect cells that were going through S-phase of the cell cycle, 5-bromo-
2-deoxyuridine (BrdU) (Sigma) was injected into the intraperitoneal cavity at 100 mg 
BrdU per kg body weight. Mice were killed by a Schedule 1 method and tissues were 
collected approximately 1 hour after BrdU injection. 
The BrdU stock (10 mg/ml) was made by dissolving BrdU powder in phosphate 
buffered saline (PBS) (Sigma, made by adding 1 PBS tablet per 200 ml distilled 
water), which was then sterile filtered, aliquoted and stored at -20oC.  
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2.2. Serum collection and analysis: 
2.2.1. Serum collection: 
Blood samples were collected by cardiac puncture using a 25G needle from Bmi-1 
wild type and knockout mice anaesthetised with carbon dioxide. All injections were 
performed by staff at the animal facility. The samples were placed immediately on ice 
in 1.5 ml microcentrifuge tubes and left for approximately 20 min to allow clotting to 
occur. The tubes were then centrifuged at 3000 rpm for 15 min, and the serum 
(supernatant) was removed and placed in a separate tube for storage. The samples 
were stored at -80oC until required for analysis. 
2.2.2. Serum analysis: 
Serum samples were sent to the Royal Veterinary College Diagnostic Laboratories for 
analysis of serum iron, albumin, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (AP) and total bilirubin. 
2.3. Genotyping of Bmi-1 knockout mice: 
2.3.1. Isolation and preparation of DNA: 
Small ear snips were taken from newly weaned mice litters at approximately 3 weeks 
of age. The samples were digested in 50 µl ear buffer (1 M Tris-HCl pH 8.0, 2 M NaCl, 
10% (wt/vol) sodium dodecyl sulphate (SDS), 10 mg/ml Proteinase K (Sigma)) at 
55°C for a total of 3 h, with vortexing after 1 h. The samples were diluted with 150 µl 
of distilled water, and heated at 95°C for 10 min to inactivate Proteinase K. Digested 
samples were stored at -20°C until required for polymerase chain reaction (PCR) 
analysis. 
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2.3.2. Genotyping PCR: 
Digested ear snip DNA samples were subjected to PCR analyses using the following 
reagents and conditions: 
2.3.2.1. Primers  
Genotyping primers were designed by Dr Danielle Lavery and purchased from Sigma-
Aldrich. Primer stocks were diluted to a final concentration of 5 µM in Nuclease Free 
Water (Ambion). 
Wild type forward: CTGCCAATGGCTCCAATGAAGAC 
Wild type reverse: CAAACTCCTAACACAACTTGGC 
Wild type expected product size: 323 bp 
Knockout forward: CTCTCGATGAGCTGATGCTTTG 
Knockout reverse: GAGTACTTCTACACAGCCATCG 
Knockout expected product size: 446 bp 
2.3.2.2. PCR reaction mix 
2 µl DNA sample 
2 µl Wild type forward and reverse primer mix (stock concentration 5 µM) 
2 µl Knockout forward and reverse primer mix (stock concentration 5 µM) 
2.5 µl 10x reaction buffer (supplied with enzyme) 
0.5 µl 10 mM dNTP mix (Invitrogen) 
1.25 µl magnesium chloride (supplied with enzyme) 
0.1 µl Platinum Pfx DNA Polymerase (Invitrogen) 
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14.65 µl ddH2O 
2.3.2.3. Cycling conditions 
1) 94°C, 4 min 
2) 94°C, 30 sec 
3) 60°C, 30 sec 
4) 72°C, 1 min 
5) To step 2, 39 times 
6) 4°C forever 
2.3.3. DNA gel electrophoresis: 
A 2% (wt/vol) agarose gel was prepared by dissolving agarose (Fisher) in 1x TAE 
buffer (diluted from 50x stock; 2 M Tris, 1 M Acetic acid, 0.05 M EDTA, pH 8.3) in a 
microwave. Ethidium bromide (Sigma, final concentration 0.4 µg/ml) was added to the 
gel mixture following cooling, and the gel was poured and left to set. A 10 µl sample of 
the completed PCR reaction was added to 1µl of TrackIt Cyan/Orange Loading Buffer 
(Invitrogen) diluted 50% with glycerol, and the samples were loaded onto the gel. 
Sizes of the amplified fragments were elucidated by including a lane loaded with 5 µl 
of 1 Kb Plus DNA ladder (Invitrogen). TAE (1x) was used as the running buffer for 
electrophoresis at 100 V. DNA fragments were visualised with an ultraviolet 
transilluminator (Uvitec), and the gel was photographed. 
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2.4. Histology and Immunohistochemistry: 
2.4.1. Tissue collection and processing: 
2.4.1.1. Human liver samples 
Paraffin-embedded human tumour-adjacent normal liver and cirrhotic liver tissue 
blocks were provided from a tissue bank maintained by my second supervisor 
Professor Malcolm Alison under the Human Tissues Act (Ethics: 06/Q0604/40). 
Paraffin-embedded human liver tissue arrays comprising a panel of hepatocellular 
carcinoma (Grades I,II,III), cholangiocarcinoma (Grades I,II,III), normal and tumour-
adjacent samples, and cirrhotic livers were purchased from US Biomax, Inc (Product 
codes LV242, T032, LV805, LV8011, BC03119). 
2.4.1.2. Mouse liver samples 
Freshly collected liver samples from Bmi-1 wild type and knockout mice killed using 
schedule 1 methods were immediately placed in neutral buffered formalin (NBF; 3.7% 
formaldehyde, 0.03 M sodium phosphate monobasic anhydrous, 0.05 M sodium 
phosphate dibasic anhydrous). Samples were fixed for a minimum of 24 h in NBF, and 
transferred to 70% ethanol for storage prior to tissue processing and paraffin 
embedding, which was carried out by the Blizard Institute Pathology Core Facility.  To 
assess Bmi-1 expression in murine oval cells, archival paraffin blocks containing livers 
collected from albumin-urokinase type plasminogen activator (AL-uPA) transgenic 
mice (Braun et al, 2003) were obtained from Eric Sandgren (University of Wisconsin-
Madison). Blocks from mice treated with dipin (Braun & Sandgren, 2000) were also 
obtained from Eric Sandgren. Tissue sections were subsequently cut from paraffin 
blocks at a depth of 5 µM onto Superfrost Plus microscope slides (VWR) for use in 
immunostaining procedures. Some section cutting was carried out by the Blizard 
Institute Pathology Core Facility. 
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2.4.2. Histological staining procedures: 
The following stains were carried out on paraffin-embedded liver sections from Bmi-1 
wild type and knockout mice by the Blizard Institute Pathology Core Facility: 
Haematoxylin and Eosin (H&E), Picro Sirius Red, Perls Prussian Blue.   
2.4.2.1. Cell counting in Bmi-1 wild type and knockout mouse sections 
The number of hepatocyte nuclei in a 40x microscope field was recorded for 5 
randomly photographed fields in each H&E stained mouse liver section. Results were 
averaged and assessed for significant differences using a 2-tailed Student’s t-test, 
with significance recognised at p<0.05. 
2.4.3. Primary antibodies used for immunohistochemistry: 
Antibody Antigen Species Company Concentration 
Bmi-1 Mouse/human 
Bmi-1 
Mouse 
monoclonal 
Millipore 05-
637 
1:100 
Mel-18 (H-115) Human/mouse 
Mel-18 
Rabbit 
polyclonal 
Santa Cruz  
SC-10744 
1:100 
Troma3 Mouse 
cytokeratin 19 
Rat 
monoclonal 
Cancer 
Research UK 
1:25 
BrdU BrdU Rat 
monoclonal 
Oxford Biotech 
0030 
1.100 
Ki67 Human/mouse 
Ki67 
Rabbit 
polyclonal 
Novacastra  
NCL-Ki67p 
1.1000 
p16 (M-156) Mouse p16Ink4a 
 
Rabbit 
polyclonal 
Santa Cruz 
SC-1207 
1.1000 
p21 Human/mouse 
p21 
Rabbit 
polyclonal 
Abcam ab7960 1.750 
Cyclin D1 
(9G2) 
Human/mouse 
cyclin D1 
Rabbit 
monoclonal 
Cell Signaling 
2978 
1.50 
Mouse IgG1 
isotype control 
n/a Mouse 
monoclonal 
Millipore 
CBL600 
Same as 
primary being 
tested 
Rabbit IgG 
isotype control 
n/a Rabbit 
monoclonal 
Cell Signaling 
3900 
Same as 
primary being 
tested 
A6 Mouse oval 
cells 
Mouse 
monoclonal 
Valentina 
Factor, NIH 
1.25 
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2.4.4. Immunoperoxidase methods: 
2.4.4.1. Deparaffination and rehydration 
Slides containing paraffin sections were dewaxed and rehydrated by incubation 
through a xylene and graded ethanol (EtOH) series: 
Dewaxing: 
Xylene 1 (5 min) 
Xylene 2 (5 min) 
100% EtOH 1 (3 min) 
100% EtOH 2 (3 min) 
90% EtOH (3 min) 
75% EtOH (3 min) 
Distilled water (3 min) 
2.4.4.2. Antigen retrieval 
Antigen unmasking was carried out by boiling slides in 10 mM tri-sodium citrate pH 
6.0 with 0.1% Tween20. The citrate solution was pre-heated in a microwave, after 
which the slide rack was added and the slides heated for 15-20 min. The slide 
container was left to cool for 20 min at room temperature, and the slides were then 
rinsed in phosphate buffered saline containing 0.1% Tween20 (PBST). Endogenous 
peroxidases were then quenched by incubation in 3% hydrogen peroxide in methanol 
for 10 min. 
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2.4.4.3. Single antigen labelling 
 Slides were blocked for 1 hour using blocking solutions from the mouse-on-mouse 
(M.O.M.) kit (Vector Laboratories) for anti-Bmi-1 antibody, or normal serum from the 
appropriate species-specific Vectastain Elite ABC kit (Vector Laboratories) for other 
antibodies, as per the manufacturer’s instructions. Primary antibodies were diluted in 
blocking solution and incubated overnight at 4oC, and slides were subsequently 
washed in PBST for 3x 5 min. Slides were then incubated with either Vector Universal 
ImmPress reagent (Vector Laboratories, for anti-Bmi-1 antibody only), or secondary 
antibody and subsequent ABC reagents supplied with the appropriate mouse, rabbit 
or rat Vectastain ABC kit (Vector Laboratories), diluted in PBS and normal serum as 
per the manufacturer’s instructions. Following further washes in PBST (3x 5 min), 
Diaminobenzidine (DAB) (Vector Laboratories) was used to visualise the specific 
binding. The DAB staining was timed and monitored under a microscope, and the 
slides were placed in distilled water when the staining intensity reached a suitable 
level. The same DAB incubation time was used for each slide examined. Slides were 
counterstained in haematoxylin for approximately 5 sec and placed in distilled water 
prior to mounting. 
2.4.4.4. Mounting and examination 
Dehydration was carried out by immersing slides through graded ethanol and xylene 
solutions, in the reverse of the procedure described in section 2.4.4.1, and slides were 
mounted in DPX mounting medium (Sigma). Slides were examined and photographed 
using a Leica DM 5000 B microscope with a Leica DFC 490 camera. Sections with 
species matched isotype control antibodies substituted for the primary antibody were 
also included in all staining procedures. No staining was observed on slides incubated 
without primary antibody or with isotype control antibody in all experiments included in 
this thesis. 
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2.4.4.5. Double labelling of Bmi-1 and CK19 
Double antigen labelling for Bmi-1 and CK19 was achieved by sequentially staining 
slides for the two antigens. The single staining procedure was performed for the anti-
Bmi-1 antibody as described in section 2.4.4.3. Prior to haematoxylin counterstaining, 
slides were subjected to a second antigen retrieval step (boiling in tri-sodium citrate 
pH 6.0 for 10 min) and blocked for 20 min using normal serum from the Vectastain 
Elite ABC-AP Rat IgG kit (Vector Laboratories). Sections were incubated with anti-
CK19 antibody diluted in blocking serum for 1 h at room temperature. Specific binding 
was visualised using the Vectastain ABC-AP kit, as per the manufacturer’s 
instructions, followed by incubation with BCIP/NBT substrate (Roche) diluted 1:50 in 
NTMT buffer (100 mM Tris-HCl pH8.5, 100 mM NaCl, 50 mM MgCl2, 0.1% Tween 20) 
until staining was observed. Slides were counterstained using nuclear fast red 
(Sigma), dehydrated and mounted in DPX. 
2.4.4.6. BrdU staining 
Paraffin sections from blocks obtained from BrdU injected mice were deparaffinised 
and hydrated through xylenes and graded alcohols, and placed in PBST for 5 min. 
The slides were then microwaved in tri-sodium citrate solution for 10 min as described 
in 3.4.4.2, cooled at room temperature for 20 min and rinsed in PBST.  Slides were 
then incubated in pre-warmed 4N HCl for 30 min at 37°C, and subsequently washed 
in borate buffer pH 7.6 (85% 0.2 M boric acid, 15% 0.05 M sodium diborate) for 3 min. 
Sections were digested in 0.01% trypsin (PAA) in 0.05 M Tris-HCl pH 7.5 for 3 min at 
37°C and washed in dH2O. Endogenous peroxidases were quenched using 3% 
hydrogen peroxide in methanol for 10 min, and slides were blocked in normal serum 
for 20 min. Sections were incubated in anti-BrdU primary antibody diluted in blocking 
serum overnight at 4°C, and specific binding was visualised using the Vectastain Elite 
ABC Rat IgG kit (Vector Laboratories) and DAB as per the manufacturer’s 
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instructions.  Slides were counterstained in haematoxylin for 5 sec, dehydrated 
through graded alcohols and mounted in DPX. 
2.4.5. Quantification of BrdU, Ki67 and Cyclin D1 positive nuclei: 
Slides containing mouse liver tissue from completed BrdU, Ki67 or Cyclin D1 staining 
procedures were labelled blindly, and 5 randomly selected images were captured per 
slide at 40x magnification. The numbers of nuclei positive for BrdU or Ki67 were 
recorded for each image, and the mean of all images was calculated to obtain an 
average per mouse. These were divided by the total number of hepatocyte nuclei per 
field for that mouse (calculated as described in section 2.4.2.1) to obtain a value for 
the percentage of cells expressing BrdU or Ki67. Significance was assessed at 
p<0.05 using a 2-tailed student’s t-test. 
2.4.6. Quantification of Bmi-1 expression in human tumour and cirrhotic microarrays: 
Human tissue microarrays containing cores from patients with liver pathologies (see 
section 2.4.1.1.) were stained for Bmi-1 as described in section 2.4.4.3. All individual 
cores were photographed, and the images were blindly labelled. All images were 
examined and scored as either positive or negative for Bmi-1, in both hepatocytes and 
cholangiocytes if applicable. Significant differences between wild type and 
tumour/cirrhotic samples were assessed using a chi-squared test 
(http://people.ku.edu/~preacher/chisq/chisq.htm), with significance recognised at 
p<0.05. 
2.4.7. Detection of mitochondrial mutations: 
2.4.7.1. Frozen sections 
Freshly excised mouse livers were embedded in O.C.T. (Fisher) on dry ice. Frozen 
sections (thickness 10 µm) were cut using an OTF5000 cryostat (Bright Instrument Co 
Ltd) and stored at -80°C until required. 
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2.4.7.2. Solutions for COX and SDH staining 
All solutions for cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) 
histochemistry were prepared in 0.2M phosphate buffer pH 7.0:  
19.5 ml 0.2 M Sodium phosphate dibasic (Sigma) 
30.5 ml 0.2 M Sodium phosphate monobasic (Sigma) 
Stored at -20°C 
500 µM cytochrome c: 
0.031 g cytochrome c (Sigma) in 5 ml phosphate buffer 
Stored at -20°C in 250 µl aliquots 
5 µM diaminobenzidine (DAB): 
0.0288 g DAB (Sigma) in 16 ml phosphate buffer 
Stored at -20°C in 800 µl aliquots 
1.875 mM Nitro blue tetrazolium (NBT): 
0.0245 g NBT (Sigma) in 16 ml phosphate buffer 
Stored at -20°C in 800 µl aliquots 
1.3 M Sodium succinate: 
2.11 g sodium succinate (Sigma) in 6 ml phosphate buffer 
Stored at -20°C in 300 µl aliquots 
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2 mM Phenazine methosulphate (PMS): 
1.84 mg PMS (Sigma) in 3 ml phosphate buffer 
Stored at -20°C in 150 µl aliquots, kept away from light 
2.4.7.3. COX/SDH Staining Protocol 
Frozen liver sections were removed from a -80°C freezer and thawed at room 
temperature for approximately 30 min. COX staining solution was prepared by adding 
200 µl of cytochrome c solution to 800 µl of DAB solution. Slides were incubated in 
COX staining solution for 15 min at 37°C. Sections were washed twice in PBST, and 
incubated in SDH staining solution (800 µl NBT solution, 100 µl sodium succinate 
solution, 100 µl PMS solution) for approximately 30 min at 37°C. The staining intensity 
was periodically monitored under a microscope to ensure the SDH counterstain did 
not mask the COX staining. Slides were then washed twice in PBS, dehydrated 
through graded alcohols (described in section 2.4.4.4.) and mounted in DPX. 
2.5. Measurement of hepatocyte size parameters using touch preparations: 
2.5.1. Touch preparations: 
Bmi-1 wild type and knockout mice were killed using schedule 1 methods, and the 
livers excised. Small pieces of liver (approx 5-10 mm wide) were placed in a solution 
of 5 mg collagenase type I (Lorne Laboratories) dissolved in 10 ml distilled water, and 
incubated at 37°C for 20 min. The liver pieces were then removed from the 
collagenase and placed into a petri dish. A scalpel was used to cut through a liver 
segment, and the freshly cut face was immediately touched firmly against a Superfrost 
Plus microscope slide (VWR). The touching procedure was repeated multiple times 
with the same piece to fill the slide with cell preparations. The slide was then air dried 
for approximately 5 sec, and placed straight into a fixative solution of 95% ethanol for 
15 min. The whole procedure was repeated for other pieces on fresh slides to obtain 
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multiple slides from each mouse. The slides were transferred to PBST prior to 
staining. 
2.5.2. Staining of touch preparations: 
The slides were incubated in methylene blue solution (0.4 g methylene blue (Sigma) 
in 100 ml of 50% methanol) for 5 min and then rinsed 3 times in distilled water. The 
slides were placed into haematoxylin solution for 1 min, and then dehydrated through 
graded ethanols and xylenes prior to mounting in DPX. 
2.5.3. Measurement of cell ploidy by analysis of touch preparation images: 
2.5.3.1. Photography and image preparation 
The touch preparation slides were photographed using a Leica DM 5000 B 
microscope with a Leica DFC 490 camera at 400x magnification and 1088x816 
resolution. Images were taken at the same time with the same exposure settings. 
Images were taken at random from areas of the slide where the cells had adhered 
adequately, resulting in a minimum of 20 images per mouse across multiple slides. 
The images were all randomly labelled with a numbered code to allow for blind 
analysis. 
2.5.3.2. Counting of binucleate cells 
The number of binucleate and mononucleate cells in the blindly labelled images were 
counted manually using the cell counter feature of ImageJ software, a public domain, 
Java based imaging program developed at the National Institutes of Health 
(http://rsb.info.nih.gov/ij/index.html). The percentage of binucleate cells was calculated 
by dividing the binucleate count by the total cell number count, and the results were 
averaged for Bmi-1 wild type and knockout mice, with significance assessed using a 
2-tailed student’s t-test. 
103 
 
2.5.3.3. Analysis of hepatocyte nuclear size 
The average nuclear size of the blindly labelled touch preparation images was 
analysed using ImageJ software. All images were analysed using consistent 
parameters and threshold values. The image was converted to 8-bit greyscale, and an 
appropriate threshold value used to highlight the nuclei to be studied. The nucleus 
counter feature was then used to obtain output data on the number of selected nuclei 
and their average area. This measurement was repeated twice for each image, with 
two different values (75 and 100 pixels) for the minimum particle size to be included in 
the analysis. Threshold values were defined in pixels, and the results subsequently 
converted to µm2. This procedure was also repeated with a minimum particle size 
threshold of 44 µm2 (425 pixels) to count the number of large hepatocyte nuclei 
present in the touch preparation. The nuclear area measurements from the blindly 
labelled images were matched with the actual image information, and an average 
area calculated for Bmi-1 wild type and knockout mice. Significance was assessed 
using a 2-tailed student’s t-test.  
2.5.3.4. Measurement of hepatocyte cell size 
Hepatocyte cell sizes were quantified from randomly selected, blindly labelled touch 
prep images using ImageJ software. A box measuring 500 by 500 pixels was placed 
in the top left corner of the image. All hepatocytes which completely fell within this 
area were manually outlined using the Freehand Selection tool, and the Multi Measure 
tool was used to obtain area measurements for each selected cell. A total of 200 
individual hepatocytes each were measured from Bmi-1 wild type and knockout mice, 
across a minimum of 10 different images. The area measurements were averaged, 
and significance assessed using a 2-tailed student’s t-test at p<0.05. 
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2.6. Analysis of average hepatocyte centromere counts 
2.6.1. Pan-centromeric in situ hybridisation 
Hepatocyte centromere numbers were estimated using pan-centromeric in situ 
hybridisation on paraffin embedded sections. This procedure was carried out with 
assistance from Rosemary Jeffery, Cancer Research UK. Sections were 
deparaffinised in xylene (2 x 5 min), and endogenous peroxidases were then blocked 
in 0.18% hydrogen peroxide (2.4 ml in 400 ml absolute alcohol), prior to dehydration 
in graded alcohols to water. The sections were permeabilised in 1 M sodium 
thiocyante (Sigma) for 10 min at 80oC, and washed 2x in PBS for 10 min. The 
sections were now digested in 0.4% pepsin (Sigma) in 0.1M hydrochloric acid for 15 
min at 37oC, the reaction was stopped in double concentrated PBS with 0.2% glycine 
for 5 min and the slides washed in PBS for 5 min. The sections were fixed in freshly 
prepared 4% paraformaldehyde for 2 min, washed 3x in PBS, and dehydrated through 
graded alcohols. 15 µl of mouse pan-centromeric probe mixture (Cambio), which had 
been pre-warmed at 37oC, was added to the air dried sections. The sections were 
then covered with a glass coverslip, and sealed with rubber cement. The slides were 
denatured on a metal plate in a 60oC oven for 10 min, and placed overnight in a moist 
chamber at 37oC. The coverslips were now removed, and slides washed in 0.5x 
standard sodium citrate (SSC; diluted from 20x solution containing 87.6 g sodium 
chloride, 44.1 g sodium citrate in 500 ml distilled water, pH 7.4) for 5 min at 37oC, 
followed by PBS washes. Anti-fluorescein-POD antibody fragments (Roche) were 
applied for 45 min (diluted 1.150 in PBS), and the slides washed 3x in PBS. Staining 
was visualised using DAB (Vector Laboratories). The slides were then washed in 
PBS, counterstained in haematoxylin, dehydrated through graded alcohols and 
xylenes, and mounted in DPX. 
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2.6.2. Quantification of centromere numbers 
Centromere numbers were quantified using images of randomly selected 400x 
microscope fields of slides exhibiting successful pan-centromeric in situ labelling. The 
number of visible centromeres in hepatocyte nuclei falling within the selected field 
were counted. Any nuclei which were not clearly identifiable as individual hepatocyte 
nuclei were not included. A total of 645 hepatocytes across four mice of each 
genotype were counted. 
2.7. Gene expression analysis in mouse liver tissue:  
2.7.1. Sample collection: 
Small pieces of freshly collected mouse liver samples (approximately 5 mm diameter) 
were immediately submerged in 6 ml of RNAlater (Qiagen). Samples were stored for a 
maximum of 3 days at 4°C until RNA extraction, and any unused were moved to -
20°C for long term storage. 
2.7.2. RNA extraction: 
RNA was extracted using the RNeasy Mini kit (Qiagen). All centrifugation steps in this 
procedure were carried out at 13000 rpm at room temperature. Samples collected in 
3.6.1 were homogenised in 600 µl RLT buffer with added β-mercaptoethanol using a 
glass homogeniser, and centrifuged for 2 min in a Qiashredder column (Qiagen). The 
resulting lysate was mixed with an equal volume of 70% ethanol, and 700 µl of the 
mixture was transferred to an RNeasy spin column and centrifuged at 10000 rpm for 
15 seconds at room temperature. On column DNase digestion was now performed 
using an RNase-Free DNase Set (Qiagen). The column was washed by adding 350 µl 
of buffer RW1 and centrifuging for 15 seconds. Flowthrough material was discarded 
after each centrifugation step. The spin column membrane was now incubated with 
DNase I solution (10 µl DNase I in 70 µl RDD buffer) for 15 min at room temperature, 
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and then centrifuged for 15 seconds following addition of 350 µl of buffer RW1.  The 
spin column was now washed twice by adding 500 µl of buffer RPE and centrifuging 
for 15 seconds (1st wash) and 2 min (2nd wash), and the empty tube centrifuged again 
for 1 min. RNA was eluted from the column into a 1.5 ml microcentrifuge tube by 
adding 50 µl of RNase free water and centrifuging for 1 min. The RNA concentration 
was determined using a NanoDrop® Spectrophotometer (Thermo Scientific), using 
distilled water as the blank control. 
2.7.3. cDNA synthesis: 
First-strand cDNA was synthesised using SuperScript RT III First Strand Synthesis 
System (Invitrogen). 1 µg of RNA extracted in 3.6.2 was added to a nuclease free 
microcentrifuge tube along with 125 ng of random primer mix, 1 µl of 10 mM dNTP 
mix and Nuclease Free Water (Ambion) up to a total volume of 13 µl. The mixture was 
heated for 5 min at 65oC and incubated on ice for 5 min. To the mixture were added 4 
µl 5x First Strand Buffer, 1 µl dithiothreitol (DTT), 1 µl RNase Out Recombinant 
RNase Inhibitor (Invitrogen) and 1 µl Superscript III RT. Appropriate control reactions 
without Superscript III RT were also included. The solution was gently mixed by 
pipetting, and incubated at 50oC for 45 min. The reaction was inactivated by heating 
at 70oC for 15 min. The cDNA obtained was diluted 1:10 in nuclease free water prior 
to PCR/Q-PCR analysis. 
2.7.4. Polymerase chain reaction (PCR): 
Qualitative expression of selected genes was identified using the following primers 
and reaction: 
2.7.4.1. Table of primers 
Primers were designed by myself and Dr Danielle Lavery.  
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Gene Target  Forward (F) and Reverse (R) Primer 
Sequence 
Annealing 
Temperature 
Size of 
amplified 
fragment 
(bp) 
Mouse β-actin F: GAGAAGCTGTGCTATGTTGCTC 
R: CCATACCCAAGAAGGAAGGCTG 
62°C 169 
Mouse 
Glyceraldehyde 3-
phosphate 
Dehydrogenase 
(Gapdh) 
F: GGTCGGTGTGAACGGATTTGG 
R: GCCGTGGGTAGAGTCATACTGGAAC 
62°C 148 
Mouse Ribosomal 
18S 
F: CGGCGGCTTTGGTGACTCTAGAT 
R: TAGGCACGGCGACTACCATCGA 
62°C 112 
Mouse Eukaryotic 
Elongation Factor 2 
(eEf2) 
F: GCCTTTGGTAGAGTGTTCTCTG 
R: CCATCATCAGAATGGTTCTCTG 
62°C 130 
Mouse Ribosomal 
Protein L27 (Rpl27) 
F: GAACATTGACGATGGCACCTCG 
R: GGACTTGATCTTGGATCGCTTG 
65°C 130 
Mouse β-
glucuronidase (Gus) 
F: CAAGATACCGACATGAGAGTGG 
R: CACTCTGGACCAGCTTGCTAATG 
62°C 142 
Mouse Bmi-1 F: GTACTTCATTGATGCCACTACC 
R: CTTGCTGGTCTCCAAGTAACG 
60°C 143 
Mouse Mel-18 F: GAGAGGAGAAGAAGAACCTCAC 
R: GATCTCCACCTTGTACTTGCTG 
60°C 155 
Mouse Mblr F: GAGATGAGCCACTTCTCTCTGC 
R: GTGGTTGCATCTATCAGGTAAC 
58°C 140 
Mouse Nspc1 F: GTTGTATCGTGAAGTACCTGC 
R: CACTGTCTTGCAAGCCTGGCAC 
58°C 143 
Mouse Cbx2 F: CACTCAGGAGTTGAGCCTTCAG 
R: CGTTGGTCATGTTTGCTCCTGTG 
62°C 167 
Mouse Cbx4 F: CTGGATGAACCCATAGACTTGC 
R: GAACTCACTCAAGGGCTCCACTG 
62°C 180 
Mouse Cbx7 F: GAAGTTACCGTGACTGACATCAC 
R: CTCCACGGATCAGCCTCCAAG 
60°C 160 
Mouse Cbx8 F: CTGGTCGCAGAAGTACAGCACG 
R: GAGTCACTTCTGAATTCATAG 
55°C 192 
Mouse Edr1 F: CTTCAGGATTGACTGGTGGAAGC 
R: CACTCCCATCTGCTTCTGCCTTC 
65°C 147 
Mouse Edr2 F: CAGTGCTCTACCACGCATGTCC 
R: GATCACAGCTGAGGTGTGCTGG 
65°C 144 
Mouse Edr3 F: CAACGAGACCCTTCTCCAGAGAG 
R: GAATGAAGAGGAATCTGCTGATG 
62°C 167 
Mouse Scmh1 F: CATCTGATGTGAGCACTGAGAAG 
R: CTGACTTGGATGGGGTAGAGGTG 
62°C 163 
Mouse Ring1 F: GAGAAGTTCTGGAAGGTGTCCAG 
R: CTCCTTTGTCCTCTTGCTGTCTG 
65°C 180 
Mouse Rnf2 F: CCATAGACGCTCTAAGTTGTTGC 
R: CTGTTCTACTCAGCAAGTTCCAG 
60°C 179 
Mouse Ezh1 F: CTGCTCCAATGCATCAGCTTC 
R: GTTAGCCTCTGAAGAACTGGAG 
60°C 100 
Mouse Ezh2 F: CTTGTGGACCACAGTGTTACCAG 
R: CTTTGACTCCAGCACACTGATG 
62°C 153 
Mouse Suz12 F: GAGAGCAAGAATCTCATAGCTTG 
R: GCAGGACTTCCAGGGTAACAG 
60°C 126 
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Mouse Eed F: CAATCAGGTTGGCAAACTGTATG 
R: CGCAGACAGCTATGAGGATGC 
65°C 149 
Mouse p16
Ink4a F: CAGACCGACGGGCATAGCTTCAG 
R: CACATGCTAGACACGCTAGCATC 
65°C 145 
Mouse p19
Arf F: CTTCCTGGACACGCTGGTGGTGC 
R: GAACGCAAATATCGCACGATGTC 
65°C 129 
Mouse p21 F: CAGATCCACAGCGATATCCAGAC 
R: CGCAACTGCTCACTGTCCACG 
65°C 131 
Mouse c-myc F: CAGCAGCGACTCTGAAGAAGAG 
R: GCACCTCTTGAGGACCAGTGG 
65°C 157 
Mouse Hepcidin anti-
microbial peptide 
(Hamp) 
F: GCAGAACAGAAGGCATGATGGC 
R: GTGCAAAGGCTGCAGCTCTGTAG 
65°C 137 
Mouse Hfe F: CCACAGTAAGGTCACGAAGTTGG 
R: GCAGAATTCCAGGTGATCTTGC 
65°C 142 
Mouse Ferroportin 
(Fpn) 
F: GACCAAGGCAAGAGATCAAACC 
R: GCTGTTTCCATAGAGTTCCACC 
62°C 169 
Mouse Transferrin 
Receptor 1 (Tfr1) 
F: CTAGGAACTGGTGATCCATACAC 
R: GTTCCATCTAGCAGGACAGCTTC 
60°C 168 
Mouse Transferrin 
Receptor 2 (Tfr2) 
F: GTCAGCAATGGGTTCAGACCTC 
R: GTCCAGGCTCACGTACACAACAG 
65°C 144 
Mouse Bone 
Morphogenetic 
Protein 6 (Bmp6) 
F: GTGGAGTACGACAAGGAGTTC 
R: CACCACACAGTCCTTGTAGAC 
58°C 129 
Mouse Insulin growth 
factor binding protein 
2 (Igfbp2) 
F: CCACAGCAGGTTGCAGACAGTG 
R: GCTCCTTCATGCCTGACTTGAG 
65°C 136 
 
2.7.4.2. PCR reaction mix 
2 µl DNA sample 
2 µl forward and reverse primer mix (5 µM stock concentration) 
2.5 µl 10x reaction buffer (supplied with enzyme) 
0.5 µl 10 mM dNTPs (Invitrogen) 
1.25 µl magnesium chloride (supplied with enzyme) 
0.1 µl Platinum Taq DNA polymerase (Invitrogen) 
16.65 µl ddH2O 
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2.7.4.3. Cycling conditions 
1) 94°C, 4 min 
2) 94°C, 30 sec 
3) Annealing temperature, 30 sec 
4) 72°C, 1 min 
5) To step 2, 39 times 
6) 4°C forever 
2.7.4.4. Gel electrophoresis 
See section 2.3.3 
2.7.5. Quantitative PCR (Q- PCR): 
2.7.5.1. Generation of standards 
Primers were tested by qualitative PCR as described in 2.7.4, and products were 
purified using a QIAquick PCR purification kit (Qiagen). 10 µl of PCR product was 
mixed with 50 µl of buffer PB, and placed in a QIAquick spin column. The column was 
centrifuged at 13000 rpm for 60 seconds at room temperature, and the flowthrough 
discarded. The spin column was washed by adding 750 µl of buffer PE and 
centrifuging at 13000 rpm for 2 min, followed by an additional 1 min centrifugation of 
the empty tube. DNA was eluted from the column into a microcentrifuge tube by 
adding 50 µl of buffer EB, and centrifuging for 1 min. The concentration of purified 
products was quantified using a NanoDrop® Spectrophotometer, and the samples 
were subsequently diluted 1:2 with Nuclease Free Water (Ambion). The absolute 
concentration of each standard was calculated by dividing the molecular weight of the 
amplicon (OligoCalc: http://www.basic.northwestern.edu/biotools/oligocalc.html) by 
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Avogadro’s number, and dividing this number by the concentration of the original 
standard to obtain a value expressed as molecules (transcripts) of gene of interest per 
µl. Prior to each Q-PCR experiment, original standards were serially diluted 1:5 to 
obtain twelve standards of decreasing concentration. The last nine of these dilutions 
were included in the Q-PCR experiment to allow creation of a standard curve. 
2.7.5.2. Q-PCR reaction 
Q-PCR reactions were set up in 96 well Q-PCR plates (Applied Biosystems) using the 
following reaction mix with 2 µl of cDNA sample, and data was collected and analysed 
using the AB7500 Fast Real Time PCR System (Applied Biosystems): 
8.125 µl ddH2O 
2 µl reverse and forward primer mix (5 µM stock concentrations) 
0.375 µl ROX dye, diluted 1.500 (Stratagene, supplied with SYBR green) 
12.5 µl Brilliant II SYBR green master mix (Stratagene)  
2.7.5.3. Analysis of results and normalisation 
A standard curve was plotted by AB7500 System Software using the standards 
generated in section 2.7.5.1. Absolute expression values of unknown samples were 
quantified using this graph. All reactions were run in triplicate, and the mean of each 
triplicate was used as the expression value for each gene measured. Two programs; 
geNorm (http://medgen.ugent.be/~jvdesomp/genorm/) (Vandesompele et al, 2002) 
and Normfinder (http://www.mdl.dk/publicationsnormfinder.htm) (Andersen et al, 
2004), were used to validate the stability of four candidate reference genes (β-actin, 
Gapdh, eEf2 and Gus). Subsequently, absolute expression values for genes of 
interest were normalised by dividing by the absolute eEf2 expression (see appendix 
section A2 for details of reference gene selection). A two-tailed student’s t-test was 
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used to assess significant differences between wild type and knockout mice at each 
time point, with significance recognised when p<0.05.  
2.8. Western blotting: 
2.8.1. Sample collection: 
Whole livers were excised from Bmi-1 wild type and knockout mice, and a small piece 
(approximate diameter 0.5 ml) was placed into a glass homogeniser containing 400 µl 
of RIPA buffer (0.75 ml 2M NaCl, 0.5 ml 10% sodium deoxycholate solution, 0.1 ml 
10% SDS solution, 0.5 ml 1M Tris pH 8.0, 8.05 ml ddH2O, 0.1 ml Triton X-100, 1 
Protease Inhibitor Cocktail Tablet (Roche). The sample was homogenised until 
liquefied, and placed into a cooled 1.5 ml microcentrifuge tube on ice. The tubes were 
then centrifuged at 13000 rpm for 25 min at 4°C, and the supernatant was transferred 
to a fresh tube. Samples were stored at -80°C prior to usage 
2.8.2. Quantification of protein concentration: 
Aliquots of the protein samples were diluted 1:10 in RIPA buffer prior to quantification 
to ensure the concentrations were within the working range of the assay kit. Protein 
concentrations were measured using the colourimetric Bio-Rad DC Protein assay as 
per the manufacturer’s instructions. Protein standards of 1.5, 1, 0.75, 0.5, 0.25 and 0 
mg/ml were prepared by diluting bovine serum albumin (BSA, Sigma) in RIPA buffer. 
5 µl of each standard and sample was added to a 96 well microtitre plate, followed by 
25 µl of assay reagent A’ and 200 µl of assay reagent B. The plate was left at room 
temperature for 15 min, and absorbance was read at 650 nm using a Wallac Victor2 
1420 Multilabel Counter plate reader (Perkin Elmer). 
2.8.3. SDS Polyacrylamide gel electrophoresis (PAGE): 
SDS-PAGE and subsequent western blotting was carried out using the Bio-Rad Mini 
Trans-Blot Cell system and accessories. 
112 
 
2.8.3.1. Preparation of gels 
Resolving gel mixtures were prepared as follows: 
10% gel: 
4.0 ml ddH2O 
3.3 ml 30% Protogel (Fisher) 
2.5 ml 1.5 M Tris pH 8.8 
0.1 ml 10% SDS 
0.1 ml 10% ammonium persulphate (APS) solution (Sigma) 
4 µl Tetramethylethylenediamine (TEMED) (Sigma) 
15% gel (used only for p16Ink4a and p21 antibodies): 
2.3 ml ddH2O 
5 ml 30% Protogel 
2.5 ml 1.5 M Tris pH 8.8 
0.1 ml 10% SDS 
0.1 ml 10% APS 
4 µl TEMED 
The resolving gel solution was poured into the gel casting apparatus, and 1 ml of 
isopropanol was added on top. Once the gel solidified, the isopropanol was poured off 
and the gel rinsed in ddH2O. 
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Stacking gel mix: 
2.1 ml ddH2O 
0.5 ml 30% Protogel 
0.38 ml 0.5 M Tris pH 6.8 
0.03 ml 10% SDS 
0.03 ml 10% APS 
3 µl TEMED 
The stacking gel mixture was poured on top of the resolving gel, and a plastic comb 
inserted into the solution. Once solidified, the gel used immediately or stored wrapped 
in wet tissue paper and cling film at 4°C until required for SDS-PAGE. 
2.8.3.2. Preparation of gel apparatus 
The comb was removed from the polymerised gel, and the gel assembled with the 
electrophoresis unit. The gel tank was filled with 1x running buffer (25 mM Tris, 192 
mM glycine, 0.1% (w/v) SDS), made by diluting 100 ml of 10x stock solution (250 mM 
Tris, 1920 mM glycine, 1 l dH2O) in 900 ml of dH2O and adding 10 ml of 10% SDS. 
2.8.3.3. Preparation of protein samples 
50 µg of protein sample as added to a 1.5 ml microcentrifuge tube, using the protein 
concentrations measured in section 2.8.2 to calculate the volume of sample required. 
The samples were made up to 15 µl by adding RIPA buffer, and then 3 µl of 6x 
Laemmli buffer (6% (w/v) SDS, 180 mM Tris-HCl pH 6.8, 15% β-mercaptoethanol, 
60% glycerol, 0.02 % bromophenol blue)(Sigma) was added to each sample. The 
samples were boiled at 95°C for 5 min prior to loading. A sample containing no protein 
was also included as a negative control. 
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2.8.3.4. Gel electrophoresis 
The protein samples were loaded into the gel along with 5 µl of Precision Plus Protein 
Standards (Bio-Rad). The gel was run at room temperature at 80 V until the proteins 
had reached the resolving gel, and then increased to 100 V. The electrophoresis was 
stopped when the marker band reached the bottom of the gel. 
2.8.4. Coomassie staining: 
Following electrophoresis, the gel apparatus was disassembled and the stacking gel 
removed using a scalpel. The gel was immediately rinsed in Tris buffered saline-
Tween buffer (TBST; 50 mM Tris, 150 mM NaCl, 0.1% Tween-20), transferred to 
Coomassie solution (0.25 g Coomassie powder (Fisher), 10 ml glacial acetic acid, 45 
ml methanol, 45 ml dH2O) and incubated overnight with agitation. The gel was 
destained in multiple changes of destain solution (10 ml glacial acetic acid, 45 ml 
methanol, 45 ml dH2O) until the protein bands were clearly visible (approximately 5 
hours). The gel was dried onto filter paper using a Model 583 Gel Dryer (Bio-Rad). 
The stained gel was used to adjust the volume of protein sample loaded for future 
experiments to ensure equal loading of each sample. 
2.8.5. Western blotting: 
2.8.5.1. Transfer 
Transfer buffer was prepared by mixing 100 ml of 10x running buffer solution (section 
2.8.3.2) with 200 ml methanol and 700 ml dH2O, and stored at 4°C until required. 
Following gel electrophoresis, the apparatus was disassembled, excess gel cut off, 
and the gel placed in 1x transfer buffer along with sponges and blotting paper. 
Polyvinylidene fluoride (PVDF) membrane (Bio-Rad) was cut to size and immersed 
briefly in 100% methanol, before being soaked in 1x transfer buffer for 10 min. The gel 
transfer unit was assembled as per the manufacturer’s instructions, and the tank filled 
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with 1x transfer buffer. The sponges, blotting paper, gel and PVDF membrane were 
placed into the apparatus in the correct orientation. Transfer was carried out at 110 V 
for 1 h at 4°C. The membrane was washed in TBST prior to the blotting procedure. 
For initial test blots, the quality of transfer was assessed by staining the membrane 
with Ponceau solution (0.2% (w/v) Ponceau S (Sigma) in 3% trichloroacetic acid) and 
then rinsing in dH2O. 
2.8.5.2. Blotting 
The membrane was incubated in blocking solution (5% w/v BSA, 5% (w/v) powdered 
milk in TBST) for a minimum of 1 h with agitation (N.B. BSA was not included in block 
for anti-Erk1/2 antibody) and subsequently incubated overnight at 4°C in primary 
antibody diluted in blocking solution. The membrane was washed 4x in TBST for a 
minimum total time of 1 h, and incubated in blocking solution containing the 
appropriate mouse, rabbit or goat horse radish peroxidase (HRP) conjugated 
secondary antibody (Dako) for 1 h at room temperature. The membrane was washed 
in TBST for a minimum of 3x 10 min prior to detection. 
2.8.5.3. Detection 
ECL chemiluminescent reagents: 
Solution A: 
2ml 250 mM luminal (Sigma) 
440 µl 90 mM p-coumaric acid (Sigma) 
100 ml 100 mM Tris pH 8.6 
Solution B: 
120 µl 30% Hydrogen peroxide 
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100 ml 100 mM Tris pH 8.6 
ECL solutions A and B were mixed 1:1 before usage, and incubated with the 
membrane for 1 min. The membrane was wrapped in cling film and transferred to a 
cassette. The membrane was exposed to a sheet of ECL Hyperfilm (GE Healthcare) 
in a dark room initially for 30 sec, and then subsequently for an appropriate period 
depending on the strength of the signal. Films were developed using an automated 
Hyperprocessor (Amersham Pharmacia Biotech). Membranes were transferred to 
TBST for storage at 4°C. 
2.8.5.4. Blot stripping 
Used blots were stripped by incubating with ReBlot Plus Mild Antibody Stripping 
Solution (Millipore) at room temperature for approximately 15 min (incubation time 
dependent on strength of original signal). The blot was washed in TBST, and 
submitted to the blotting and subsequent detection procedures described in section 
2.8.5.2. 
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2.8.5.5. Antibodies used for western blotting 
Antibody Antigen Species Company Concentration 
Bmi-1 Mouse/human 
Bmi-1 
Mouse 
monoclonal 
Millipore       
05-637 
1.500 
Mel-18  Human/mouse 
Mel-18 
Goat 
polyclonal 
Abcam 
ab5267 
1.500 
Cyclin D1 
(9G2) 
Human/mouse 
cyclin D1 
Rabbit 
monoclonal 
Cell Signaling 
2978 
1.1000 
Phospho-Akt 
(Ser473) 
(D9E) 
Human/mouse 
phospho-Akt 
(Ser473 
Rabbit 
monoclonal 
Cell Signaling 
4060 
1.500 
p16 (M-156) Mouse p16Ink4a 
 
Rabbit 
polyclonal 
Santa Cruz 
SC-1207 
1.2000 
p21 Human/mouse 
p21 
Rabbit 
polyclonal 
Abcam 
ab7960 
1.1000 
α-tubulin Human/mouse 
α-tubulin 
Mouse 
monoclonal 
Sigma T6199 1.10000 
Erk1/2 Human/ 
mouse Erk1/2 
Rabbit 
monoclonal 
Cell Signaling 
4695 
1.2000 
β-actin Human/mouse 
β-actin 
Mouse 
monoclonal 
Abcam 
ab8226 
1.1000 
 
2.8.6. Selection of housekeeping gene for western blotting: 
Equal volumes of protein samples from Bmi-1 wild type and knockout mice of varying 
ages (based on Coomassie staining, see section 2.8.4) were loaded onto gels and 
transferred as described previously. The membranes were blotted with antibodies 
against three commonly used reference genes: α-tubulin, Erk1/2 and β-actin. Erk1/2 
was selected as the optimal reference gene for future experiments based on the 
detection of strong, consistent signals for each lane, the intensities of which correlated 
with the protein loading observed on the Coomassie stained gel. 
2.8.7. Densitometric analysis of western blots: 
The intensity of bands on western blots was quantified on scanned images of the blot 
using ImageJ software. Blot scans were converted to 8-bit greyscale images, and the 
threshold feature of ImageJ was used to highlight the bands. Only bands from the 
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same blot image were directly compared to prevent differences in image processing 
from affecting the results. The band to be measured was outlined using a manually 
drawn rectangle, and ImageJ used to measure the integrated density within this 
region. The rectangle was then moved to enclose the next band, and the 
measurement repeated. These were normalised by dividing by the intensity of 
housekeeping gene (Erk1/2) bands from a stripped and re-probed blot. The mean 
intensity was calculated to obtain averages for Bmi-1 wild type and knockout mice, 
and significance assessed at p<0.05 using a 2-tailed student’s t-test. 
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Chapter 3 
 
Expression of Bmi-1 in normal liver 
and regenerating tissue 
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3. Expression of Bmi-1 in normal liver and regenerating tissue: 
3.1. Reliability of anti-Bmi-1 antibodies: 
Problems with commercially available anti-Bmi-1 antibodies (and also in situ 
hybridisation) have previously been described, with the absence of a reliable Bmi-1 
staining pattern reported in pancreatic tissue (Sangiorgi & Capecchi, 2009). This may 
be reflected by the contradictory staining patterns observed in some previous studies 
of Bmi-1 expression in tumour patients, where cytoplasmic staining has been reported 
(Wang et al, 2008), despite the fact that Bmi-1 is believed to be a nuclear protein. In 
agreement with this, we observed that some older archival paraffin blocks had high 
levels of background staining. These problems were exacerbated in mouse tissue, as 
the most prominently used antibody is a mouse monoclonal. To generate optimal 
immunohistochemistry data, multiple lots of anti-Bmi-1 antibody (Millipore) were tested 
to find one which gave the most robust and consistent staining pattern in paraffin 
sections made from freshly collected liver tissue. The selected lot was then used for 
all future experiments. The validity of these staining results in mouse was assured by 
including control tissue from Bmi-1 knockout mice, which do not express any residual 
protein, in all experiments. These tissues were taken from littermates of the wild type 
animals used, and were identically fixed and processed to eliminate variability. Only 
experiments which yielded no Bmi-1 labelling in Bmi-1 knockout tissue were 
considered for analysis. 
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3.2. Bmi-1 protein is primarily expressed in biliary cells in normal murine liver: 
3.2.1. Bmi-1 is expressed in cholangiocytes: 
To begin elucidating the functional consequences of Bmi-1 expression in liver, the first 
step was to confirm the protein expression pattern of Bmi-1 in normal mouse liver. 
Paraffin-embedded liver sections from multiple 8 week old Bmi-1 wild type and 
knockout mice were stained for Bmi-1 using indirect immunohistochemistry (Figure 8). 
Bmi-1 is reported to be a predominantly nuclear protein (Chiba et al, 2007), so any 
background cytoplasmic staining was discounted. Bmi-1 expression was consistently 
high in the cholangiocytes that form bile ducts in the portal regions in all tissue 
sections examined (Figure 8a). Bmi-1 staining was absent in all nuclei in the Bmi-1 
knockout tissue, demonstrating that antibody reactivity is specific to the Bmi-1 epitope 
(Figure 8b). The expression pattern for Bmi-1 is consistent with that previously 
observed in the Bmi-1-GFP-knock-in mouse, which showed strong expression in the 
biliary region (Hosen et al, 2007). The expression pattern of Bmi-1 is also broadly in 
agreement with a proposed role for Bmi-1 in adult stem cell maintenance, as liver 
stem cells are believed to derive from the intrahepatic biliary tree (canals of Hering). 
3.2.2. Bmi-1 is expressed in hepatocytes: 
The question of whether Bmi-1 is also expressed in hepatocytes has previously 
remained unclear. The Bmi-1-GFP-knock-in mouse appears to show some expression 
within the hepatic parenchyma (Hosen et al, 2007), and faint Bmi-1 expression in 
human hepatocytes has also previously been reported (Sasaki et al, 2006). A direct 
comparison of Bmi-1 stained hepatocyte nuclei from wild type and Bmi-1 knockout 
mice appeared to show light staining in some wild type nuclei, suggesting low level 
Bmi-1 expression in some hepatocytes (Figure 8a,b). However, levels of 
hepatocellular Bmi-1 staining were difficult to evaluate conclusively, due to the 
aforementioned issues with commercially available anti-Bmi-1 antibodies (Section 
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3.1). Because of this, it was decided to have sections independently  stained and 
assessed by Dr. Bradley Spencer-Dene of the Experimental Pathology Core Facility at 
Cancer Research UK. Wild type and Bmi-1 knockout murine liver sections (n=3) were 
submitted for staining and analysis. Some hepatocytes in wild type mice clearly 
exhibited Bmi-1 expression within particular subnuclear compartments (Figure 8c,e). 
This expression was not definitively identifiable in all hepatocytes, and labelling was 
absent in all sections from Bmi-1 knockout mice (Figure 8d,f). A similar nuclear 
punctate pattern of Bmi-1 expression is also seen in HCC cell lines (Effendi et al, 
2010) and cultured putative murine hepatic/stem progenitor cells (Chiba et al, 2007). 
Electron immunomicroscopy has also demonstrated that polycomb proteins are 
concentrated at the perichromatin compartment within the nucleus (Cmarko et al, 
2003). These data demonstrate that Bmi-1 is strongly expressed in the nuclei of 
murine cholangiocytes, and is expressed at lower levels within some hepatocytes. 
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Figure 8: Bmi-1 is expressed in cholangiocytes and hepatocytes in murine liver. 
Labelling of paraffin-embedded 8 week old mouse liver sections using indirect 
immunohistochemistry to detect Bmi-1. Antibodies were visualised with DAB and 
counterstained with haematoxylin. a) Tissue from wild type mouse showing 
expression of Bmi-1 in biliary cells (black arrow) and hepatocytes (red arrow). b) 
Immunolabelling is absent in cholangiocytes and hepatocytes in Bmi-1 knockout 
mouse. c,d) Tissue from Bmi-1 wild type (c) and knockout (d) mice, again showing 
expression in wild type cholangiocytes (black arrow) and punctate nuclear labelling 
pattern in some hepatocytes (red arrow). e,f) Enlarged images of selected hepatocyte 
nuclei from e) wild type and f) Bmi-1 knockout mouse. Scale bars 50 µm. 
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3.3. Bmi-1 protein is expressed in mouse oval cell nuclei: 
Bmi-1 has been previously associated with maintenance of stem cell populations, both 
in cells from foetal liver (Chiba et al, 2010) and in many other tissues (see 
introduction). To begin investigating a potential role for Bmi-1 in the adult liver stem 
cell response, Bmi-1 protein expression was assessed by immunohistochemical 
methods in tissue sections from mice undergoing an oval cell response. Oval cells are 
believed to be derived from resident liver stem cells. The tissues stained were 
obtained from archival paraffin-embedded blocks from two different mouse models of 
oval cell induction. The first were from transgenic mice with an albumin-urokinase type 
plasminogen activator transgene (AL-uPA), which develop liver disease following uPA 
expression in hepatocytes (Braun et al, 2003). The second set of blocks was from 
mice treated with the DNA alkylating agent dipin, which induces an oval cell response 
(Braun & Sandgren, 2000). Double-label immunohistochemistry revealed high Bmi-1 
expression in the nuclei of oval cells in tissue sections from several mice, using both 
models of oval cell activation (Figure 9) (n=5 from each line). Oval cells were 
identified by parenchymal localisation, nuclear shape and staining for cytokeratin 19 
(CK19), a marker for bile ducts and oval cells (Jelnes et al, 2007). CK19 gave the 
same ductal cell labelling pattern as the more commonly used A6 antibody (Figure 9d) 
(A6 antibody kindly supplied by Dr Valentina Factor, NIH, Bethseda, MD, USA).  Bmi-
1 was expressed in all oval cell nuclei within a CK19 positive ductular reaction. These 
results are the first to demonstrate that Bmi-1 is strongly expressed in oval cells from 
two different mouse models, suggesting a possible functional relevance for Bmi-1 in 
the hepatic stem cell response. 
 
126 
 
 
Figure 9: Bmi-1 is expressed in CK19 positive murine oval cells. 
Labelling of paraffin-embedded liver sections from mice treated with dipin (a,b,c,d) 
and from AL-uPA transgenic mice (e,f) using indirect immunohistochemistry. Sections 
co-labelled with Bmi-1 (brown) and CK19 (blue) antibodies and counterstained with 
nuclear fast red, except d) which was labelled with A6 antibody (brown) and 
counterstained with haematoxylin. a,e) Negative control slides with isotype control 
antibody instead of anti-Bmi-1, with absence (a) and presence (d) of anti-CK19 
antibody. b,c,e) Bmi-1 positive oval cells (black arrow). d) A6 positive oval cells (black 
arrow). Scale bars in a,b): 200 µm; in c,e,f): 50 µm; in d): 100 µm. 
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3.4. Bmi-1 protein is expressed in some biliary cells in human liver: 
To determine whether the expression pattern observed in mouse liver was similar in 
humans, paraffin-embedded sections of tumour-adjacent normal human liver 
(provided by Professor Malcolm Alison with appropriate ethical approval) were stained 
for Bmi-1 (n=3) (Figure 10). As in mouse, nuclear labelling was observed for Bmi-1 in 
cholangiocytes (Figure 10b). However, unlike in the mouse samples examined, there 
appeared to be a degree of heterogeneity in the intensity of staining in individual 
cholangiocytes, with some nuclei displaying very strong staining and some very 
weak/absent staining. Bmi-1 expression was not obvious in hepatocytes in human 
tissue, unlike in mouse, although this was difficult to evaluate conclusively due to the 
lack of Bmi-1 depleted human tissue for comparison. These data were supported by 
staining commercially purchased hepatic tissue microarrays (US Biomax) which 
contained normal and tumour-adjacent hepatic tissue. Interestingly, a number of bile 
ducts (7/21) in normal hepatic tumour microarray cores appeared not to express Bmi-
1 (Figure 10c). This suggests that some human bile ducts may not express Bmi-1, in 
contrast to mice. Other cores on the same slide did show immunoreactivity for Bmi-1 
(Figure 10d), suggesting that the antibody was working correctly under the staining 
conditions. However, the possibility that the cores were not all identically fixed cannot 
be ruled out, which could cause variability in the staining intensity.  
In summary, these results demonstrate that strong Bmi-1 expression is found in some 
cholangiocytes in the livers of different species, and that experiments in mice are 
likely to have relevance to human tissue. 
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Figure 10: Bmi-1 is expressed in cholangiocytes in human liver. 
a,b) Labelling of paraffin-embedded human sections using indirect 
immunohistochemistry to detect Bmi-1. Antibodies were visualised with DAB and 
sections counterstained with haematoxylin. a) Isotype control demonstrating absence 
of staining in cholangiocytes (black arrow) b) Tissue labelled with anti-Bmi-1 antibody, 
showing cholangiocytes both negative (black arrow) and positive (red arrow) for Bmi-
1. c,d) Normal liver cores from tissue microarrays labelled for Bmi-1, showing bile 
ducts without (c) and with (d) Bmi-1 immunolabelling. Scale bars 50 µm. 
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3.5. Bmi-1 protein is expressed in human cirrhotic liver tissue: 
Liver cirrhosis is a consequence of hepatic injury, including alcoholism, hepatitis and 
fatty liver diseases. Cirrhotic livers contain regions of advanced liver fibrosis, which 
involves the replacement of injured hepatic tissue by fibrous connective tissue. Found 
within the fibrotic regions are ductular reactions, which are believed to contain hepatic 
progenitor cells. These are thought to be derived from cells in the terminal biliary 
ducts (canals of Hering) (Theise et al, 1999). Cirrhotic tissue also contains 
regenerative nodules; these are regions of hepatocytes undergoing clonal proliferation 
following liver damage. As such, cirrhotic tissue provides a model to examine human 
cells undergoing a localised hepatic regenerative response. Expression changes in 
Bmi-1 have not previously been assessed in human cirrhotic livers. To address this 
question, paraffin-embedded tissue arrays containing samples from liver cirrhosis 
patients (US Biomax) were stained for Bmi-1 (Figure 11) and scored for Bmi-1 
expression (Table 2).  
Bmi-1 expression was assessed in ductal cells within fibrotic tissue, which were 
histologically identified on some cores on the microarray (Figure 11a,b). 59% of these 
cores exhibited ductal cells with positive Bmi-1 labelling. However, this does not 
represent a significant increase in frequency compared with bile ducts in normal liver 
samples (Table 2). Bmi-1 staining was also scored in hepatocyte regenerative 
nodules, with 22% exhibiting Bmi-1 expression. This represents a significant 
difference in comparison to normal hepatocytic samples, none of which expressed 
detectable Bmi-1 (Table 2). These results were supplemented with sections from 
cirrhotic liver patients containing much larger areas of tissue, provided by Professor 
Malcolm Alison (n=5). These again exhibited heterogeneity in Bmi-1 staining, with the 
presence and absence of Bmi-1 observed in both regenerative nodules and ductal 
cells (Figure 11 c-f). Together, these results provide some evidence that Bmi-1 may 
be involved in both hepatocyte mediated regeneration and progenitor cell responses 
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in human tissue. However, it is unlikely to be critical, as Bmi-1 expression was not 
observed in the majority of regenerative nodules examined. As with the tissue array 
cores with normal hepatic tissue, it cannot be ruled out that fixation differences 
between cores could account for some of the heterogeneity observed in the Bmi-1 
staining. 
 
 Positive Negative 
Normal bile ducts 14 7 
Cirrhotic ductal cells 17 12 
p=0.563 
 Positive Negative 
Normal tissue (hepatocytes) 0 20 
Cirrhotic regenerative 
nodules 
11 38 
p=0.0208 * 
Table 2: Bmi-1 expression in human cirrhotic livers. 
Table showing number of tumour samples of each type positive and negative for Bmi-
1 immunolabelling. p values calculated for each table using a chi-squared test. 
*=significant at p<0.05. 
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Figure 11 (overleaf): Bmi-1 expression in human cirrhotic livers. 
Cirrhotic liver samples were labelled using indirect immunohistochemistry to detect 
Bmi-1. Antibodies were visualised with DAB and sections counterstained with 
haematoxylin. a,b) Human cirrhotic cores from tissue microarray, with absence (a) 
and presence (b) of Bmi-1 expression in ductular epithelial cells (black arrow) and 
hepatocyte regenerative nodules (red arrow), scale bars 50 µm. c-f) Sections from 
human cirrhotic patients. c) Negative control tissue section incubated with isotype 
control antibody. d) Cirrhotic liver with absence of labelling for Bmi-1. e) Bmi-1 
expression in cholangiocytes (black arrow), but not in regenerative nodules (red 
arrow). f) Bmi-1 expression in both cholangiocytes and adjacent regenerative nodule. 
Scale bars 100 µm. 
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Figure 11: Bmi-1 expression in human cirrhotic livers. 
See previous page for figure legend. 
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3.6. Expression of Bmi-1 in hepatic tumours: 
3.6.1. Bmi-1 expression in human hepatocellular carcinomas: 
As described in the introduction (section 1.12.2), Bmi-1 overexpression has been 
reported in human liver cancers. However, it is unclear whether Bmi-1 expression 
correlates with tumour progression, as different groups have reported contrasting 
results. Some have shown a correlation between Bmi-1 expression and well 
differentiated tumours (Effendi et al, 2010; Wang et al, 2008), while others report high 
Bmi-1 expression in poorly differentiated tumours (Sasaki et al, 2008a). This may be 
in part due to previously described issues with the consistency of anti-Bmi-1 
antibodies. To try and address this issue, liver cancer tissue array slides (US Biomax) 
containing different grades of hepatocellular carcinomas (HCCs) and normal or 
tumour-adjacent hepatic tissue were stained to detect expression of Bmi-1. These 
arrays eliminate the possibility of any variability in staining procedures between 
different slides, although conversely it is not possible to ensure that all cores are 
identically fixed.  The tumour cores were graded by the manufacturer as Grade I (well 
differentiated), Grade II (moderately differentiated) or Grade III (poorly differentiated). 
Images of the tumour cores were blindly labelled and scored as positive or negative 
for Bmi-1 expression (Table 3). Significance was assessed using a chi-squared test, 
and representative images are shown in Figure 12. Bmi-1 was significantly 
upregulated in HCC samples compared to normal or tumour-adjacent liver. However, 
only 40% of the tumour samples examined expressed Bmi-1, indicating high Bmi-1 
expression is not essential for tumour development. In contrast to some previously 
published results, there was no significant difference in Bmi-1 expression between 
different tumour grades. This suggests that Bmi-1 is unlikely to be a prognostic factor 
for more aggressive tumours, although increased sample numbers (especially Grade I 
tumours) will be required to confirm this conclusion. It also cannot be guaranteed that 
all tumour cores on the array were identically fixed, which could cause variability in the 
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staining intensity. This makes it difficult to draw robust conclusions from both our data 
and published studies on whether Bmi-1 is a suitable prognostic factor for HCC. 
3.6.2. Bmi-1 expression in human cholangiocarcinomas: 
The tissue arrays obtained from US Biomax also contained various human CC 
samples, which were also stained for Bmi-1 to see whether any alterations in Bmi-1 
could be detected in CC samples compared to normal biliary cells (Figure 13) (Table 
3). Bmi-1 was expressed in 56% of CC samples examined. Given that a third of the 
normal bile ducts scored did not exhibit Bmi-1 expression, this does not represent a 
significant difference based on a chi-squared test. There is also no correlation 
between tumour grade and Bmi-1 expression. As Bmi-1 appeared to be expressed in 
some biliary cells in normal livers, it seems that Bmi-1 expression in CC cells may not 
represent an abnormality. As such, it is unclear whether it would have any relevance 
to the progression of the disease, as CC is believed to be derived from 
cholangiocytes. 
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 Positive Negative 
Normal tissue (hepatocytes) 0 20 
HCC samples (all grades) 52 78 
p=0.000467 * 
 Positive Negative 
HCC Grade I 3 11 
HCC Grade II 38 55 
HCC Grade III 11 12 
p=0.269 
 Positive Negative 
Normal bile ducts 14 7 
CC samples (all grades) 15 12 
p=0.435 
 Positive Negative 
CC Grade I 2 2 
CC Grade II 9 3 
CC Grade III 4 7 
p=0.171 
Table 3: Bmi-1 expression in human liver tumours. 
Table showing the number of tumour samples of each type positive and negative for 
Bmi-1 immunolabelling. p values calculated for each table using chi-squared test. 
*=significant at p<0.05 
 
 
Figure 12 (overleaf): Bmi-1 expression in human hepatocellular carcinomas. 
Selected cores from paraffin-embedded human HCC tissue microarrays labelled with 
indirect immunohistochemistry to detect Bmi-1. Antibodies were visualised with DAB 
and sections counterstained with haematoxylin. a) Negative staining in normal hepatic 
tissue. b) Grade I HCC sample showing light immunoreactivity for Bmi-1. c,d) Grade II 
HCC samples, both negative (c) and positive (d) for Bmi-1. e,f) Grade III HCC 
samples, both negative (e) and positive (f) for Bmi-1. Scale bars 50 µm. 
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Figure 12: Bmi-1 expression in human hepatocellular carcinomas. 
See previous page for figure legend. 
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Figure 13: Bmi-1 expression in human cholangiocarcinomas. 
Selected cores from paraffin-embedded human CC tissue microarrays labelled using 
indirect immunohistochemistry to detect Bmi-1. Antibodies were visualised with DAB 
and sections counterstained with haematoxylin. a,b) Examples of Grade II CC 
samples without (a) and with (b) Bmi-1 expression. Scale bars 50 µm. 
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3.7. Discussion: 
Immunohistochemical analysis of murine liver tissue demonstrated strong Bmi-1 
expression in all cholangiocytes. Bmi-1 staining in hepatocytes was more difficult to 
conclusively evaluate, as commercially available anti-Bmi-1 antibodies did not always 
give a consistent staining pattern (see section 3.1). To address this issue, murine liver 
tissue sections were independently analysed by Dr. Bradley Spencer-Dene of the 
Experimental Pathology Core Facility, Cancer Research UK. From these data sets, it 
can be concluded that Bmi-1 is expressed in some hepatocytes at a lower level than 
cholangiocytes. The robustness of these results was assured by the inclusion of 
isotype controls, and more importantly, the absence of labelling in all Bmi-1 knockout 
mouse tissue used as a negative control. The data could be improved in the future by 
assessing Bmi-1 expression in pure cholangiocyte and hepatocyte cell populations 
freshly isolated from murine livers (Cho, 2002; Klingmuller et al, 2006), or by obtaining 
cells from tissue sections using laser capture microdissection. Western blotting and/or 
Q-RT-PCR could then be used to define more precisely the level of Bmi-1 expression 
within these hepatic sub-populations. 
It is interesting that Bmi-1 expression was observed in all murine cholangiocytes and 
some hepatocytes in vivo, given that both in vitro work in liver cell populations and in 
vivo work in other tissues have predominantly associated high levels of Bmi-1 
expression with stem and progenitor cell populations (see introduction). Although 
stem cells within the liver are thought to reside within the portal region, it has not 
generally been believed that mature cholangiocytes themselves have stem/progenitor 
cell function, either in terms of contributing to normal hepatocyte turnover or the oval 
cell response. However cholangiocytes and hepatocytes do maintain the ability to 
proliferate extensively and give rise to identical daughter cells during regenerative 
responses, so can be considered as unipotent stem/progenitor cells. There is also 
recent lineage tracing based evidence that Sox9 positive cells within biliary structures 
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can both self-renew and give rise to hepatocytes during normal liver turnover 
(Furuyama et al, 2011), providing support for the theory that some cells within the 
biliary population do have stem/progenitor cell activity, although not necessarily 
mature cholangiocytes. Interestingly, in both normal and cirrhotic human liver tissue, 
some biliary cholangiocytes and cells involved in ductular reactions appeared to 
express Bmi-1 at higher levels than others. This raises the question of whether the 
Bmi-1 expressing human cholangiocytes represent cells with stem/progenitor cell 
properties, which may contribute to normal liver turnover or to regenerative nodules in 
cirrhosis. There is lineage tracing evidence that regenerative nodules can be clonally 
derived from progenitor cells within ductal reactions (Lin et al, 2010), and 3-
dimensional reconstructions have also shown hepatocyte buds linked to mature bile 
ducts in cirrhotic livers (Falkowski et al, 2003). From our studies, Bmi-1 was 
expressed in all murine oval cells, suggesting a link between Bmi-1 expression and 
cells with stem/progenitor cell properties in murine liver. These questions could be 
addressed in future by performing lineage tracing of Bmi-1 expressing cells in liver 
using Bmi-1-Cre-ER transgenic mice, as already carried out in intestine and pancreas 
(Sangiorgi & Capecchi, 2008; Sangiorgi & Capecchi, 2009). This would provide 
clearer insight into the fate and function of Bmi-1 expressing cells within the liver. 
There are also other published examples of Bmi-1 expression in more differentiated 
cell types. In the pancreas, the Bmi-1+ lineage in Bmi-1-Cre-ER transgenic mice has 
been reported to co-localise with differentiation markers for acinar cells, glucagon 
positive cells and endothelial cells, as opposed to pancreatic progenitor markers 
Nestin and Pdx1 (Sangiorgi & Capecchi, 2009). These pancreatic acinar cells also 
maintain the ability to proliferate despite their differentiated state, similar to 
hepatocytes and cholangiocytes in the liver. Bmi-1 expression has also been identified 
in all cells in the mouse mammary gland, as opposed to just stem cell subpopulations 
(Pietersen et al, 2008a). Together with the Bmi-1 expression pattern in liver described 
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above, these data suggest that Bmi-1 could have unspecified roles in more 
differentiated cell populations in addition to stem cells.  
3.8. Summary of Chapter: 
In summary, this chapter has demonstrated that Bmi-1 is expressed in cholangiocytes 
in normal murine and human liver, and appears to be expressed at lower levels in 
some murine hepatocytes. In addition to this, Bmi-1 is expressed in murine oval cells, 
along with some ductal progenitors and hepatocyte regenerative nodules in human 
cirrhotic livers. These results suggest that Bmi-1 may have a function in various forms 
of liver regeneration, a hypothesis that will be addressed in future experiments (see 
final discussion section 7.2.2). The expression of Bmi-1 in hepatic tumours was also 
examined. Bmi-1 was overexpressed in HCC samples compared to normal tissue, but 
no correlation was observed with tumour grade. As such, it is uncertain whether Bmi-1 
is a suitable prognostic factor for HCC. 
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Chapter 4 
 
Liver structure and function in   
Bmi-1 knockout mice 
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4. Liver structure and function in Bmi-1 knockout mice: 
4.1. Breeding and genotyping of Bmi-1 knockout mice: 
To begin characterising the effects of global in vivo deletion of Bmi-1 on liver 
physiology, Bmi-1 knockout mice were generated by inter-crossing Bmi-1 +/- mice 
(generously provided by Professor Silvia Marino) (van der Lugt et al, 1994). Ear snips 
from the resulting progeny were genotyped using primers designed to distinguish the 
wild type and knockout DNA sequences. The genotyping results indicated repeated 
successful generation of Bmi-1 knockout mice (Figure 14a). To confirm that Bmi-1 
knockout mice did not express any residual protein, western blotting was used to 
assess Bmi-1 protein levels in whole mouse liver extracts at 8 weeks of age. These 
results demonstrated expression of Bmi-1 protein in the livers of wild type mice, and a 
complete absence in the knockout mice (Figure 14b) 
Newborn Bmi-1 knockout mice were obtained at a frequency of 16.9% (Figure 14c), 
which does not differ from expected Mendelian ratios based on a chi-squared test 
(p=0.283). Following genotyping at 3-4 weeks of age, the frequency of Bmi-1 
knockout mice was 11.0%, which deviates significantly from expected Mendelian 
ratios (p<0.001). This is consistent with previously published results reporting that 
knockout mice are selectively cannibalised by the mothers (van der Lugt et al, 1994). 
The Bmi-1 knockout mice were outwardly normal in appearance at birth and at the 
postnatal day 7 time point. By 3 weeks of age, the knockout mice appeared noticeably 
smaller than wild type littermates. This is illustrated by growth curves comparing the 
body weight of wild type and knockout mice (Figure 15a). The knockouts also began 
to exhibit previously characterised abnormalities, most notably an ataxic gait and 
hunched phenotype due to skeletal transformations. 
Studies of other organs have demonstrated that Bmi-1 knockout mice are relatively 
normal at birth, and then display phenotypes which become progressively worse with 
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age (van der Lugt et al, 1994). Because of this, it was decided to focus analysis on 
Bmi-1 knockout livers from adult mice, although livers from newborn mice and 
postnatal day 7 were also initially examined. The Bmi-1 knockout mice have 
previously been reported to live to 3-5 months of age (van der Lugt et al, 1994), 
although in our animal colony, the mice appeared generally unwell by 12 weeks of 
age, so it was decided not to keep them alive beyond this stage. To reduce the 
possibility of secondary effects due to the illness of the mice, an earlier adult time 
point at which the mice appeared healthier (8 weeks) was also chosen for analysis. 
Despite this, the fact that the mice are complete knockouts as opposed to liver 
specific Bmi-1 knockouts means that secondary effects cannot be ruled out in the 
subsequent work. 
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Figure 14: Breeding and genotyping of Bmi-1 knockout mice. 
a) Representative photograph of agarose gel showing results of genotyping PCR from 
mice ear snips. Lower band represents Bmi-1 wild type allele (product size 323 bp); 
upper band is knockout allele (product size 446 bp). Labelled are examples of Bmi-1 
wild type (Wt), heterozygote (Het) and knockout (KO) mice. b) Western blotting for 
Bmi-1 on whole liver protein extracts from 8 week old Wt and KO mice. Erk1/2 was 
used as a housekeeping gene. c) Table of obtained frequencies of Bmi-1 knockout 
mice. 
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Figure 15: Liver and body weights in Bmi-1 knockout mice. 
a) Growth rates of Bmi-1 wild type (Wt) and knockout (KO) mice. Points represent 
body weight of an individual mouse at one particular time point. b) Liver to body 
weight ratio in 12 week old male Bmi-1 Wt and KO mice (n=5), p value calculated 
using 2-tailed Student’s t-test. 
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4.2. Characterisation of Bmi-1 knockout mouse liver phenotype: 
4.2.1. Liver function in Bmi-1 knockout mice: 
The livers in Bmi-1 knockout mice were smaller than in wild type littermates due to the 
reduced size of the mice. However, the liver to body weight ratio tends to remain 
constant in mammals, and any alterations can be an indicator of abnormal liver 
physiology. The liver to body weight ratio was calculated for Bmi-1 knockout mice at 8 
and 12 weeks of age, and no significant differences were observed (Figure 15b). 
To further assess abnormalities in the hepatic function of Bmi-1 knockout mice, serum 
from 8 week old mice was analysed for commonly used biomarkers indicative for liver 
disease or dysfunction (Fox et al, 2006) at the Royal Veterinary College, Hawkshead. 
The results are shown in Figure 16. Serum levels of albumin, the primary protein 
constituent of blood plasma, were normal in Bmi-1 knockout mice (Figure 16a), 
demonstrating that the synthetic capacity of the knockout livers is not diminished. 
Total bilirubin levels were also no different in Bmi-1 knockout mice compared to wild 
types (Figure 16b). Bilirubin is a breakdown product of haem which is excreted by the 
liver, and can be increased in liver diseases such as cholestasis. Bmi-1 knockout mice 
showed elevated levels of alkaline phosphatase (AP) compared to wild types (Figure 
16c). AP is often elevated in cases of bile duct obstruction or cholestasis, suggesting 
that there may be some impairment of bile flow in Bmi-1 knockout mice. However, 
serum AP can also become elevated in bone diseases (Johnston, 1999), so a liver-
specific phenotype will require further confirmation. Alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) are both enzymes present in liver parenchymal 
cells, and are commonly used as markers of liver injury, as hepatocyte damage and 
necrosis causes them to leak into the blood. They tend to be greatly increased 
following acute liver injury, and more moderately increased in chronic diseases 
(Johnston, 1999). Levels of ALT appeared to be slightly increased in Bmi-1 knockout 
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mice (Figure 16d), however this is not statistically significant (p=0.097). AST levels 
were significantly increased in the knockout mice compared to wild types (Figure 16e). 
These results are indicative of some liver damage in Bmi-1 knockout mice, however it 
should be noted that unlike ALT, AST also shows significant activity in cardiac muscle, 
so can be indicative of cardiac muscle damage as well as hepatocellular damage (Fox 
et al, 2006). 
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Figure 16: Liver function biomarkers in Bmi-1 knockout mice. 
Serum was collected from Bmi-1 wild type (Wt) and knockout (KO) mice and analysed 
for levels of a) albumin, b) total bilirubin, c) alkaline phosphatase (AP), d) alanine 
aminotransferase (ALT), e) aspartate aminotransferase (AST). a,b,c) n=3 Wt, 4 KO 
mice. d,e) n=4 Wt, 5 KO mice. * p<0.05 using 2-tailed Student’s t-test. 
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4.2.2. Histology of Bmi-1 knockout mouse livers: 
To assess the effects of Bmi-1 deletion on liver histology, liver tissue sections from 
newborn, postnatal day 7, 8 week old and 12 week old Bmi-1 knockout mice were 
stained with haematoxylin and eosin (H&E) for histological assessment. The sections 
were also blindly labelled and analysed by my second supervisor Professor Malcolm 
Alison, a recognised expert in mouse hepatic pathology. Histologically, livers from 
newborn Bmi-1 knockout mice did not present any detectable phenotype (Figure 
17a,b). Given that Bmi-1 was found to be highly expressed in cholangiocytes, the 
morphology of portal regions in Bmi-1 knockout mice was closely examined to assess 
whether loss of Bmi-1 had any effect on biliary organisation. Tissue sections from wild 
type and knockout mice were labelled with an antibody against the bile duct marker 
cytokeratin 19 (CK19) (Figure 17c,d). Newborn Bmi-1 knockout mice exhibited normal 
CK19 labelling with no obvious abnormalities in cholangiocyte appearance or biliary 
structure. The same results were observed in mice at postnatal day 7, with no 
difference between wild types and knockouts (data not shown). 
In adult mice, at both 8 and 12 weeks of age, the Bmi-1 null mice exhibited cellular 
disorganisation within the hepatic parenchyma (Figure 18). Blind analysis consistently 
identified Bmi-1 knockout livers as having an abundance of smaller hepatocytes, 
which appeared more uniform in size than in wild type livers. CK19 labelling did not 
uncover any noticeable differences in either cellular structure or distribution of bile 
ducts within the liver parenchyma in 8 week old Bmi-1 knockout mice (Figure 19a-d). 
Picro Sirius red staining also demonstrated normal deposition of collagen surrounding 
the biliary regions in Bmi-1 knockout mice, with no evidence of fibrosis (Figure 19e,f). 
Taken together, these data suggest bile duct development is not noticeably affected 
by deletion of Bmi-1. 
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Figure 17: Histology of newborn Bmi-1 knockout mouse livers. 
a,b) H&E stained paraffin-embedded sections from newborn Bmi-1 wild type (a) and 
knockout (b) mice. c,d) Paraffin-embedded sections labelled using indirect 
immunohistochemistry to detect cytokeratin 19 in Bmi-1 wild type (c) and knockout (d) 
mouse livers, showing bile duct labelling (black arrows). Antibodies visualised with 
DAB. Scale bars 100 µm. 
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Figure 18: Histology of adult Bmi-1 knockout mouse livers. 
Haematoxylin and eosin (H&E) stained paraffin-embedded liver sections from 8 week 
old Bmi-1 wild type (left panels) and knockout mice (right panels). Images at 100x, 
200x and 400x magnification, all scale bars 50 µm. BD = bile duct, CV = central vein. 
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Figure 19: Portal structure in Bmi-1 knockout mice. 
a-d) Paraffin-embedded liver sections from 8 week old Bmi-1 wild type and knockout 
mice labelled using indirect immunohistochemistry to detect cytokeratin 19. Antibody 
visualised using DAB, and sections counterstained with haematoxylin. Images shown 
at low (a,b) and high (c,d) magnification. e,f) Picro Sirius red stained paraffin-
embedded liver sections from 8 week old mice, to detect collagen fibres. All scale bars 
100 µm. BD = bile duct, CV = central vein. 
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4.3. Bmi-1 knockout mice exhibit reduced hepatocyte size and ploidy: 
4.3.1. Bmi-1 knockout mice have increased hepatocyte nuclear density: 
Initial qualitative assessment of H&E stained sections from Bmi-1 knockout mice 
appeared to show abnormalities in the organisation of the liver parenchyma, with 
many hepatocytes appearing smaller and more uniform in size than in the wild type 
livers. This was unexpected, given that Bmi-1 was expressed most highly in 
cholangiocytes in normal murine liver. It was therefore decided to further characterise 
the hepatocellular abnormalities. To quantify the phenotype, the ‘Cell counter’ feature 
of ImageJ software (http://rsbweb.nih.gov/ij/) was used to count the total number of 
nuclei per 400x microscope field in H&E stained sections from Bmi-1 wild type and 
knockout mice, at both 8 and 12 weeks of age. This analysis revealed a significant 
increase in the number of nuclei per field in Bmi-1 knockout mice at both time points 
(Figure 20).  
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Figure 20: Bmi-1 knockout mice have increased hepatocyte density. 
Average number of hepatocyte nuclei in a 400x microscope field for Bmi-1 wild type 
(Wt) and knockout (KO) mouse liver tissue. Hepatocyte numbers were counted in 5 
randomly selected fields of an H&E stained section for each mouse and averaged. a) 
8 week old mice (n=10 animals per group). b) 12 week old mice (n=4). Data are 
means ± standard deviation, *p<0.05 using 2-tailed Student’s t-test. 
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4.3.2. Bmi-1 knockout mice have reduced hepatocyte cell and nuclear size: 
The histological observation that Bmi-1 knockout livers had larger numbers of small 
hepatocytes led to the hypothesis that these mice showed impaired development of 
polyploidy. Cell ploidy is correlated with cellular and nuclear size (Rajvanshi et al, 
1998), so any reductions in ploidy would potentially provide an explanation for the 
increased hepatocyte numbers, and hence reduced cell size, observed in the 
knockout liver sections. The DNA content of a cell is correlated with the size of the 
nucleus, and cell/nuclear size has been previously used as a measure of polyploidy in 
a number of publications (Nunez et al, 2000) (Chipchase et al, 2003). It has also been 
noted that measurement of nuclear size correlates well with FACS analysis of DNA 
content (Danielsen et al, 1986; Sigal et al, 1999). To investigate further, it was first 
decided to quantify hepatocyte cell and nuclear size to confirm that these parameters 
were reduced in Bmi-1 knockout mice. The polyploidisation process begins around 
weaning and develops as the mice age (Celton-Morizur et al, 2009), so 12 week old 
mice were used to assess this phenotype.  Nuclear area measurements were carried 
out on images of hepatocyte touch preparations from freshly isolated livers, using 
ImageJ software (see appendix section A3 for more detail of procedure). Analysis of a 
minimum of 20 randomly selected microscope field images per mouse revealed a 
significant reduction in average nuclear area of Bmi-1 knockout mouse hepatocytes 
(Figure 21a). A ranking of the average nuclear areas in individual images illustrates a 
clear divide between Bmi-1 wild type and knockout mice (Figure 21b). These results 
suggested that the average nuclear ploidy in the Bmi-1 knockout hepatocytes may 
have been reduced. A similar reduction in average nuclear area was also observed in 
preliminary analysis of Bmi-1 knockout mice at 8 weeks of age (data not shown), 
indicating that the phenotype is not restricted to the most aged animals. 
To further characterise the phenotype, the image analysis was repeated for five 
randomly chosen images per mouse to count the number of nuclei per field classed 
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above a threshold value of 44 µm2. This value was chosen to select only the largest 
nuclei, based on previous analysis of nuclear area distribution and ploidy in wild type 
hepatocytes (Nunez et al, 2000). The counts were expressed as a percentage of total 
nuclei, and are shown in Figure 21c. An average of 12% of wild type hepatocyte 
nuclei had an area above the threshold, whereas these larger nuclei were rarely 
observed in hepatocytes from Bmi-1 knockout mice. This result demonstrates a virtual 
absence of large hepatocyte nuclei, which are potentially of higher ploidy classes, in 
12 week old Bmi-1 knockout mice. 
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Figure 21: Bmi-1 knockout mouse hepatocytes have reduced nuclear area. 
a) Average nuclear area (µm2) of hepatocytes isolated by touch preparation from Bmi-
1 wild type (Wt) and knockout (KO) mice at 12 weeks of age. n=3 female mice, 20 
images per mouse. Individual images were averaged to obtain mean nuclear area per 
mouse. Data presented are means of individual mice ± standard deviation. b) Ranking 
of all analysed images from highest to lowest average nuclear area. Red = wild type 
mice, blue = Bmi-1 knockout. c) Percentage of touch preparation hepatocyte nuclei 
above 44 µm2 in size. n=3 female mice, 5 images per mouse. Data are means of 
individual mice ± standard deviation, * p<0.05 using 2-tailed Student’s t-test. 
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To confirm whether the reduced hepatocyte nuclear size in Bmi-1 knockout mice 
correlated with cell size, randomly selected, blindly labelled touch preparation images 
were used to measure hepatocyte areas. Hepatocytes falling within a defined region 
of the image were manually outlined (Figure 22a), and the area of each cell calculated 
using ImageJ software. Hepatocytes from Bmi-1 knockout mice had significantly 
decreased cell areas compared to wild type littermates (Figure 22b). The distribution 
of individual hepatocyte areas is shown in Figures 22 c & d, showing an absence of 
larger hepatocytes in Bmi-1 knockout mice. This also demonstrates that the 
hepatocytes in the wild type mice show a greater diversity in size, while the Bmi-1 
knockout hepatocytes are more uniform. This agrees with the initial observations in 
H&E stained sections. These results support the hypothesis that polyploidisation is 
impaired in Bmi-1 knockout mice, given the correlation between cell size and ploidy 
(Epstein, 1967). They also suggest that the reason for the increased number of nuclei 
per microscope field in Bmi-1 knockout mice is because the hepatocytes are smaller 
on average. 
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Figure 22: Hepatocytes in 12 week old Bmi-1 knockout mice are smaller in size. 
a) Example of hepatocyte area calculation procedure. All hepatocytes falling 
completely within a 500x500 pixel area of the touch preparation image were manually 
outlined, and their area calculated using ImageJ software. Scale bar 50 µm. b) 
Average area of hepatocytes in Bmi-1 wild type (Wt) and knockout (KO) mice. Data 
represent mean ± standard deviation. n=200 hepatocytes. *p<0.05 using 2 tailed 
Student’s t-test. c,d) Number of individual hepatocytes falling within defined area 
classes for c) wild type and d) Bmi-1 knockout mice. 
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4.3.3. Bmi-1 knockout mouse hepatocytes exhibit fewer centromeres: 
To provide evidence that the reduced hepatocyte nuclear size phenotype was related 
to a decrease in ploidy, in situ hybridisation using a pan-centromeric probe was 
carried out to allow estimation of the chromosome content of wild type and Bmi-1 
knockout hepatocytes. This method has previously been used to analyse ploidy in 
hepatocytes (Mayhew et al, 2005). As expected, the larger hepatocytes found in wild 
type mice appeared to have greater numbers of visible centromeres (Figure 23a,b). 
This was quantified by counting the number of centromeres per hepatocyte nucleus, 
which showed a significant reduction in average centromere numbers in Bmi-1 
knockout mice (Figure 23c). Plots of the distribution of centromere numbers in 
individual hepatocytes demonstrate a near absence of nuclei with high centromere 
numbers in Bmi-1 knockout mice (Figure 23d,e). Together, these results provide 
support for the hypothesis that polyploidisation is impaired in Bmi-1 knockout mouse 
hepatocytes. 
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Figure 23: Bmi-1 knockout hepatocytes have reduced centromere numbers. 
In situ hybridisation on paraffin embedded 12 week old wild type (a) and Bmi-1 
knockout (b) murine liver sections using a pan-centromeric probe, indirectly visualised 
using DAB. Scale bars 10 µm. c) Quantification of average numbers of visible 
centromeres per hepatocyte nucleus. Data presented are means of individual mice ± 
standard deviation. n=4 mice, with a total of 645 hepatocytes of each genotype 
assessed. Significance assessed using 2-tailed Student’s t-test. d,e) Distribution of 
individual centromere counts for wild type and Bmi-1 knockout mice. 
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4.3.4. Hepatocyte binucleation is unimpaired in Bmi-1 knockout mice: 
One well characterised pathway by which polyploid nuclei develop is via the formation 
of binucleated cells (Guidotti et al, 2003). To assess whether the binucleation process 
was impaired in Bmi-1 knockout mice, binucleate cell numbers were manually counted 
using the previously described touch preparation images. This analysis demonstrated 
no significant reduction in the frequency of binucleate cells at 12 weeks of age (Figure 
24). This result suggests that Bmi-1 knockout hepatocytes are still able to become 
binucleate at the same frequency as wild type cells, and that any reduction in the 
ploidy of Bmi-1 knockout hepatocyte nuclei did not occur through impaired 
binucleation.  
 
 
Figure 24: Binucleation is unimpaired in Bmi-1 knockout mouse hepatocytes. 
The numbers of binucleate hepatocytes in touch preparation images from 12 week old 
female mice (minimum 20 images per mouse) were manually counted, and expressed 
as a percentage of the total number of cells. n=3 wild type (Wt) and 3 Bmi-1 knockout 
(KO) mice. Data presented are means of individual mice ± standard deviation. 
Significance assessed using 2-tailed Student’s t-test. 
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4.3.5. Bmi-1 knockout livers exhibit increased expression of the ploidy marker Igfbp2: 
To provide further evidence for a reduction in polyploidisation in Bmi-1 knockout mice, 
the expression levels of insulin growth factor binding protein 2 (Igfbp2) were 
examined. Igfbp2 mRNA expression has previously been proposed as a marker of 
polyploid cells, as it is upregulated in polyploid nuclei (Kirschner et al, 2007). 
Quantitative reverse transcriptase PCR (Q-RT-PCR) analysis revealed reduced levels 
of Igfbp2 mRNA in Bmi-1 knockout mouse livers at 12 weeks of age (Figure 25), 
supporting the previous conclusion that there are fewer polyploid hepatocytes.  
 
 
Figure 25: Bmi-1 knockout mice express reduced levels of Igfbp2. 
Q-RT-PCR data on cDNA made from mRNA extracted from Bmi-1 wild type (Wt) and 
knockout (KO) whole mouse livers for the polyploidy marker Igfbp2. Values expressed 
as transcripts of Igfbp2 per transcript of reference gene (eEf2). Data are means ± SD 
from 3 animals per group. * p<0.05 using 2-tailed Student’s t-test. 
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4.3.6. Bmi-1 knockout mouse livers have normal levels of phosphorylated Akt: 
The polyploidisation process is driven by a program of incomplete cytokinesis, but the 
signals which control this have not been fully elucidated. It seems that insulin may 
regulate the process via the Akt signalling pathway, as inhibition of Akt signalling in 
primary rat hepatocytes leads to a reduction in the number of cytokinesis failure 
events (Celton-Morizur et al, 2009). It has also been observed that depletion of BMI-1 
can lead to a decrease in the levels of phosphorylated (active) Akt in breast (Guo et 
al, 2007b) and pancreatic (Song et al, 2010) cancer cell lines. To assess the 
hypothesis that reductions in Akt signalling could be the cause of the decreased 
polyploidisation observed in Bmi-1 knockout mice, levels of phosphorylated Akt 
(Ser473) protein in whole liver extracts from 8 week old mice were examined using 
western blotting. No apparent reduction in phospho-Akt levels was observed in mice 
at 8 weeks of age (Figure 26a), this was quantified by densitometric analysis of the 
blot (Figure 26b). This finding indicates that any reduction in polyploidisation in Bmi-1 
knockout mouse livers is not due to a reduction in Akt activity. 
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Figure 26: Bmi-1 knockout mice exhibit normal levels of phosphorylated Akt. 
a) Western blotting of whole liver protein extracts from 8 week old Bmi-1 wild type and 
knockout mice for phosphorylated Akt (Ser473) (pAkt). Total Erk1/2 was used as a 
housekeeping gene. b) Densitometric analysis of blot photograph using ImageJ. Data 
expressed as mean ± SD of the integrated density of pAkt band divided by Erk1/2 
band. Significance assessed using 2-tailed Student’s t-test. 
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4.4. Expression changes of other Polycomb genes in Bmi-1 knockout mouse 
liver: 
4.4.1. The Bmi-1 homologue Mel-18 is upregulated in Bmi-1 knockout mouse liver: 
The Bmi-1 knockout mice appeared to present a relatively subtle abnormal hepatic 
phenotype in comparison to other organs, especially in cholangiocytes where Bmi-1 
was strongly expressed in wild type mice. These observations raised the question of 
whether other polycomb family members are able to compensate for the loss of Bmi-
1. The most obvious candidate is the partial Bmi-1 homologue, Mel-18, which shows a 
large degree of sequence homology to Bmi-1 and may be functionally redundant in 
some, but not all, cases (discussed in introduction section 1.10). Potential Mel-18 
compensation was first investigated by using Q-RT-PCR to examine gene expression 
levels of both Bmi-1 and Mel-18 mRNA in Bmi-1 wild type and knockout mice at three 
time points. As expected, Bmi-1 expression was absent in livers of Bmi-1 knockout 
mice, while in wild type mice mRNA levels did not change significantly between time 
points (Figure 27a). Mel-18 expression was highest in newborn wild type mice, and 
then decreased dramatically in adult mice (Figure 27b). Newborn Bmi-1 knockout 
mice expressed Mel-18 at similar levels to wild type mice, however the adult knockout 
mice exhibited upregulation of Mel-18 relative to the wild types (Figure 27b). This Mel-
18 upregulation was small but significant at 8 weeks of age, and greater in 12 week 
old mice. To confirm that the increased Mel-18 mRNA translated to increased protein 
expression, protein levels of Mel-18 were assessed by western blotting on whole liver 
extracts. The blots were quantified using densitometry, using Erk1/2 levels as a 
reference gene. In contrast to the Q-RT-PCR results, there was no upregulation of 
Mel-18 protein in 8 week old Bmi-1 knockout mice (Figure 27c,e). However, mice at 
12 weeks of age showed an approximate doubling of Mel-18 protein expression levels 
relative to the wild type mice (Figure 27d,e), confirming the Q-RT-PCR result. One 
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potential explanation is that Mel-18 is being upregulated in the older knockout mice to 
compensate for the loss of Bmi-1. 
To assess whether Mel-18 and Bmi-1 are expressed within the same cellular 
compartments, the localisation of Mel-18 protein in adult murine liver was assessed 
using immunohistochemistry (Figure 28). No labelling was observed in slides 
incubated with an isotype control antibody (Figure 28a). The expression pattern of 
Mel-18 was virtually identical to that of Bmi-1, with high Mel-18 immunoreactivity 
observed in all cholangiocytes (Figure 28b). Due to the sequence similarity between 
Mel-18 and Bmi-1, it was considered possible that the anti-Mel-18 antibody was cross-
reacting with Bmi-1. To rule this out, liver sections from Bmi-1 knockout mice were 
also immunolabelled for Mel-18. The same expression pattern as in the wild type mice 
was observed (Figure 28c), demonstrating that the anti-Mel-18 antibody was not 
cross-reacting with Bmi-1. There did not appear to be any clear evidence of Mel-18 
protein upregulation in biliary cells of Bmi-1 knockout mice using 
immunohistochemistry, however it is likely that the antibody is not sensitive enough to 
detect changes in protein level using this method. Together, these results suggest that 
Mel-18 may be able to compensate for the absence of Bmi-1, given that potential 
redundancy between the two proteins has previously been reported (see introduction 
section 1.10). This may account for the apparent absence of structural biliary 
abnormalities observed in Bmi-1 knockout mice. 
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Figure 27: Mel-18 is upregulated in Bmi-1 knockout mice during ageing. 
a,b) Q-RT-PCR data on cDNA made from mRNA extracted from Bmi-1 wild type (Wt) 
and knockout (KO) whole mouse livers from newborn (n=5 animals per group), 8 
week (n=7) and 12 week (n=3) old mice, for expression of Bmi-1 (a) and Mel-18 (b). 
Values expressed as transcripts of gene of interest per transcript of reference gene 
(eEf2). Data are means ± SD from n animals per group. c,d) Western blotting on 
whole liver protein extracts from 8 week (c) and 12 week old (d) Wt and KO mice for 
Mel-18. e) Densitometric analysis of Mel-18 blot photographs using ImageJ software 
(n=3). Data expressed as mean ± SD of the integrated density of Mel-18 band divided 
by Erk1/2 band. Significance assessed using 2-tailed Student’s t-test, * p<0.05. 
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Figure 28: Mel-18 is expressed in cholangiocytes in murine liver. 
Paraffin-embedded sections of 12 week old murine livers labelled using indirect 
immunohistochemistry to detect Mel-18; antibody visualised with DAB and sections 
counterstained with haematoxylin. a) Section incubated with isotype control antibody. 
b) Wild type mouse. c) Bmi-1 knockout mouse. Mel-18 expression was observed in 
bile ducts (black arrow). All scale bars 50 µm. 
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4.4.2. Expression of Bmi-1 homologues Mblr and Nspc1 are not altered in Bmi-1 
knockout liver: 
In addition to Mel-18, there are two other published Bmi-1 homologues; MBLR and 
Nspc1. To investigate whether expression changes in these genes could have a 
compensatory effect following loss of Bmi-1, mRNA levels of Mblr and Nspc1 were 
assessed by Q-RT-PCR in 8 week old Bmi-1 wild type and knockout mouse livers. 
Both Mblr and Nspc1 were expressed in murine liver, however no alterations in the 
expression of either mRNA were observed in the knockout liver relative to the wild 
type (Figure 29a,b). It is possible the presence of MBLR and Nspc1 in Bmi-1 knockout 
livers allows them to perform some compensatory functions, however there is no 
published data suggesting these proteins exhibit functional redundancy with Bmi-1, so 
it is not possible to draw firm conclusions on this issue. 
4.4.3. Expression of other PRC members in Bmi-1 knockout mouse liver: 
There have been no previous studies of the expression changes in other PRC 
members following Bmi-1 knockdown in mice, so preliminary Q-RT-PCR studies were 
performed to ascertain whether other PRC complex members were differentially 
expressed in Bmi-1 knockout mouse livers. Initially, the PRC2 members Eed, Ezh1, 
Ezh2 and Suz12, were chosen for analysis as these are essential core components 
the complex. No changes in expression of any of these genes were detected in 8 
week old Bmi-1 knockout livers relative to wild types (Figure 29c). Preliminary analysis 
of the expression of other PRC1 members was carried out on a single pair of wild type 
and knockout mice at 8 weeks of age. For the majority of genes, no significant 
changes in expression were observed (Figure 29d). It was therefore decided not to 
continue with further analysis of these PRC1 members. There was however an 
upregulation of the PRC1 member Cbx7 in the Bmi-1 knockout livers at 8 weeks of 
age, which was confirmed in samples from multiple mice (Figure 29e). This suggests 
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that increased Cbx7 expression could be part of a compensatory response to the 
deletion of Bmi-1. 
 
Figure 29: Expression of other Polycomb genes in Bmi-1 knockout mice. 
Q-RT-PCR data using cDNA made from mRNA extracted from Bmi-1 wild type (Wt) 
and knockout (KO) whole mouse livers. Data expressed as transcripts of gene of 
interest per transcript of reference gene (eEf2). a) Mblr (n=3). b) Nspc1 (n=3). c) Core 
PRC2 genes in 8 week old mice (n=3, all p values >0.05). d) Preliminary analysis of 
PRC1 members in 8 week old mice (n=1). e) Cbx7 in 8 week old mice (n=3). All data 
except (d) are mean ± SD. * p<0.05 using 2-tailed Student’s t-test. 
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4.5. Discussion: 
4.5.1. Liver function in Bmi-1 knockout mice: 
The results from serum analysis of liver function markers hint at some liver damage in 
8 week old Bmi-1 knockout mice, based on increased levels of AST. However, as 
noted earlier, AST is also expressed in other tissues such as cardiac muscle, so it is 
not necessarily an exclusive marker of liver dysfunction. ALT levels, which are a better 
indicator of liver damage, did appear slightly increased in Bmi-1 knockout mice, 
however the change was not statistically significant, suggesting that any damage is 
mild. There were also no obvious histological signs of liver disease which could 
account for the elevated levels of these markers in Bmi-1 knockout livers. Serum AP 
levels were elevated in Bmi-1 knockout mice, which suggests that there may be some 
impairment in bile flow, possibly due to bile duct damage. However, as noted earlier, 
serum AP can also be induced in cases of bone disease, and it is known that Bmi-1 
knockout mice have defects in skeletal formation (van der Lugt et al, 1994). Levels of 
serum bilirubin, which can also be increased in bile duct obstruction and cholestasis 
(Fox et al, 2006) were normal in Bmi-1 knockout mice, suggesting against any biliary 
damage. There was also no histological evidence of bile duct damage. The potential 
for impaired bile flow could be assessed in the future using further serum biomarkers, 
such as gamma-glutamyltransferase (GGT), which can also be elevated in biliary 
obstruction. 
4.5.2. Liver structure and polyploidisation in Bmi-1 knockout mice: 
Assessment of blindly labelled H&E stained sections from newborn Bmi-1 knockout 
mice revealed no obvious defects in hepatic histology. This is unsurprising given that 
other organs in the Bmi-1 knockout mouse tend to exhibit defects that get 
progressively worse with ageing (van der Lugt et al, 1994). For example, the knockout 
mice are born with a normal thymus, which then becomes depleted of mature 
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thymocytes in adult mice. They also have a progressive haematopoietic defect which 
only becomes apparent postnatally, and only exhibit an ataxic gait from 2-4 weeks of 
age. These factors have led to the conclusion that Bmi-1 function is more important in 
adult tissues than during development; this appears to fit with the lack of obvious 
phenotype in the livers of newborn Bmi-1 knockout mice. 
Despite the fact that Bmi-1 was strongly expressed in cholangiocytes in wild type 
mice, biliary structures examined appeared to be morphologically normal in both 
newborn and adult Bmi-1 knockout mice. This was based on expression of the bile 
duct marker CK19 and histological analysis of blindly labelled H&E sections. This 
result suggests that Bmi-1 is not essential for normal bile duct development or 
homeostasis. Instead, the phenotypic alterations in adult Bmi-1 knockout mice were 
found in hepatocytes. This is interesting given that Bmi-1 expression in wild type 
hepatocytes appeared much weaker than in cholangiocytes, and was not clearly 
observed in all cells. Examination of H&E stained sections revealed abnormal 
organisation within the parenchyma, with hepatocytes appearing smaller and more 
uniform in size. Image analysis of individual hepatocytes isolated using touch 
preparations demonstrated that the hepatocyte nuclei in Bmi-1 knockout mice are on 
average smaller in area than the wild types. Given that nuclear size is correlated with 
polyploidy, this result infers that Bmi-1 knockout mice suffer from an impaired liver 
polyploidisation process. This hypothesis was supported by data demonstrating that 
Bmi-1 knockout livers have on average fewer centromeres per hepatocyte, suggesting 
reduced DNA content. Bmi-1 knockout livers also expressed lower levels of Igfbp2, a 
marker associated with polyploid cells. This ploidy phenotype appears to be due to a 
lack of accumulation of larger polyploid nuclei as opposed to a reduction in hepatocyte 
binucleation, as binucleate cell numbers were unchanged. A more comprehensive 
analysis of the different distribution of 2n, 4n, 8n etc. hepatocytes could be achieved 
in future through FACS analysis, although this is unable to distinguish between some 
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types of mononuclear and binuclear hepatocytes (for example 4n mononuclear vs. 
2x2n binuclear cells) (Funk-Keenan et al, 2008). 
The function of polyploidy in hepatocytes has been the subject of debate and is not 
well understood (see introduction section 1.5). It is therefore difficult to draw 
conclusions, both in terms of the reasons for the reduced polyploidisation and the 
functional consequences of it for the Bmi-1 knockout mice. The signalling pathways 
that control the generation of polyploid cells have not been well defined, however one 
factor that does appear to be involved is insulin signalling. Rats treated with 
streptozotocin to destroy pancreatic β-cells have decreased numbers of binucleated 
tetraploid hepatocytes, as do ob/ob mice with impaired insulin signalling (Celton-
Morizur et al, 2009). Furthermore, injection of insulin into rats increases the number of 
tetraploid hepatocytes, providing strong evidence for the involvement of insulin 
signalling in the tetraploidisation process. Bmi-1 knockout mice do suffer from reduced 
pancreatic β-cell mass, and their serum insulin levels fail to increase in response to 
glucose challenge (Dhawan et al, 2009). It was therefore considered possible that 
reduced insulin levels were responsible for the impaired polyploidisation process in 
Bmi-1 knockout mice. Moreover, Celton-Morizur et al also report that the PI3K/Akt 
pathway lies downstream of insulin signalling to regulate the generation of tetraploid 
cells. This was based on data showing a correlation between ploidy and levels of 
phospho-Akt (Ser473) in rodents with either impaired or increased insulin signalling, 
and that inhibition of Akt signalling in cultured hepatocytes reduces the number of 
cytokinesis failure events that lead to polyploidisation. Depletion of BMI-1 in human 
cell lines also leads to a reduction in phospho-Akt levels (Guo et al, 2007b), 
suggesting that impaired Akt signalling could be a factor in the ploidy defects in Bmi-1 
knockout mice. However, Bmi-1 knockout mice did not exhibit any changes in 
phospho-Akt levels, based on western blotting analysis. This appears to show that 
reduced activity of the Akt signalling pathway is not responsible for the impaired 
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polyploidisation process in Bmi-1 knockout hepatocytes, and that if insulin signalling is 
involved then it must act via other pathways. It cannot be ruled out that Akt signalling 
is only impaired in a small number of Bmi-1 knockout hepatocytes, and that phospho-
Akt levels would be normal in most liver cells. Western blotting may not have been 
sensitive enough to detect small variations of this type, and the antibody failed to work 
for immunohistochemistry.  
It is possible there is a link between the mass and growth rates of Bmi-1 knockout 
mice and their reduced polyploidisation. Mice strains selected for low body weight 
gain (both between birth and 10 days, and 28 and 56 days of age) appear to show 
increased numbers of 2C cells (C = DNA content), and reduced 4C, at 56 days of age 
(Funk-Keenan et al, 2008). One study has also found a strong correlation between the 
postnatal growth rate of animals and mean cell ploidy (Vinogradov et al, 2001). 
However, their analysis was based on comparing growth rates and ploidy levels 
across different mammalian species, so the relevance of these results within a single 
species is unclear. Nevertheless, growth rates of Bmi-1 knockout mice were reduced 
relative to wild type littermates, so it would appear that this could be a factor in the 
impaired polyploidisation phenotype. The smaller size of Bmi-1 knockout mice means 
that the mice have smaller livers, as the liver to body weight ratio remained constant. 
Given that polyploidisation is a means of increasing mass through hypertrophic 
growth, it is possible that there is a reduced requirement for this process in the Bmi-1 
knockout mice. As discussed in the introduction, there have also been some 
suggestions that polyploid hepatocytes have improved function compared to diploid 
cells, based on upregulation of some key liver-specific genes (Anatskaya & 
Vinogradov, 2010). If this was the case, then the reduced levels of polyploid 
hepatocytes in Bmi-1 knockout mice could be associated with impaired liver function. 
However, this link remains tenuous at present, as the studies are not entirely 
convincing, being based on comparisons between livers of different species. Diploid 
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hepatocytes also synthesise higher levels of proteins such as albumin than polyploid 
ones (Rajvanshi et al, 1998), while other work has shown a negative correlation 
between hepatic ploidy and metabolic scope when comparing across different species 
(Vinogradov et al, 2001), so the link between ploidy and cell function is not conclusive. 
4.5.3. Similarities to mice with inactivated c-myc: 
The hepatic phenotype in Bmi-1 knockout mice, particularly in terms of abnormal cell 
size and ploidy, bears similarities with that described by Baena et al in mice with 
inactivated c-myc (Baena et al, 2005). The authors bred c-mycfl/fl mice with inducible 
mx-cre transgenic mice to create a system capable of c-myc deletion in the liver, 
although it should be noted that c-myc did not appear to be deleted in all hepatocytes. 
In addition, the mice also showed c-myc deletion in the bone marrow, so it is possible 
that secondary effects could be contributing to the hepatic phenotype. Following 
postnatal c-myc deletion, the authors found that 10 week old mice exhibit a large 
reduction in total body weight, and a small but significant increase in liver to body 
weight ratio. The mice also have abnormalities in parenchymal organisation, reduced 
hepatocyte size and a reduced population of polyploid cells.  
The results described above show similarities with the phenotype observed in Bmi-1 
knockout mouse livers, in particular in terms of the reduced mouse body weight, 
reduced hepatocyte size and polyploidy. These similarities are interesting given the 
long established relationship between c-myc and Bmi-1. Bmi-1 was initially discovered 
as an oncogene cooperating with c-myc in the generation of mouse lymphomas (van 
Lohuizen et al, 1991b). It has since been shown that the human BMI-1 promoter 
contains a c-myc binding site and that c-myc can positively regulate BMI-1 expression 
(Guo et al, 2007a), demonstrating that c-myc can act as an upstream regulator of 
Bmi-1. It therefore appears plausible that c-myc and Bmi-1 could be collaborating in 
the regulation of some processes in murine liver, which leads to similar phenotypic 
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abnormalities when either is deleted. It would be interesting in future to examine Bmi-
1 expression in c-myc deficient mice to assess this hypothesis further. It is also 
notable that the mice with c-myc deletion have severe anaemia and die after 3 
months, similar to Bmi-1 knockout mice. This is likely to be due to deletion of c-myc in 
the bone marrow rather than liver, however again illustrates similarities between the 
two mouse strains. 
4.5.4. Expression of other Polycomb genes in Bmi-1 knockout livers: 
As described earlier, the livers of newborn Bmi-1 knockout mice appeared 
phenotypically normal, as in other tissues. There were also no obvious abnormalities 
in biliary structures in adult Bmi-1 knockout mice, despite the fact that Bmi-1 was 
highly expressed in cholangiocytes in wild type animals. These observations suggest 
that other pathways can compensate for the deletion of Bmi-1. It is possible that this 
includes compensation by other members of the Polycomb group family. The most 
likely candidate is the partial Bmi-1 homologue, Mel-18, which is structurally very 
similar and therefore would seem likely to have similar functions. There is some 
debate over the function of Mel-18, with studies suggesting it may act as an oncogene 
or tumour suppressor in different contexts (see introduction section 1.10.1). However, 
the fact that Mel-18 and Bmi-1 knockout mice show many similar defects, and that 
double knockout mice exhibit more severe versions of them, suggests the proteins 
can act in synergy. In addition to this, some human cell lines (such as WI-38 lung 
fibroblasts) only show proliferative defects when both BMI-1 and MEL-18 are depleted 
(Wiederschain et al, 2007). These data suggest that functional redundancy between 
the two proteins exists in some contexts. Q-RT-PCR analysis of wild type mice 
showed high Mel-18 mRNA expression in newborn animals, and much lower 
expression in adult mice. This result suggests that Mel-18 may be more important in 
fetal development, which could possibly be a factor in the lack of noticeable 
phenotypic abnormalities observed in newborn Bmi-1 knockout mice. Upregulation of 
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Mel-18 mRNA was not found in newborn Bmi-1 knockout mice relative to wild types. 
In contrast, adult knockout mice (8 and 12 weeks) did have higher levels of Mel-18 
mRNA expression than wild types. This hints that Mel-18 could be upregulated in 
older Bmi-1 knockout mice to compensate for the loss of Bmi-1.  However, this was 
only found at the protein level in 12 week old mice, based on western blotting 
analysis. The physiological importance of this upregulation is therefore unclear, 
especially given that the mice become generally unwell by this age. Of more interest 
is the discovery that the Mel-18 expression pattern in murine liver is the same as for 
Bmi-1, with strong expression in cholangiocytes. This finding advances the possibility 
that Mel-18 may be able to compensate for the loss of Bmi-1 in cholangiocytes. Future 
in vitro work could further this work by examining whether knockdown of either Bmi-1 
and/or Mel-18 leads to similar phenotypic effects in cultured hepatic cell populations, 
as this has not specifically been done in liver cells before. We have recently 
established a collaboration (with Vasanta Subramanian, University of Bath) which will 
provide access to Mel-18 knockout mice, generating future opportunities to assess 
whether these mice suffer similar hepatic abnormalities, which would suggest 
cooperation between the two proteins in liver function. 
It is also possible that other Polycomb proteins may be involved in compensating for 
the loss of Bmi-1. Two other Bmi-1 homologues, MBLR and Nspc1, were expressed 
at the mRNA level in murine livers, although these were not upregulated in Bmi-1 
knockout mice. Functional redundancy between these proteins and Bmi-1 has not 
previously been investigated. The majority of other Polycomb genes examined by Q-
RT-PCR were also expressed in liver, but were not upregulated in Bmi-1 knockout 
mice. The exception was the PRC1 component Cbx7, which showed increased 
expression in 8 week old Bmi-1 knockout mouse livers compared to wild types. Cbx7 
is able immortalise mouse fibroblasts via repression of the Ink4a/Arf locus, and Cbx7 
overexpression can also bypass the premature senescence observed in Bmi-1 null 
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fibroblasts in culture (Gil et al, 2004). This suggests that Cbx7- and Bmi-1-containing 
complexes may act independently, and that Cbx7 upregulation could be part of a 
compensatory mechanism in Bmi-1 knockout mice. This could be examined in more 
detail in future by looking at the localisation of Cbx7 protein in Bmi-1 knockout liver 
tissue.  
4.6. Summary of Chapter: 
In summary, Bmi-1 knockout mice did not exhibit obvious histological abnormalities in 
biliary structure. This could potentially be due to compensatory effects of Mel-18, 
which has a similar expression pattern. Instead, the major structural defect was within 
the hepatic parenchyma, with increased numbers of hepatocytes per microscope field 
found in Bmi-1 knockout livers. Analysis of hepatocyte cell and nuclear size and 
centromere numbers suggested that the Bmi-1 knockout mice suffer from impaired 
polyploidisation. It is unclear if this phenotype is directly caused by the loss of 
hepatocyte Bmi-1 expression, or is a secondary effect arising from other defects in the 
mice. The apparently low levels of Bmi-1 in normal hepatocytes, together with the fact 
that parameters such as reduced growth rate and insulin levels have been linked with 
reduced ploidy, suggests that it could be a secondary effect. However, the fact that 
mice with hepatic deletion of c-myc exhibit similar defects is interesting given the 
established link between c-myc and Bmi-1, and suggests that Bmi-1 could play a 
direct role in hepatocyte polyploidisation. This link could be further assessed in future 
by examining Bmi-1 expression levels in mice following c-myc deletion, or by 
attempting to rescue defects in the c-myc deficient mice by overexpressing Bmi-1. In 
the longer term, the creation of a liver specific Bmi-1 knockout mouse could further 
examine these issues without the complication of defects in other organs. In vitro 
experiments involving knockdown of Bmi-1 in primary hepatocytes which exhibit 
different ploidy classes would also help address whether Bmi-1 has a direct role in 
polyploidisation.  
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5. The effect of Bmi-1 deletion on the cell cycle in murine liver: 
5.1. Hepatocyte proliferation in Bmi-1 knockout mice: 
The loss of Bmi-1 in cultured cells tends to result in a reduction in self-renewal and 
proliferation. The same effect is seen in vivo, for example Bmi-1 knockout mice exhibit 
reduced proliferation of pancreatic β-cells (Dhawan et al, 2009) and granule cell 
precursors in the cerebellum (Leung et al, 2004). There have been no in vitro or in 
vivo studies examining the effects of Bmi-1 depletion on normal hepatocytes or 
cholangiocytes, however Bmi-1 knockdown does lead to reduced proliferation in HCC 
(Sasaki et al, 2008a) and CC (Sasaki et al, 2009) cell lines. To investigate differences 
in the proliferation of liver cells following Bmi-1 deletion in vivo, Bmi-1 wild type and 
knockout mice were injected with BrdU one hour prior to sacrifice, and tissue sections 
were subsequently labelled with an antibody against BrdU to identify cells undergoing 
DNA synthesis (examples in Figure 30a,b). The slides were labelled blindly to prevent 
bias, and results were quantified by counting the number of BrdU positive hepatocyte 
nuclei across five randomly selected 400x microscope fields per mouse. The results 
were adjusted for the increased number of nuclei per field observed in the Bmi-1 
knockout mice (see chapter 4). There were no qualitative differences in proliferation in 
both newborn and p7 Bmi-1 knockout mice, although it was not possible to quantify 
this in hepatocytes due to the large number of BrdU positive cells in regions of 
haematopoiesis. At 8 weeks of age, Bmi-1 knockout mice showed a small but 
significant increase in hepatocyte BrdU incorporation compared to wild types, 
indicating increased hepatocyte proliferation, although there was some heterogeneity 
among different knockout animals (Figure 30c). However, by 12 weeks of age the 
knockout mice had decreased hepatocyte proliferation compared to the wild types 
(Figure 30d). To provide validation for these data, tissue sections were also labelled 
with an antibody against the proliferation marker Ki67, a protein present in all phases 
of the cell cycle (Scholzen & Gerdes, 2000). The Ki67 immunolabelling data confirmed 
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an increase in hepatocyte proliferation in 8 week old Bmi-1 knockout mice, and a 
decrease in 12 week old mice (Figure 30e,f).  
These results demonstrate that the loss of Bmi-1 does not lead to a decrease in 
hepatocyte proliferation in mice up to 8 weeks of age. In contrast, there was actually a 
slight increase in hepatocyte proliferation in 8 week old Bmi-1 knockout mice. By 12 
weeks of age, a decrease in hepatocyte proliferation was observed in Bmi-1 knockout 
mice. It is possible that this may be secondary to the physiological consequences of 
Bmi-1 deletion in other organs, as the health of the mice progressively declines with 
age, leading them to become visibly unwell by 12 weeks of age.  
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Figure 30: Bmi-1 knockout mice show altered hepatocyte proliferation. 
a,b) Examples of immunolabelling to detect BrdU in Bmi-1 wild type (a) and knockout 
(b) paraffin-embedded liver sections. Antibody visualised using DAB and 
counterstained with haematoxylin. Scale bars 50 µm. c-d) Average percentages of 
hepatocyte nuclei positive for BrdU in a 400x microscope field for wild type (Wt) and 
Bmi-1 knockout (KO) mice. Hepatocytes were counted in 5 randomly selected 
microscope fields per section at 8 weeks (c, n=10) and 12 weeks (d, n=6) of age. Data 
are means ± SD. e,f) Incorporation of Ki67 in hepatocyte nuclei. Results were 
obtained using the same method as for BrdU in 8 week (e, n=7) and 12 week (f, n=6) 
old mice. * p<0.05 using 2-tailed Student’s t-test. 
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5.2. Cholangiocyte proliferation in Bmi-1 knockout mice: 
Due to the high expression in cholangiocytes, it was postulated that the loss of Bmi-1 
could lead to impairment in the proliferation of normal cholangiocytes, as occurs in CC 
lines depleted of Bmi-1 (Sasaki et al, 2009). To investigate this hypothesis, BrdU and 
Ki67 labelled liver sections from Bmi-1 wild type and knockout mice were examined. 
However, the proliferation rate of wild type cholangiocytes is very low in vivo under 
resting conditions, having been previously reported as 0.4% (Glaser et al, 2007). 
Because of this, and the relatively low number of visible cholangiocytes per tissue 
section, there were insufficient numbers of cholangiocytes which incorporated BrdU or 
Ki67 to perform any meaningful quantification, as many sections even in wild type 
mice did not contain any proliferating cholangiocytes. It was however observed that 
sporadic cholangiocytes in Bmi-1 knockout mice expressed Ki67 (Figure 31), although 
these were not seen on the majority of sections. This observation suggests that Bmi-1 
deficient cholangiocytes retain some capacity to proliferate, however more work would 
be required to address this issue.  
 
Figure 31: Cholangiocytes in Bmi-1 knockout mice sporadically express Ki67. 
Indirect immunolabelling of paraffin-embedded liver sections to detect Ki67. Antibody 
visualised with DAB and sections counterstained with haematoxylin. Example of 
tissues from a) a Bmi-1 wild type mouse and b) a Bmi-1 knockout mouse, showing 
Ki67 positive cholangiocytes (black arrow). Scale bars 50 µm. 
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5.3. Expression changes of cyclin D1 and c-myc in Bmi-1 knockout mice: 
5.3.1. Cyclin D1 protein is overexpressed in Bmi-1 knockout mouse livers: 
The increased hepatocyte proliferation observed in livers of 8 week old Bmi-1 
knockout mice raised the question of whether any proteins involved in facilitating 
progression of the cell cycle were upregulated. To examine this, the expression of 
cyclin D1 was assessed by western blotting and immunohistochemistry. Cyclin D1 
forms complexes with Cdk4 or Cdk6, which are required for progression through the 
G1 phase of the cell cycle. Its expression has previously been found to be decreased 
in pancreatic cancer cell lines depleted of Bmi-1 (Song et al, 2010). In contrast to this 
result, liver extracts from 8 week old Bmi-1 knockout mice contained increased levels 
of cyclin D1 protein in comparison to wild type mice, as measured using western 
blotting (Figure 32a,b). Immunohistochemical analysis revealed that the majority of 
hepatocytes in 8 week old Bmi-1 wild type mice were negative for cyclin D1, with only 
occasional hepatocytes displaying weak immunoreactivity (Figure 32e,g). In Bmi-1 
knockout mice, the number of positive hepatocytes was greatly increased (Figure 
32f,h,i), confirming the western blotting data. These results show that cyclin D1 
expression is increased in 8 week old Bmi-1 knockout mouse livers, which is 
consistent with the increased hepatocyte proliferation. 
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Figure 32 (overleaf): Cyclin D1 is overexpressed in Bmi-1 knockout mice. 
a) Western blotting of whole liver protein extracts from 8 week old Bmi-1 wild type and 
knockout mice for cyclin D1. Total Erk1/2 was used as a housekeeping gene. b) 
Densitometric analysis of blot photograph using ImageJ software. Data expressed as 
mean ± SD of the integrated density of cyclin D1 band divided by Erk1/2 band. 
Significance assessed using 2-tailed Student’s t-test, * p<0.05. c-h) Indirect 
immunohistochemistry on paraffin-embedded liver sections to detect cyclin D1. 
Antibody visualised with DAB and counterstained with haematoxylin. c,e,g) Sections 
from wild type mouse. d,f,h) Sections from Bmi-1 knockout mouse. c,d) Sections 
incubated with isotype control antibody instead of cyclin D1. All scale bars 50 µm. i) 
Quantification of percentage of cyclin D1 positive nuclei in Bmi-1 wild type (Wt) and 
knockout (KO) mice. n=4 mice, 10 images per mice. Significance assessed using 2-
tailed Student’s t-test, * p<0.05. 
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5.3.2. c-myc is overexpressed in Bmi-1 knockout mouse livers: 
Preliminary analysis of expression changes in the pro-proliferative transcription factor 
c-myc were also carried out using Q-RT-PCR. This revealed a significant upregulation 
of c-myc mRNA expression in Bmi-1 knockout livers from 8 week old mice (Figure 33). 
Future work will assess whether this upregulation is maintained at the protein level. C-
myc has an important role in cell cycle progression, so its upregulation would again be 
consistent with increased hepatocyte proliferation in 8 week old Bmi-1 knockout mice. 
 
 
 
 
Figure 33: c-myc mRNA is overexpressed in Bmi-1 knockout mice. 
Q-RT-PCR data on cDNA made from mRNA extracted from Bmi-1 wild type (Wt) and 
knockout (KO) whole mouse livers at 8 weeks of age (n=5 mice per group). Values 
expressed as molecules of gene of interest per molecule of reference gene (eEf2). 
Data are means ± SD from 3 animals per group. * p<0.05 using 2-tailed Student’s t-
test. 
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5.4. Expression of cell cycle inhibitors in Bmi-1 knockout livers: 
5.4.1. p16Ink4a, p19Arf and p21 are upregulated in Bmi-1 knockout mouse liver: 
The absence of any decrease in proliferation in hepatocytes in 8 week old Bmi-1 
knockout mice appeared to be at odds with the well characterised role of Bmi-1 in 
repressing the expression of cell cycle inhibitors. These include the Ink4a/Arf locus, 
which encodes p16Ink4a and p19Arf (Jacobs et al, 1999a), and p21 (Fasano et al, 2007). 
It was therefore expected that expression of these would increase in Bmi-1 knockout 
mice. To determine whether this was the case, Q-RT-PCR was used to assess RNA 
expression of p16Ink4a, p19Arf, and p21 at three time points (Figure 34). In wild type 
mouse livers, p16Ink4a expression was negligible in newborn and adult mice. In the 
Bmi-1 knockout livers, significant upregulation of p16Ink4a was observed at all three 
time points (Figure 34a). This result agrees with published data that Bmi-1 represses 
the Ink4a/Arf locus (Jacobs et al, 1999a). A similar result was seen for p19Arf in mice 
of 8 and 12 weeks of age, although there was no upregulation of this gene in newborn 
Bmi-1 knockout mice (Figure 34b). Low expression of p21 was observed in both Bmi-
1 wild type and knockout newborn mice, and levels remained low in the wild type in 
older mice (Figure 34c). However, there was a small but significant upregulation of 
p21 mRNA in 8 week old Bmi-1 knockout mice, and then a much more dramatic 
upregulation at 12 weeks of age. Therefore, deletion of Bmi-1 results in increased 
expression of several cell cycle inhibitors at the mRNA level. 
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Figure 34: p16Ink4a, p19Arf and p21 are upregulated in Bmi-1 knockout mice. 
Q-RT-PCR data on cDNA made from mRNA extracted from Bmi-1 wild type (Wt) and 
knockout (KO) whole mouse livers for a) p16Ink4a, b) p19Arf and c) p21. All genes were 
assessed in livers from newborn (n=5 animals per group), 8 week (n=7) and 12 week 
(n=3) old mice. Values expressed as molecules of gene of interest per molecule of 
reference gene (eEf2). Data are means ± SD from n animals per group. * p<0.05 
using 2-tailed Student’s t-test. 
 
 
 
 
 
191 
 
5.4.2. Expression of p16Ink4a and p21 proteins are increased in Bmi-1 knockout livers: 
Western blotting was then used to assess whether these results were also relevant at 
the protein level. Expression of p16Ink4a protein was strongly upregulated in Bmi-1 
knockout liver protein extracts at both 8 and 12 weeks of age (Figure 35a,b), in 
agreement with the Q-RT-PCR results. The same result was observed with p21 
protein (Figure 35c,d), although in this case the degree of upregulation appeared 
similar in knockout mice at both 8 and 12 weeks of age. This was confirmed by 
densitometric analysis of the p21 blot (Figure 35e). This result was not completely in 
agreement with the Q-RT-PCR results, where the p21 upregulation was much more 
dramatic in 12 week old Bmi-1 knockout livers, suggesting the possibility of post-
transcriptional regulation. Attempts to detect p19Arf protein by western blotting were 
unsuccessful.  
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Figure 35: p16Ink4a and p21 protein are overexpressed in Bmi-1 knockout mice. 
a-d) Western blotting on whole liver protein extracts from Bmi-1 wild type (Wt) and 
knockout (KO) for p16Ink4a (a,b) and p21 (c,d). Erk1/2 was used as a housekeeping 
gene. a,c) 8 week old mice. b,d) 12 week old mice. e) Densitometric analysis of p21 
blot photographs using ImageJ software (n=3). Data expressed as mean ± SD of the 
integrated density of the p21 band divided by Erk1/2 band. Significance assessed 
using 2-tailed Student’s t-test, *p<0.05. N.B. Densitometric analysis of the p16Ink4a 
band was not robust due to the close proximity to a non-specific band (data not 
shown).  
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5.4.3. Localisation of p16Ink4a and p21 in Bmi-1 knockout livers: 
The Q-RT-PCR and western blotting results both confirmed the upregulation of 
various cell cycle inhibitors in Bmi-1 knockout mouse livers. To investigate the 
relevance of these data, especially with regard to the increased proliferation observed 
in Bmi-1 knockout hepatocytes, immunohistochemistry was used to examine the 
localisation of p16Ink4a and p21 within mouse livers. It was again not possible to 
assess p19Arf localisation due to a lack of robust antibodies. 
As expected given the western blotting results, p16Ink4a labelling was absent in 
paraffin-embedded liver sections from wild type mice at 8 weeks of age (Figure 36c). 
Immunolabelling of liver sections from Bmi-1 knockout mice revealed that p16Ink4a was 
predominantly expressed in non-parenchymal cells within the liver parenchyma 
(Figure 36d). There was also sporadic expression of p16 in individual cholangiocytes 
(Figure 36e), although many bile ducts were completely negative (Figure 36f). There 
was no p16Ink4a immunolabelling observed in hepatocytes, suggesting that the 
overexpression of p16Ink4a would not affect hepatocyte proliferation in Bmi-1 knockout 
livers.  
Expression of p21 was virtually absent in liver sections from wild type mice at 8 weeks 
of age, with only occasional hepatocytes within the parenchyma showing detectable 
nuclear expression (Figure 37c,e). In Bmi-1 knockout mouse livers, p21 was 
predominantly expressed in hepatocytes. There appeared to be greater heterogeneity 
in the hepatocyte labelling, with the parenchyma consisting of a mixture of positive 
and negative nuclei, and some of the positive cells showing stronger p21 expression 
than others (Figure 37d,f). This work has confirmed the p21 upregulation seen in the 
Q-RT-PCR and western blotting. 
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Figure 36: Localisation of p16Ink4a protein in Bmi-1 knockout mouse livers. 
Paraffin-embedded 8 week old mouse liver tissue sections labelled to detect p16Ink4a 
using indirect immunohistochemistry. Antibody visualised with DAB and sections 
counterstained with haematoxylin. a) Absence of p16Ink4a labelling in wild type mouse. 
b) p16Ink4a expression in non-parenchymal cells (blue arrow) in Bmi-1 knockout 
mouse. c) p16Ink4a positive (red arrow) and negative (black arrow) cholangiocytes in 
Bmi-1 knockout liver. d) Bmi-1 knockout bile duct with complete absence of p16Ink4a 
expression. All scale bars 50 µm. 
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Figure 37: Localisation of p21 protein in Bmi-1 knockout livers. 
See next page for figure legend. 
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Figure 37 (overleaf): Localisation of p21 protein in Bmi-1 knockout livers. 
Paraffin-embedded 8 week old mouse liver tissue sections labelled using indirect 
immunohistochemistry to detect p21. Antibody visualised with DAB and sections 
counterstained with haematoxylin. a-b) Sections incubated with isotype control 
antibody instead of p21. c-f) Sections from 8 week old mice at low (a,b) and high (c,d) 
magnification. c,e) p21 labelling was generally absent in hepatocyte nuclei wild type 
livers. d,f) p21 expression in numerous hepatocyte nuclei (black arrows) in 8 week old 
Bmi-1 knockout mouse livers. All scale bars 50 µm. 
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5.5. Discussion: 
5.5.1. Changes in proliferative frequency in Bmi-1 knockout livers: 
The analysis of BrdU incorporation and Ki67 expression revealed a small but 
significant increase in hepatocyte proliferation in 8 week old Bmi-1 knockout mice. It 
should however be noted that this was not a dramatic increase, and that the level of 
hepatocyte proliferation in wild type mice was already very low. It is therefore 
uncertain whether the small increase in hepatocyte proliferation in Bmi-1 knockout 
mice would have significant physiological consequences. There was also a degree of 
heterogeneity in hepatocyte proliferation between different individual Bmi-1 knockout 
mice, reflected by the large standard deviation. It is however clear that the loss of 
Bmi-1 did not lead to a reduction in hepatocyte proliferation in 8 week old livers. This 
appears at odds with several in vitro and in vivo studies demonstrating that Bmi-1 
depletion leads to reduced proliferation, both in hepatic cells (Chiba et al, 2007) and 
cells from other tissues (e.g. external granular layer cells in the cerebellum (Leung et 
al, 2004)). However, it is worth noting that proliferation in the exocrine pancreas is 
also unchanged following Bmi-1 deletion (Dhawan et al, 2009). Bmi-1 did appear to be 
expressed at low levels in hepatocytes, so it is unclear how much influence it has on 
hepatocyte proliferation. It is therefore possible that any proliferative increase in Bmi-1 
knockout mice is not directly due to the loss of Bmi-1, and is a secondary effect. It is 
however worth considering that most in vitro studies on the effects of Bmi-1 depletion 
or overexpression have been in putative liver stem cell lines or tumour cells, so its 
function may be slightly different under physiological conditions, or in the context of a 
more differentiated cell such as the hepatocyte. Indeed, Chiba et al report that 
transduction of Bmi-1 only affects proliferation and colony forming potential in foetal 
liver cell fractions which give rise to hepatic colony forming units in culture (H-CFU-C), 
a characteristic of stem cell populations (Chiba et al, 2007). This suggests that Bmi-1 
knockdown may have less consequence for the proliferation of liver cells with more 
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limited growth potential. In 12 week old mice, there was a decrease in hepatocyte 
proliferation in Bmi-1 knockout animals compared to wild types. The reasons for the 
difference between this and 8 weeks are unclear, however it may be secondary to the 
fact that the knockout mice develop increasingly abnormal physiological 
consequences during ageing. 
The precise reasons for the small increase in hepatocyte proliferation in 8 week old 
Bmi-1 knockout mice are unclear, although it is possible to speculate on some 
potential causes. A number of hepatocytes in Bmi-1 knockout mice expressed the cell 
cycle inhibitor p21, so their proliferation may be inhibited. In this case, it is possible 
that the proliferation of non-p21 expressing hepatocytes may increase as a 
compensatory response. There is also some lineage tracing evidence that a portal 
stem/progenitor cell contributes to hepatocyte turnover in resting liver (see 
introduction section 1.3.5). Bmi-1 has an important role in the maintenance of hepatic 
stem cell populations in vitro, so it is possible that the putative portal stem cell 
population is reduced or defective in Bmi-1 knockout mice. This could be 
demonstrated experimentally in the future using lineage tracing techniques, based on 
the stable genetic labelling of cells expressing putative hepatic stem/progenitor cell 
markers, such as Sox9 (Furuyama et al, 2011). Initial attempts to assess defects in 
portal stem cell populations using lineage tracing of mitochondrial mutations were 
unsuccessful (see appendix section A1). If the stem cell response was in fact 
compromised, then the increased hepatocyte proliferation in Bmi-1 knockout mice 
may compensate for the loss of the putative portal stem cell contribution to hepatocyte 
turnover.  
It is also possible that there is a link between the reduction in polyploid cell numbers 
observed in Bmi-1 knockout mice (Chapter 4) and the increased hepatocyte 
proliferation at 8 weeks of age. Polyploidy has often been considered to represent a 
shift towards reduced proliferative potential and terminal differentiation (Gupta, 2000), 
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and diploid rat hepatocytes have higher proliferative potential than normal 
hepatocytes in culture (Rajvanshi et al, 1998) (Gerlyng et al, 1993). However, 
hepatocytes of all ploidy classes can contribute equally to repopulate damaged mouse 
livers (Duncan et al, 2009a). It is possible there are differences between the 
proliferative potential of polyploid cells in rats and mice, although in general, the 
published data seem to suggest that hepatocytes of all ploidy classes maintain the 
ability to proliferate, but the proliferative capacity of diploid hepatocytes is higher. 
Therefore, it is possible that reduced polyploidy in Bmi-1 knockout mice results in 
hepatocytes with higher proliferative potential.  The onset of polyploidy at weaning is 
also correlated with a shift from hyperplastic to hypertrophic liver growth in rodents 
(Funk-Keenan et al, 2008). Given the reduced polyploidy in Bmi-1 knockout mice, it is 
possible that they have a greater requirement for hyperplastic growth (represented by 
increased proliferation) to compensate for the reduced hypertrophic growth 
(represented by polyploidisation). It is also unclear what proportion of hepatocytes 
usually express Bmi-1 under resting conditions due to the limitations of the 
immunohistochemical analysis, so it cannot be determined whether the hepatocytes 
able to proliferate are those that do not normally express Bmi-1. 
The points above have discussed some speculative reasons for an increase in 
hepatocyte proliferation in Bmi-1 knockout mice. Given that previous studies in 
hepatic cell lines and other organs have associated loss of Bmi-1 with reduced 
proliferation, it seems more likely that the alterations in hepatocyte proliferation in 
Bmi-1 knockout mice are not cell-autonomous. With regards to cholangiocyte 
proliferation, conclusions cannot be drawn due to the low levels of proliferation in wild 
type mice. Given the high levels of Bmi-1 expression in cholangiocytes, the 
expectation is that cholangiocyte proliferation should decrease in Bmi-1 knockout 
mice. However, occasional Ki67 positive cholangiocytes were observed in Bmi-1 
knockout mice, suggesting that some may maintain the capacity to proliferate. This 
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will have to be investigated in future work, potentially through performing bile duct 
ligations on Bmi-1 knockout mice to induce cholangiocyte proliferation. It would also 
be interesting to use FACS analysis to further examine the cell cycle status of Bmi-1 
deficient hepatic cells, to provide support for the in vivo data based on BrdU 
incorporation. One very recent study has noted that cultured Bmi-1 null 
haematopoietic stem cells (HSCs) exhibit an increase in cell cycling (decreased 
number of cells in G0) compared to control cells (Chagraoui et al, 2011). The Bmi-1 
deficient HSCs then accumulate in G2, suggesting a defective G2/M checkpoint, and 
suffer from chromosome instability. It would be interesting to assess whether 
something similar is occurring in Bmi-1 knockout hepatocytes, given that the BrdU and 
Ki67 data suggests an increase in the numbers of cycling hepatocytes in Bmi-1 
knockout mice. 
5.5.2. Upregulation of cyclin D1 and c-myc in Bmi-1 knockout livers: 
The livers of 8 week old Bmi-1 knockout mice exhibited increased levels of c-myc 
mRNA and cyclin D1 protein. These findings are consistent with the increase in 
hepatocyte proliferation observed in 8 week old knockout mice. As detailed in the 
introduction, the most well characterised Bmi-1 targets have generally been 
associated with inhibition of the cell cycle. It therefore would appear unlikely that the 
upregulation of cyclin D1 and c-myc is directly due to the loss of Bmi-1 mediated 
repression. There is no direct evidence in the literature that cyclin D1 is a direct target 
of Bmi-1, although a recent study has found a putative Bmi-1 response element (BRE) 
in the promoter of the related cyclin D3 gene (Meng et al, 2010), and suggests that a 
few other genes involved in promotion of the cell cycle, such as Cdk6, may be Bmi-1 
targets. However, the majority of cell cycle related genes identified in this study are 
inhibitory, supporting the consensus view that Bmi-1 represses cell cycle inhibitors. 
Cooperation between c-myc and Bmi-1 has been previously characterised (see 
introduction section 1.8), however it is thought that c-myc acts upstream of Bmi-1, as 
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the human BMI-1 promoter contains a binding site for c-myc (Guo et al, 2007a). The 
upregulation of c-myc mRNA in the Bmi-1 knockout mice hints at the possibility that c-
myc may also be a Bmi-1 target, although this cannot be confirmed. It would be 
interesting in future to perform ChIP studies to assess whether c-myc and cyclin D1 
are targets of Bmi-1, or whether their upregulation in Bmi-1 knockout mice is 
secondary to the effects of other pathways. 
5.5.3. Upregulation of p16Ink4a and p19Arf in Bmi-1 knockout livers: 
The cell cycle inhibitors p16Ink4a and p19Arf were both upregulated at the mRNA level 
in Bmi-1 knockout livers, with p16Ink4a protein also increased. Examination of p19Arf 
protein levels was not possible due to the lack of antibodies which gave robust 
labelling patterns. Immunolabelling studies revealed that the localisation of p16Ink4a 
protein is restricted mainly to non-parenchymal cells. These appeared to include 
Kupffer cells based on morphology, however this would need to be confirmed in future 
by immunohistochemistry using the F4/80 antibody. The lack of p16Ink4a expression in 
hepatocytes means that it would not have any impact on hepatocyte proliferation, 
hence the increased p16Ink4a levels are not incompatible with the slight increase in 
hepatocyte proliferation observed in the Bmi-1 knockout mice. It is also notable that 
p16Ink4a labelling was only sporadically observed in cholangiocytes in Bmi-1 knockout 
mice, despite the fact that Bmi-1 was strongly expressed in cholangiocytes in wild 
type mice (see Chapter 3), and that Bmi-1 is commonly regarded as a repressor of 
p16Ink4a expression. There is some published work suggesting that the function of Bmi-
1 in hepatocytes and HCC cells is independent of Ink4a/Arf repression, due to the lack 
of Ink4a/Arf expression changes in cultured cells with altered Bmi-1 expression (Xu et 
al, 2009). These data would agree with the lack of any p16Ink4a overexpression 
observed in hepatocytes in Bmi-1 knockout mice, despite apparent low level Bmi-1 
expression in wild type cells. It could be hypothesised that the function of Bmi-1 in 
cholangiocytes may also be Ink4a/Arf independent. However, Sasaki et al report 
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increased p16Ink4a expression in cholangiocytes from primary biliary cirrhosis patients, 
which express lower levels of Bmi-1 than normal cholangiocytes, suggesting that 
p16Ink4a is a Bmi-1 target in cholangiocytes. One possibility is that the repression of 
p16Ink4a is maintained by another protein or polycomb complex in the absence of Bmi-
1, potentially involving Mel-18 due to its similar expression pattern to Bmi-1 (see 
Chapter 4). Mel-18 is able to bind to and repress the INK4A/ARF locus in human 
fibroblasts (Maertens et al, 2009), so it is possible that Mel-18 could carry out this 
function in mouse cholangiocytes in the absence of Bmi-1. It is also possible that 
other growth stimuli are able to override the effects of Bmi-1 deletion. This occurs in 
the mammary gland, where pregnancy rescues the mammary outgrowth deficiencies 
in Bmi-1 knockout mice, despite the fact that Ink4a/Arf levels remain high (Pietersen 
et al, 2008a). The apparent lack of p16Ink4a overexpression in two major hepatic cell 
populations (hepatocytes and cholangiocytes) may also explain why the liver 
phenotype in the Bmi-1 knockout mouse is relatively mild compared to other tissues. 
5.5.4. p21 expression in Bmi-1 knockout livers: 
Both p21 mRNA and protein were upregulated in Bmi-1 knockout livers, and 
immunohistochemical analysis demonstrated that it was predominantly localised in 
hepatocytes. p21 has widely been regarded as a cell cycle inhibitor, and has been 
previously shown to inhibit hepatocyte proliferation when overexpressed in the liver 
(Wu et al, 1996). Based on this, its upregulation in hepatocytes in Bmi-1 knockout 
mice would be expected to lead to a reduction in proliferation. However, as described 
in section 5.1, this was not the case in 8 week old Bmi-1 knockout mice, with a small 
proliferation increase being observed instead. From the hepatocytic p21 
immunolabelling pattern observed in Bmi-1 knockout mice (Figure 37), it appears 
there is heterogeneity in the degree of expression. Some hepatocytes expressed high 
levels of p21, while others expressed little or no protein. It is therefore possible that 
the cells which escape p21 upregulation are those that maintain the ability to 
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proliferate. This could be tested in the future by double labelling experiments for p21 
and a proliferation marker such as Ki67. Based on western blotting data, there was no 
increase in p21 protein levels in 12 week old Bmi-1 knockout mice compared to 8 
week old animals, so this does not provide an explanation for the decrease in 
hepatocyte proliferation seen at 12 weeks.  
As discussed in the introduction (section 1.9.3), it also appears that p21 does not 
always act as a cell cycle inhibitor. It is in fact required for assembly of Cdk4/cyclin D 
complexes at basal levels, so the expression level of p21 and stoichiometry relative to 
other cell cycle regulators is important. Given that p21 expression appeared to be low 
in some Bmi-1 knockout hepatocytes, it is possible that this would not have an 
inhibitory effect on the cell cycle. There is also some evidence that cyclin D proteins 
are able to sequester excess p21 away from Cdk complexes, thus preventing 
overexpressed p21 from repressing their activity. This is interesting given that Bmi-1 
knockout livers overexpressed both p21 and cyclin D1. Elevated levels of cyclin D3 in 
breast cancer cells leads to both reduced association of p21 with Cdk4- and Cdk2-
containing complexes, and an increase in their kinase activity (Russell et al, 1999). 
The authors suggest elevated cyclin D1 will also be able to perform the same function, 
although they do not provide specific experimental evidence. It has also been shown 
that c-myc activation results in increased protein synthesis of cyclin D1 and cyclin D2 
in cell lines, which in turn leads to increased binding of the cyclins to p27 and p21 
(Perez-Roger et al, 1999). This sequestering effect of cyclins D1 and D2 is required 
for the pro-proliferative effect of c-myc, as c-myc does not increase proliferation in 
primary cells deficient for cyclin D1 and D2. This potentially links with what was 
observed in Bmi-1 knockout livers, as preliminary Q-RT-PCR analysis demonstrated 
upregulation of c-myc. It is therefore possible that the sequestering effect of 
overexpressed cyclin D1 allows p21 overexpressing Bmi-1 knockout hepatocytes to 
retain the ability to proliferate. It would be interesting to investigate in the future 
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whether c-myc overexpression may be responsible for this by assessing both its 
protein localisation, and whether c-myc, cyclin D1 and p21 co-localise, using 
immunolabelling techniques or co-immunoprecipitation.  
There have also been studies demonstrating concurrent overexpression of p21 and 
cyclin D1 in tumour samples, which is similar to what was seen in Bmi-1 knockout 
hepatocytes. Rey et al show that p21 overexpression in breast cancers is 
accompanied by increased protein levels of cyclin D1, and that the p21 
overexpressing tumour samples also show an increase in proliferation (Rey et al, 
1998). A correlation between p21 and cyclin D1 expression has also been 
demonstrated by Van Oijen et al in head and neck cancers (van Oijen et al, 1998). 
Together, these data provide support for the idea that the increase in both p21 and 
cyclin D1 observed in 8 week old Bmi-1 knockout mouse livers is not necessarily 
counter-intuitive to the concurrent increase in hepatocyte proliferation. 
It is also not clear whether the loss of Bmi-1 in hepatocytes is directly responsible for 
the altered expression of cell cycle regulatory molecules, or whether the changes are 
secondary to other signals. It has been demonstrated that p21 is a direct target of 
Bmi-1 mediated repression in cells isolated from mouse cerebellum (Subkhankulova 
et al, 2010), so it is possible that the loss of Bmi-1 in hepatocytes results in 
derepression of p21. However, Bmi-1 expression appeared to be low or negative in 
many hepatocytes, so it is unclear whether loss of Bmi-1 would directly have this 
dramatic an effect on p21 levels. It is also possible that the p21 upregulation is 
indirect, as p21 can be activated by p53 (see introduction section 1.9.3). Activity of 
p53 could potentially be increased in Bmi-1 knockout mice due to the upregulation of 
p19Arf, as p19Arf blocks the activity of the p53 inhibitor Mdm2. However, for this to be 
the case, p19Arf levels would have to be increased in Bmi-1 knockout hepatocytes, 
and this could not be demonstrated due to lack of a robust antibody. Furthermore, Xu 
et al have reported that Bmi-1 acts independently of Ink4a/Arf in hepatocytes (Xu et 
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al, 2009). Expression of p21 protein was also observed in some cholangiocytes, 
however this was not appreciably stronger than in hepatocytes, despite the fact that 
all murine cholangiocytes expressed high levels of Bmi-1. This result either suggests 
that alternative repressive mechanisms of p21 may be maintained in cholangiocytes in 
Bmi-1 knockout mice, or that p21 is not a direct target of Bmi-1 in these cells. This 
could be assessed in future by ChIP analysis, to examine whether Bmi-1 directly 
binds the p21 promoter in hepatic cell populations. 
Consequences of p21 overexpression in hepatocytes 
The effects of p21 overexpression in hepatocytes have previously been studied using 
a transgenic mouse model (Wu et al, 1996). It is interesting to compare these 
observations with the Bmi-1 knockout liver phenotype, given that the Bmi-1 knockout 
mice also appear to overexpress p21 in hepatocytes. The authors report increased 
expression of cyclin D1 protein in the transgenic livers, in agreement with the results 
observed in the Bmi-1 deficient livers. The p21 overexpressing mice themselves 
exhibit stunted growth and a lifespan of 2-3 months, both of which appear very similar 
to the Bmi-1 knockout mice. It is therefore interesting to speculate whether the 
reduced size and lifespan of the Bmi-1 knockout mice is related to the accumulation of 
p21 in the liver. However, there were also some differences in the phenotypes 
observed. In particular, the transgenic p21 overexpressing mice have reduced 
hepatocyte numbers due to a decrease in proliferation, as measured by BrdU 
incorporation, although this was analysed in younger mice. This is accompanied by 
the accumulation of large numbers of oval cells, which tend to emerge when 
hepatocyte proliferation is impaired. These results appear at odds with the phenotype 
observed in the Bmi-1 knockout livers. However, it is important to note that the work 
by Wu et al involved driving p21 overexpression using the promoter for transthyretin 
(TTR), a thyroid hormone carrier produced in hepatocytes. Therefore, more 
widespread hepatocytic p21 expression would be expected, as opposed to the 
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heterogeneous p21 expression observed in Bmi-1 knockout mice, although this is not 
entirely clear from the published p21 immunohistochemistry. In addition to this, the 
authors report predominantly cytoplasmic p21 expression, whereas p21 appeared to 
be localised in the nucleus in Bmi-1 knockout hepatocytes. It is also likely that levels 
of p21 overexpression were much greater in the Ttr-p21 mice than the Bmi-1 
knockout. The phenotypic differences can potentially be attributed to these factors, as 
it is probable that hepatocytes in Bmi-1 knockout mice which do not overexpress p21 
retain the ability to proliferate. It is also possible, as mentioned earlier, that 
upregulated cyclin D1 in Bmi-1 knockout mice can sequester excess p21 and facilitate 
proliferation. Wu et al do report increased cyclin D1 expression in transgenic p21 
overexpressing livers, however they also found that all of the protein is in a complex 
with p21. It therefore seems that the increased cyclin D1 protein is unable to 
sequester all of the excess p21, and that remaining unsequestered p21 will inhibit cell 
cycle progression. The stoichiometry of p21 in relation to other cell cycle regulators is 
important for its function, and this may be different between the transgenic p21 
overexpressing mice and the Bmi-1 knockout mice. This could be studied in future by 
immunoprecipitating cyclin D1 and p21 containing complexes from Bmi-1 knockout 
livers to assess their relative stoichiometries. 
Polyploidisation and p21 expression 
The decrease in hepatocyte polyploidy (Chapter 4) and increase in p21 expression 
observed in Bmi-1 knockout mice initially appear contradictory based on some 
previous studies linking polyploidisation with increased p21 expression. Partial 
hepatectomy in rats results in the development of more advanced ploidy in 
hepatocytes, along with increased p21 levels and decreased proliferative potential of 
isolated hepatocytes in culture (Sigal et al, 1999). However, the authors do not 
specifically demonstrate p21 expression in cells of higher ploidy, and propose p21 
may be involved in regulating cell cycling after partial hepatectomy. It is therefore 
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possible that the upregulation of p21 is not linked to the increased polyploidisation. 
Mice deficient for Ercc1, an endonuclease involved in DNA repair pathways, also have 
increased hepatocyte ploidy and p21 expression at 3 weeks of age, with p21 
expression skewed towards nuclei with larger areas (Chipchase et al, 2003). This 
appears to suggest a link between p21 expression and nuclei of higher ploidy, 
although p21 was found in some cells with lower ploidy, suggesting p21 
overexpression does not cause cells to become polyploid. In addition to this, 2 year 
old wild type mice, which have similar levels of ploidy to the younger Ercc1 knockout 
mice, do not exhibit significant upregulation of p21 mRNA. The authors also observed 
a large degree of heterogeneity in p21 expression in different Ercc1 deficient mice, all 
of which had highly polyploid livers, with some mice exhibiting virtually no p21 
expression. Therefore, these results are not able to demonstrate a simple link 
between p21 expression and liver polyploidy, and suggest any connection may be 
limited to Ercc1 deficient mice. Finally, Wu et al report occasional polyploid nuclei in 
transgenic mice which exclusively overexpress p21 in the liver (Wu et al, 1996). 
However, these nuclei represent only 2% of total hepatocytes, and no ploidy analysis 
was performed on the remaining cells. The nuclei are also two to four times the 
diameter of the largest nuclei in wild type mice, suggesting they are not related to the 
physiological development of polyploidy. In conclusion, the work discussed above 
does not demonstrate a direct causative link between p21 expression and increased 
polyploidy, and thus is not contradictory to the finding of high p21 levels and low 
polyploidy Bmi-1 knockout mice. 
5.5.5. Similarities to mice with inactivated c-myc: 
As discussed in chapter 4 (section 4.5.3), there are similarities between the 
polyploidisation phenotype observed in the Bmi-1 knockout mice with that found in 
transgenic mice with inactivated c-myc (Baena et al, 2005), which are interesting 
given that Bmi-1 is reported to be a c-myc target. These phenotypic similarities are 
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also apparent regarding proliferation. Deletion of c-myc did not result in inhibition of 
hepatocyte proliferation; in contrast BrdU incorporation was increased in 6 week old 
mice with c-myc deletion compared to wild types. The authors also used PCR analysis 
of individual laser-dissected cells to confirm that proliferating cells contained the 
deleted c-myc transgene, thus demonstrating that c-myc is not required for hepatocyte 
proliferation. It is interesting that both the Bmi-1 and c-myc knockout livers exhibit an 
increase in hepatocyte proliferation in adult mice at one time point (8 weeks and 6 
weeks respectively), despite the fact that c-myc and Bmi-1 are commonly associated 
with the promotion of cell proliferation. The mice did however show impaired 
proliferation following partial hepatectomy, suggesting a requirement for c-myc in the 
regenerative response. It would be interesting to perform partial hepatectomies on 
Bmi-1 knockout mice in the future to assess whether they show a similar defect. Q-
RT-PCR analysis of Bmi-1 knockout mouse livers actually revealed an increase in c-
myc mRNA expression. However, given that c-myc appears to function upstream of 
Bmi-1, this would be not preclude dysregulation of c-myc pathways regulated through 
promotion of Bmi-1 expression. 
5.6. Summary of Chapter: 
To summarise this chapter, the deletion of Bmi-1 did not appear to result in any 
deficiencies in hepatocyte proliferation in 8 week old mice. In contrast, knockout mice 
actually exhibited a small proliferation increase in hepatocytes relative to wild type 
mice. The precise reasons for this are unclear, and would be unlikely to result in a 
dramatic phenotypic effect due to the low hepatocyte proliferation rate in resting liver. 
The proliferation increase was correlated with increased expression of cyclin D1 
protein and c-myc mRNA, both of which are pro-proliferative. This occurred despite 
the expected upregulation of cell cycle inhibitors p16Ink4a, p19Arf and p21, which are 
established Bmi-1 targets. However, p16Ink4a appeared to be expressed in non-
parenchymal cells, so would not affect hepatocyte proliferation. p21 protein was 
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expressed in some, but not all hepatocytes in Bmi-1 knockout mice. It is possible that 
those hepatocytes which escape p21 upregulation maintain the ability to proliferate, or 
that the increased cyclin D1 protein present is able to sequester excess p21. It was 
not possible to evaluate changes in cholangiocyte proliferation due to the low 
frequency at which they divide in wild type mice. A summary of the potential effects of 
Bmi-1 deletion on other cell cycle regulators is provided in Figure 38. 
 
 
 
 
 
Figure 38 (overleaf): The effects of Bmi-1 deletion on the cell cycle.     
Suggested effects of Bmi-1 on cell cycle genes in liver cell populations. a) Kupffer 
cells: i) Bmi-1 represses p16Ink4a expression in wild type cells. ii) Deletion of Bmi-1 
results in upregulation of p16Ink4a. b) Cholangiocytes: i) Bmi-1 is involved in repressing 
p16Ink4a expression in wild type cells. ii) Repression of p16Ink4a is maintained in the 
majority of Bmi-1 knockout cholangiocytes, possibly by Mel-18 containing PRC 
complexes or other unidentified mechanisms. c) Hepatocytes: i) Bmi-1 is involved in 
repressing p21 expression in some or all wild type hepatocytes. ii) Deletion of Bmi-1 
results in p21 upregulation in many hepatocytes, which is likely to inhibit their 
proliferative capacity. Hepatocyte proliferation is maintained by either: iii) hepatocytes 
which maintain p21 repression in the absence of Bmi-1 through other unidentified 
mechanisms, or iv) hepatocytes which also upregulate cyclin D1 (and potentially c-
myc), resulting in the sequestering of excess repressive p21 away from cdk 
complexes.  
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Figure 38: The effects of Bmi-1 deletion on the cell cycle. 
See previous page for figure legend.                               
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Chapter 6 
 
Iron overload in Bmi-1 knockout 
mice 
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6. Iron overload in Bmi-1 knockout mice: 
6.1. Hepatic iron accumulation in Bmi-1 knockout mice: 
A notable observation that arose during analysis of blindly labelled H&E stained 
sections from Bmi-1 wild type and knockout mice was the occasional presence of a 
yellow refractive pigment in Kupffer cells (Figure 39). This was only observed in Bmi-1 
knockout mice, and was particularly prominent at 12 weeks of age. A literature review 
of basic liver pathology resources raised the possibility that the pigment was 
haemosiderin, an insoluble iron storage complex found in cells following breakdown of 
ferritin and haem. To assess whether the Bmi-1 knockout mice were exhibiting 
increased hepatic accumulation of iron compounds, paraffin-embedded tissue 
sections were subjected to a Perls Prussian Blue stain to detect the presence of iron. 
Iron deposits were sporadically detectable at very low levels in Bmi-1 wild type mice at 
both 8 and 12 weeks of age (Figure 40a,c,g,e). Bmi-1 knockout mice at 8 weeks of 
age exhibited accumulation of iron in hepatocytes, predominantly around portal 
regions (Figure 40b,d) (n=4). There was some heterogeneity in the degree of 
overload, with some mice appearing more severe than others. However, all knockout 
mice examined showed evidence of iron deposition. At 12 weeks of age, the Bmi-1 
knockout mice (n=4) showed a similar distribution of hepatocytic iron to the 8 week old 
mice, however the staining generally appeared more intense (Figure 40f,h). In 
addition, 12 week old knockout mice exhibited much stronger Perls staining in Kupffer 
cells (Figure 40f), indicating a greater degree of iron deposition. 
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Figure 39: Kupffer cell pigmentation in Bmi-1 knockout mouse livers. 
Haematoxylin stained paraffin-embedded liver sections from 12 week old wild type (a) 
and Bmi-1 knockout (b) mice, showing presence of yellow/brown refractive pigment in 
Kupffer cells in Bmi-1 knockout tissue (black arrow). Scale bars 50 µm. 
 
 
 
 
 
Figure 40 (overleaf): Iron deposition in Bmi-1 knockout mouse livers. 
Paraffin-embedded liver sections stained with Perls Prussian Blue and counterstained 
with eosin. PT = portal triad, CV = central vein. a-d) 8 week old mice, e-h) 12 week old 
mice. Iron deposition was absent in both 8 week (a,c) and 12 week old (e,g) wild type 
mice. Parenchymal iron overload was evident in 8 week old (b,d) and 12 week old 
(f,h) Bmi-1 knockout mice. b) Low magnification showing periportal iron deposition 
pattern in 8 week old Bmi-1 knockout mouse liver. f) Extensive iron accumulation in 
Kupffer cells 12 week old Bmi-1 knockout mouse liver (black arrows). All scale bars 50 
µm. 
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6.2. Expression of iron regulatory genes in Bmi-1 knockout mice: 
A review of literature identified several proteins involved in iron regulatory pathways 
as potential Bmi-1 and Polycomb targets. Bracken et al performed genome wide 
mapping of Polycomb target promoters using ChIP-on-chip analysis in human 
embryonic fibroblasts (Bracken et al, 2006). This study revealed enrichment of one or 
more of the H3K27me3 mark, Suz12 or Cbx8 on promoters of genes involved in iron 
homeostasis, namely HAMP (hepcidin antimicrobial peptide), HFE 
(haemochromatosis protein) and TFR2. ChIP experiments using an anti-Bmi-1 
antibody have also identified iron regulatory protein 2 (IRP2) as a potential Bmi-1 
target (Meng et al, 2010). These data suggested that the expression of genes 
involved in iron homeostasis could be directly regulated by Polycomb complexes. To 
begin to investigate the possibility that impairment of the iron regulatory pathway was 
responsible for the excessive iron accumulation seen in Bmi-1 knockout mice, the 
expression levels of several key genes in the pathway were examined using Q-RT-
PCR (Figure 41).  
Figure 41 (overleaf): Altered expression of iron regulatory genes in Bmi-1 
knockout mice. 
Q-RT-PCR data on cDNA made from mRNA extracted from Bmi-1 wild type (Wt) and 
knockout (KO) whole mouse livers. a) Hepcidin antimicrobial peptide (Hamp) in 8 
week (n=5 mice per group) and 12 week old (n=4) mice. b) Ferroportin (Fpn), 8 weeks 
(n=4) and 12 weeks (n=3). c) Transferrin receptor 1 (Tfr1), 8 weeks (n=4) and 12 
weeks (n=3). d) Tfr2, 8 weeks (n=3) and 12 weeks (n=3). e) Haemochromatosis 
protein (Hfe), 8 weeks (n=5) and 12 weeks (n=4). f) Iron regulatory protein 2 (Irp2), 8 
weeks (n=5) and 12 weeks (n=3). g) Bone morphogenetic protein 6 (Bmp6), 8 weeks 
(n=5) and 12 weeks (n=3). Values expressed as transcripts of gene of interest per 
transcript of reference gene (eEf2). Data are means ± SD. * p<0.05 using 2-tailed 
Student’s t-test. 
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Figure 41: Altered expression of iron regulatory genes in Bmi-1 knockout mice. 
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6.2.1. Hepcidin antimicrobial peptide: 
Hepcidin, encoded by the Hamp gene, is a small peptide which is the major regulator 
of bodily iron homeostasis. It is synthesised in iron replete conditions to reduce iron 
uptake via degradation of the iron export protein ferroportin (FPN) (see introduction 
section 1.6 for further details of iron regulatory pathways). At 8 weeks of age, Bmi-1 
knockout mice exhibited a significant upregulation in Hamp expression compared to 
wild types of the same age (Figure 41a). The increase in Hamp levels at 8 weeks is 
consistent with published studies showing that hepcidin expression reflects body iron 
stores, and that levels are increased in the livers of iron overloaded mice (Pigeon et 
al, 2001). Increased hepcidin levels should result in degradation of the FPN protein to 
reduce both the absorption of iron in the small intestine and the release from stores. 
Therefore, the iron levels in hepatocyte and macrophage stores should be increased; 
this is in agreement with the phenotype observed in the Bmi-1 knockout mice. By 12 
weeks of age, the Bmi-1 knockout mice no longer exhibited upregulation of Hamp. 
This appears contradictory to the hepatic iron overload exhibited on histological 
sections (Figures 39 & 40), however may reflect the fact that the health of the 
knockout mice becomes progressively worse by 12 weeks of age. Hepcidin production 
is suppressed by erythroid regulators, hypoxia and anaemia, so it is possible that 
secondary factors exert effects in 12 week old Bmi-1 knockout mice. In support of this, 
it has been reported that iron overload is less dominant than anaemia and hypoxia in 
regulating hepcidin expression, as mice with severe iron loading anaemias have 
reduced hepcidin levels despite hepatic iron overload (Adamsky et al, 2004), and 
erythropoiesis inhibitors increase hepcidin expression in mice with iron deficiency 
(Pak et al, 2006).  
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6.2.2. Ferroportin: 
The mRNA levels of the iron exporter ferroportin (Fpn) were the same in 8 week old 
wild type and Bmi-1 knockout mice (Figure 41b). This is not unexpected, given that 
hepcidin acts to internalise and degrade FPN at the protein level, so mRNA levels 
would be unaffected by the increase in Hamp expression in 8 week old knockout 
mice. In contrast, 12 week old Bmi-1 knockout mice had a small but significant 
decrease in levels of Fpn mRNA relative to wild types. It is unclear why this would be, 
although it is unlikely to be directly due to the loss of Bmi-1, as Bmi-1 is a 
transcriptional repressor. If the reduced Fpn mRNA translates to a decrease in protein 
levels at 12 weeks, it would theoretically lead to a reduction in iron export, which is 
consistent with an iron overload phenotype. A notable difference between the iron 
overload phenotype in Bmi-1 knockout mice at 12 weeks compared to 8 weeks was 
an increase in Kupffer cell iron staining (Figure 40d vs. 40h). Given that Kupffer cells 
express high levels of Fpn (Delaby et al, 2005), it is possible that decreased Fpn 
expression relative to wild types could result in increased iron retention in 12 week old 
knockout mice. However, this remains speculation without any protein expression or 
localisation data. The change in Fpn expression in 12 week old Bmi-1 knockout mice 
was also small, so it seems unlikely that it would have a dramatic effect on the 
phenotype.  
6.2.3. Transferrin Receptor 1: 
The 3’ UTR of Transferrin receptor 1 (Tfr1), which mediates transferrin uptake into 
cells, contains an iron regulatory element (IRE). This is bound by iron regulatory 
proteins (IRPs) in iron starved cells to increase mRNA stability. Therefore, the 
expectation would be that Tfr1 mRNA levels would decrease in cells with abundant 
iron due to increased degradation. The effect of this would be to reduce TfR1 protein 
levels, and therefore reduce iron uptake to try and prevent overloading the cell. In 
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agreement with this, Tfr1 mRNA (Adamsky et al, 2004) and protein (Wallace et al, 
2009) levels are decreased in mice with iron overload. In contrast to this, iron 
overloaded livers of 8 week old Bmi-1 knockout mice did not exhibit any change in 
Tfr1 expression (Figure 41c). By 12 weeks of age, Tfr1 mRNA levels were significantly 
increased in knockout mice compared to wild types. This result suggests that Tfr1 
expression is dysregulated in Bmi-1 knockout mice, although it is possible that Tfr1 is 
only upregulated in individual hepatocytes or Kupffer cells which are not already iron 
overloaded. Increased Tfr1 levels are consistent with the iron overloaded liver 
phenotype observed in Bmi-1 knockout mice, as cells expressing higher levels of Tfr1 
should have increased iron uptake. TFR1 was not one of the genes identified as a 
potential Polycomb/Bmi-1 target in genome wide screens, so it is unclear whether the 
upregulation in 12 week old knockout mice could be directly due to Bmi-1 loss. The 
fact that it was not upregulated at 8 weeks of age suggests against this, although it is 
possible that mRNA degradation due to the IRE-IRP system could negate some 
transcriptional increase due to lack of Bmi-1 mediated repression. Tfr1 expression is 
also regulated by other mechanisms, such as hypoxia, which could also be a factor in 
Bmi-1 knockout mice (Graham et al, 2007). It is also worth considering whether the 
upregulation of Tfr1 seen in 12 week old knockout mice could be linked to the 
increased iron deposition relative to 8 weeks, especially in Kupffer cells which are 
able to obtain iron from transferrin (van Berkel et al, 1987). Immunohistochemical 
studies to assess localisation of the protein could address this in the future. 
6.2.4. Transferrin Receptor 2 and HFE: 
Both TfR2 and HFE are thought to be involved in pathways which regulate hepcidin 
expression at the transcriptional level in response to iron levels. Increased levels of 
diferric transferrin lead to the displacement of HFE from TfR1, and the stabilisation of 
TfR2. HFE and TfR2 subsequently facilitate hepcidin production via pathways which 
have not been well defined, either as a complex or individually. Both TFR2 and HFE 
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were identified as putative Polycomb targets in genome wide screens (Bracken et al, 
2006), suggesting that their expression may be dysregulated in Bmi-1 knockout mice. 
In 8 week old knockout mice, mRNA levels of Tfr2 and Hfe were unchanged 
compared to wild type mice (Figure 41d,e). This indicates that the increased hepcidin 
production in 8 week old knockouts relative to wild types was not driven by increases 
in HFE or TfR2 levels. Expression of both Tfr2 and Hfe were significantly decreased in 
12 week old Bmi-1 knockout mice compared to wild types. This would theoretically 
lead to a decrease in hepcidin expression, as seen in Hfe and Tfr2 null mice (Fleming 
et al, 2002; Zhou et al, 1998). This is in agreement with the fact that 12 week old 
knockout mice did not exhibit hepcidin upregulation compared to wild types, although 
it is unclear if the level of Tfr2 and Hfe downregulation is dramatic enough to be the 
direct cause. It is also unclear why expression of Tfr2 and Hfe was decreased in 12 
week old Bmi-1 knockout mice. It is unlikely to be directly due to the absence of Bmi-
1, as Bmi-1 acts as a transcriptional repressor, so any direct targets should be 
derepressed in Bmi-1 knockout mice. 
6.2.5. Iron Regulatory Protein 2: 
Iron regulatory protein 2 (IRP2) is synthesised in iron depleted cells, and 
proteasomally degraded as iron levels increase. It acts by binding to IREs in the 3’ 
UTR of Tfr1 mRNA to stabilise the transcript, or in the 5’ UTR of Fpn and ferritin 
mRNA to inhibit translation. High levels of IRP2 therefore promote increased 
transferrin uptake and reduced iron storage when iron levels are low, and the reverse 
when iron is plentiful. Irp2 was of particular interest as ChIP studies identified a Bmi-1 
responding element (BRE) in its promoter (Meng et al, 2010), suggesting it could be a 
direct Bmi-1 target. If this was the case, then it may have been aberrantly upregulated 
in Bmi-1 knockout mice, and could have been responsible for the unexpected 
increase in Tfr1 levels described earlier. However, mRNA expression of Irp2 was 
unchanged in both 8 and 12 week old Bmi-1 knockout mice compared to wild types 
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(Figure 41f), suggesting that alterations in IRP2 expression are not contributing 
towards the iron overload phenotype of the mice. 
6.2.6. Bone Morphogenetic Protein 6: 
Another signalling molecule that may play an important role in hepcidin regulation is 
bone morphogenetic protein 6 (BMP6), as Bmp6 knockout mice exhibit decreased 
levels of hepcidin despite severe iron overload (Meynard et al, 2009). Members of the 
BMP family, including BMP6, have been implicated as potential Polycomb targets 
based on genome wide mapping (Bracken et al, 2006), so it was considered possible 
that Bmp6 levels could be altered in Bmi-1 knockout mice. Q-RT-PCR analysis of 
Bmp6 expression revealed no significant changes in 8 week old Bmi-1 knockout mice 
(Figure 41g), suggesting altered BMP6 signalling was not responsible for the 
increased hepcidin expression. In contrast, 12 week old Bmi-1 knockout mice did 
exhibit a small but significant upregulation of Bmp6 compared to wild types. This 
agrees with previous work demonstrating that Bmp6 expression increases with iron 
loading in mouse models (Kautz et al, 2010). However, the significance of this is 
unclear given that 12 week old knockout mice did not have increased Hamp mRNA 
levels, again suggesting that alterations in hepcidin levels in Bmi-1 knockout mice do 
not result from abnormal BMP6 signalling. 
6.3. Serum iron analysis: 
Iron overload disorders can generally be classed as either primary or secondary. 
Primary iron overload, often known as haemochromatosis, is usually hereditary and 
results from mutations in genes involved in iron regulatory pathways. Secondary iron 
overload characterises disorders where the iron regulatory pathway remains intact, 
but iron builds up due to other factors such as excessive dietary iron or blood 
transfusions. The work described above has characterised some abnormalities in the 
expression of genes involved in iron regulatory pathways in Bmi-1 knockout mice. 
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However, it is unclear whether these were actually causing the hepatic iron overload 
phenotype, or resulted from secondary iron overload. To begin to assess potential 
causes of the iron overload observed in Bmi-1 knockout mice, serum samples from 8 
week old female mice were analysed for iron levels. There was no significant change 
in serum iron levels in 8 week old Bmi-1 knockout mice compared to wild type 
littermates (Figure 42). This suggests that the liver iron overload was not caused by a 
dramatic increase in serum iron levels. It also shows that the mice were not suffering 
from iron deficiency as a result of increased hepcidin expression in 8 week old 
knockout mice, suggesting that the altered hepcidin levels did not have a dramatic 
effect. Due to limitations in the amount of serum that could be obtained from the 
knockout mice due to their small size, only the total serum iron was measured. In 
future, the measurement of total iron binding capacity (TIBC), transferrin saturation, 
which is usually increased in haemochromatosis (Batts, 2007) and NTBI, which can 
be taken up by hepatocytes in an unregulated manner (Chua et al, 2004), will provide 
a more detailed picture of whether there are abnormalities in plasma iron transport in 
Bmi-1 knockout mice.  
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Figure 42: Serum iron levels are unchanged in Bmi-1 knockout mice. 
Analysis of serum from 8 week old wild type (Wt) and Bmi-1 knockout (KO) mice for 
total iron levels. n=4 mice per group, p=0.86 using 2-tailed Student’s t-test. 
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6.4. Discussion: 
6.4.1. Summary of iron overload phenotype: 
The results detailed in this chapter have demonstrated a hepatic iron overload 
phenotype in Bmi-1 knockout mice at 8 and 12 weeks of age, in both hepatocytes and 
non-parenchymal cells which were histologically identified as Kupffer cells. This 
identification could be confirmed in future by double labelling immunohistochemistry 
using the Kupffer cell specific F4/80 antibody. There was also some preliminary 
evidence of aberrant regulation of iron regulatory pathways based on altered mRNA 
expression. However, a detailed picture of the phenotype is not yet clear. It is notable 
that the iron overload in Bmi-1 knockout mice does not appear as severe as in several 
other models, for example in mice with transgenic overexpression of hepcidin in the 
liver (Nicolas et al, 2002a) or in Hfe null mice (Zhou et al, 1998). The changes in 
expression of some genes involved in iron regulatory pathways, although significant, 
are also less dramatic than in these models. These expression changes were also 
only determined for mRNA, so it is not certain that they will also apply at the protein 
level. This will be addressed in future experiments. There was also no obvious iron 
related parenchymal damage in the Bmi-1 knockout mice, such as sideronecrosis, 
fibrosis or iron-free foci (Turlin & Deugnier, 1998); therefore it seems unlikely that the 
phenotype has a dramatic effect on the livers of the mice. As such, the phenotype can 
be described as haemosiderosis (the presence of excess iron in the liver) rather than 
haemochromatosis (a pathological state of haemosiderin deposition) (Batts, 2007). 
With these caveats in mind, the following section will speculate on some potential 
causes of the iron accumulation based on the data available. 
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6.4.2. Potential causes of iron overload: 
Secondary iron overload 
As detailed previously, iron overload disorders are either primary (caused by 
mutations in genes involved in iron regulatory pathways) or secondary (due to factors 
such as increased dietary iron or iron-loading anaemias). Due to the fact that the Bmi-
1 knockout mouse is not liver specific, it is possible that the hepatic iron overload is a 
secondary consequence of defects in other organ systems, in particular anaemias. 
Iron overload is a consequence of anaemias involving ineffective erythropoiesis, such 
as β-thalassaemia. Ineffective erythropoiesis results in continued production of 
erythroid regulators such as erythropoietin, increased levels of which indicate high 
demand for iron. Therefore, erythroid regulators continuously signal to reduce 
hepcidin expression and thus increase iron absorption (Pak et al, 2006), ultimately 
leading to iron overload. Adult Bmi-1 knockout mice have dramatic reductions in HSC 
numbers (Park et al, 2003), hence their phenotype has been described by others as 
aplastic anaemia (Chagraoui et al, 2006). Aplastic anaemia is characterised by 
insufficient production of new blood cells, and usually arises due to the destruction of 
haematopoietic stem cells (HSC) (Leguit & van den Tweel, 2010). Aplastic anaemias 
are often accompanied by increased iron deposition, in particular in macrophages 
(Leguit & van den Tweel, 2010), presumably due to excess iron that is not 
incorporated into red blood cells. This pattern appears consistent with the iron 
overload observed in Bmi-1 knockout mice, particularly in 12 week old mice which 
have significant iron accumulation in Kupffer cells. It therefore appears possible that 
anaemia in Bmi-1 knockout mice is responsible for the iron overload phenotype. 
However, a caveat to the hypothesis that anaemia in Bmi-1 knockout mice is causing 
the excessive hepatic iron accumulation is that Van der Lugt et al report that 
erythropoiesis is normal in adult Bmi-1 knockout mice in the FvB background, and that 
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haematopoiesis defects occur in lymphopoiesis and myelopoiesis (van der Lugt et al, 
1994). They detail that adult (2-3 month old) Bmi-1 knockout mice have normal red 
blood cell counts, mean red blood cell volume, haemoglobin concentration and 
haematocrit. If robust, these results suggest that there are no defects within the red 
blood cell population, which should in turn mean no abnormalities in incorporation of 
iron into these populations. However, this does not explain why the same authors 
report anaemia in moribund Bmi-1 knockout mice, which suggests that erythropoiesis 
defects must occur at some stage. It also appears inconsistent with the findings that 
adult Bmi-1 knockout mice have significantly reduced numbers of long term 
repopulating HSCs (Park et al, 2003). Given that erythrocyte lineages are derived 
from HSCs, it seems surprising that a dramatic reduction in total HSC numbers would 
have no effect on red blood cell counts or erythropoiesis as the mice age. It may be 
necessary in the future to repeat the analysis undertaken by Van der Lugt et al on 
blood cell parameters such as haemoglobin content and cell volume, which are 
indicative of restricted erythropoiesis. The anaemic phenotype in Bmi-1 knockout mice 
could also be further defined by examining erythrocyte morphology using Wright-
Giemsa stained blood smears, to determine whether erythropoiesis is altered (Nicolas 
et al, 2002a). It would also be interesting to examine serum levels of erythroid 
regulators, such as erythropoietin, to assess whether Bmi-1 knockout mice have 
increased erythropoeitic demand. 
Iron loading anaemias are also usually characterised by reduced hepcidin expression 
(Origa et al, 2007), whereas in 8 week old Bmi-1 knockout mice, hepcidin expression 
was significantly increased. The erythroid regulation of hepcidin dominates over 
hepcidin regulation by iron overload (Pak et al, 2006), suggesting against the idea that 
anaemias involving ineffective erythropoiesis cause the iron overload in Bmi-1 
knockout mice. However, the regulation of hepcidin is complex, with factors such as 
hypoxia and inflammation also affecting its expression, so these may be a factor in 
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Bmi-1 knockout mice. It is also possible that other uncharacterised defects in other 
tissues in Bmi-1 knockout mice may lead to abnormal iron absorption or release from 
stores. Further analysis of other organs important in iron homeostasis may shed 
further light on this possibility, in particular in the duodenum which is the site of dietary 
iron absorption. 
Primary iron overload 
An alternative possibility to consider is that the iron accumulation in Bmi-1 knockout 
mouse livers is due to primary defects in iron regulatory pathways within the liver, 
either directly or indirectly due to the absence of Bmi-1. Some of the findings from the 
Q-RT-PCR analysis of iron regulatory pathway components were consistent with an 
iron overload phenotype in Bmi-1 knockout mice. In 8 week old mice, the increased 
hepcidin expression should result in degradation of the iron exporter FPN, and hence 
increased iron retention in hepatic stores. The HAMP gene has been identified as a 
putative Polycomb target (Bracken et al, 2006), so it is possible in theory that it is 
directly derepressed due to loss of Bmi-1. However, regulation of hepcidin is complex, 
so there are many other secondary factors such as inflammation which could cause 
fluctuations in its expression. The fact that hepcidin levels are not increased in 12 
week old Bmi-1 knockout mice also suggests against the idea that Hamp is a direct 
Bmi-1 target. However, it is also possible that other secondary effects could become 
dominant, such as increased severity of anaemia or hypoxia due to the worsening 
health of the mice. The downregulation of Hfe and Tfr2 expression in 12 week old 
knockout mice also fits with the decreased hepcidin levels, as these proteins are 
involved in regulating hepcidin synthesis. Future ChIP experiments could assess 
whether Hamp is actually a Bmi-1 target in liver. The expression of these genes has 
also only been examined at the mRNA level, so it will be important in future to look at 
protein expression to determine whether the effects are the same. 
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As discussed above, it is theoretically possible that abnormal Hamp upregulation in 8 
week old Bmi-1 knockout mice is directly causing the hepatic iron accumulation. 
However, this is not fully consistent with the fact that 8 week old Bmi-1 knockout mice 
exhibited normal levels of serum iron. Hepcidin also acts to degrade FPN in digestive 
enterocytes which absorb iron from the diet, so the overall effect of increased hepcidin 
levels should be a reduction in total body iron levels. In agreement with this, C57BL/6 
transgenic mice overexpressing hepcidin in the liver suffer severe iron deficiency 
anaemia and early death (Nicolas et al, 2002a), although this may be linked to the fact 
that they express hepcidin during embryonic development, whereas wild type mice do 
not. If increased hepcidin levels in Bmi-1 knockout mice were having a significant 
prolonged effect, the mice should suffer from iron deficiency anaemia due to lack of 
iron release into the blood. Although anaemia has been reported in older moribund 
Bmi-1 knockout mice (van der Lugt et al, 1994), the fact that serum iron levels were 
unchanged in 8 week old Bmi-1 knockout mice suggests against this. It could also be 
that the level of Hamp upregulation in 8 week old Bmi-1 knockout mice is not dramatic 
enough to have severe effects on bodily iron levels, and only causes some gradual 
accumulation within the liver.  
In 12 week old Bmi-1 knockout mice, mRNA expression levels of Fpn were decreased 
relative to wild types, while Tfr1 expression was increased. If these translate to protein 
levels, increased TfR1 and decreased FPN should lead to an increase in iron uptake 
and decrease in iron export respectively. This would be consistent with an iron 
overload phenotype. However, the fact that expression of these genes was 
unchanged in 8 week old knockout mice suggests these effects were not directly due 
to Bmi-1 loss, and were unlikely to be major causative factors of the iron overload. 
They could potentially explain the increased iron accumulation in Kupffer cells in 12 
week old knockout mice relative to animals at 8 weeks, as Kupffer cells should 
express both proteins, although it has to be noted that the change in Fpn expression 
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in particular was not large. Immunohistochemical assessment of the localisation of 
these proteins in Bmi-1 knockout livers could help investigate this in the future. As 
detailed earlier, Tfr1 mRNA should be degraded in cells with abundant iron due to the 
IRP-IRE regulatory system. The fact that Tfr1 mRNA was not decreased in either 8 or 
12 week old Bmi-1 knockout mice suggests this was not happening as expected. It is 
therefore possible there is some dysregulation of pathways that control its expression, 
although it is unclear at this stage what these may be. 
Overall, it appears unlikely that the iron overload in Bmi-1 knockout livers can be 
completely explained by the expression changes in the iron regulatory genes studied. 
It seems more probable that adult Bmi-1 knockout mice also have increased bodily 
iron levels due to secondary factors, possibly including anaemias as discussed earlier. 
This could potentially lead to increased hepcidin production (in 8 week old mice), 
resulting in increased iron retention in hepatic stores to maintain serum concentrations 
in the normal range. It is also possible that the Bmi-1 knockout mice have increased 
levels of non-transferrin-bound iron (NTBI), which can be taken up into cells in a much 
less regulated manner than iron bound to transferrin. 
6.4.3. Histopathology of iron deposition in Bmi-1 knockout mice: 
Another consideration is the localisation of the iron accumulation in Bmi-1 knockout 
mice. Primary haemochromatosis is usually associated with iron deposition in 
hepatocytes and biliary cells, as opposed to Kupffer cells. It tends to begin with iron 
accumulation in periportal hepatocytes, and progressively spreads towards 
centrilobular cells as the disease worsens (Batts, 2007). The initial parenchymal iron 
overload in Bmi-1 knockout mice does appear to be predominantly periportal. 
However, loading of macrophages only appears much later in haemochromatosis, 
when hepatocytes accumulate lethal levels of iron leading to necrosis and iron release 
(Batts, 2007). In contrast, Kupffer cell iron is more associated with secondary 
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overload, for example due to haematological disorders. Given that there was no 
obvious parenchymal damage or necrosis in 12 week old Bmi-1 knockout mice, the 
excessive iron accumulation in Kupffer cells would appear to suggest a secondary 
effect. However, it is unclear why 8 week old Bmi-1 knockout mice exhibited much 
less Kupffer cell iron deposition than at 12 weeks, given that the 8 week old animals 
all displayed some hepatocyte deposition. 
6.4.4. Iron overload and the cell cycle: 
It is also worth noting the established link between iron levels and cell cycle 
progression. Iron depletion causes G1/S phase arrest (Yu et al, 2007), along with 
reductions in the protein levels of cyclin D1 and p21 through proteasome mediated, 
ubiquitin independent degradation pathways in cultured cells (Fu & Richardson, 2007; 
Nurtjahja-Tjendraputra et al, 2007). Moreover, increases in proliferating hepatocytes 
(measured by incorporation of proliferating cell nuclear antigen (PCNA) and 
upregulated cyclin D1 protein levels are seen in iron overloaded rat livers (Brown et al, 
2006). Increased cyclin D1 mRNA levels are also found in murine livers with iron 
overload (Troadec et al, 2006), with the authors also observing increases in mitotic 
index and DNA synthesis in cultured hepatocytes isolated from iron overloaded mice.  
These data are broadly in agreement with the phenotype observed in the Bmi-1 
knockout mice at 8 weeks of age, which exhibited both excessive iron loading in 
hepatocytes and increased protein levels of cyclin D1 and p21 (see chapter 5). It 
therefore appears plausible that the increased hepatic iron levels may be a 
contributory factor to the altered proliferation levels observed in Bmi-1 knockout mice. 
However, there did not appear to be any correlation between the localisation of the 
iron overload, which was predominantly around portal regions, and the localisation of 
the overexpressed p21 and cyclin D1, which did not appear specifically periportal. 
This suggests against the idea that increased p21 and cyclin D1 levels are caused 
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directly by reduced proteasomal degradation due to increased iron levels in individual 
cells. 
6.5. Summary of Chapter: 
The work presented in this chapter has shown that adult Bmi-1 knockout mice suffer 
from a degree of iron overload, which appears to worsen slightly as the mice age 
towards 12 weeks. Based on the fact that serum iron levels were unchanged, and that 
there was no visible iron-related parenchymal damage, it seems unlikely that this 
would have a dramatic effect on the health of the mice. It is possible that the iron 
accumulation would result in tissue damage in the longer term, however the short 
lifespan of the mice may preclude this from becoming apparent. It is also unclear 
whether the hepatic iron accumulation is directly due to the deletion of Bmi-1 in the 
liver, or a secondary effect, as the pathological distinction between primary and 
secondary iron overload is often difficult (Batts, 2007). The Bmi-1 knockout is not liver 
specific, and the mice become progressively unwell as they age towards 12 weeks, so 
may suffer from other pathologies which could lead to iron overload. Regulation of iron 
homeostasis, and hepcidin expression in particular, is very complex, with factors such 
bodily iron levels, anaemia, hypoxia and inflammation all having an effect. As such, it 
is difficult to untangle these competing effects in the Bmi-1 knockout mice, and the 
potential reasons for the overload discussed previously in this chapter are speculative 
at this stage. The best way to address these issues in the future would be to create a 
liver specific Bmi-1 knockout mouse, to assess whether the iron overload phenotype 
is directly due to Bmi-1 deletion in hepatic cells. 
It would also be interesting to examine whether other key organs in Bmi-1 knockout 
mice suffer a similar iron overload phenotype. Iron is absorbed by duodenal 
enterocytes, so a histological examination of iron loading in the small intestine would 
help determine whether iron absorption is proceeding normally in Bmi-1 knockout 
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mice. In addition to this, iron overload disorders can lead to iron accumulation in 
cardiac tissue. This can lead to cardiomyopathy and heart failure, and is a major 
determinant of survival in secondary iron overload (Murphy & Oudit, 2010). 
Examination of iron loading in the hearts of Bmi-1 knockout mice will allow further 
assessment of whether iron overload is potentially a contributor to the shortened 
lifespan of the mice. 
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7. Final Discussion: 
7.1. Conclusions: 
This thesis set out to investigate the role of Bmi-1 in hepatic growth and function in 
vivo. This was achieved firstly by examining the expression of Bmi-1 in normal and 
regenerating hepatic tissue, and then using a mouse model to assess the effect of 
Bmi-1 deletion on liver structure and function. This is one of the first studies 
investigating the role of a PcG family member in hepatic physiology in vivo. The 
important findings from the thesis have been discussed in the respective chapters, 
and can be summarised as follows: 
1. Bmi-1 protein is expressed in all cholangiocytes and some hepatocytes in 
normal murine liver.  
 
2. Bmi-1 is strongly expressed in murine oval cells, and in some ductular cells 
and regenerative nodules in human cirrhotic liver tissue. These results suggest 
that Bmi-1 may have a function in hepatic repair. 
 
3. Mel-18, a partial Bmi-1 homologue, is also expressed in biliary cells in murine 
liver, and is upregulated in older Bmi-1 knockout mice. This suggests that Mel-
18 may have a compensatory effect following Bmi-1 deletion, and may account 
for the lack of obvious abnormalities in biliary structure observed in Bmi-1 
knockout mice. 
 
4. Bmi-1 knockout mice have reduced hepatocyte cell and nuclear size, and 
average centromere numbers which are indicative of impairment in the 
postnatal hepatocyte polyploidisation process. This suggests a novel function 
for Bmi-1 in cellular polyploidisation, which has not previously been reported. 
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5. Bmi-1 knockout mice exhibit a small increase in hepatocyte proliferation at 8 
weeks of age, which is in contrast to findings in other cell types in vivo and in 
vitro. This occurs together with an increase in expression of cyclin D1 and c-
myc, which are positive regulators of cell cycle progression. This shows that 
Bmi-1 is not essential for the proliferation of mature hepatocytes.  
 
6. The expression of Bmi-1 targets, namely the cell cycle inhibitors p16Ink4a, p19Arf 
and p21 is increased in Bmi-1 deficient livers, despite the increase in 
hepatocyte proliferation. 
 
7. Bmi-1 knockout mice suffer from a hepatic iron overload phenotype, which 
increases in severity as the mice age. This is coupled with alterations in the 
expression of some genes involved in iron regulatory pathways. The iron 
overload is potentially secondary to other defects in Bmi-1 knockout mice, 
most notably their anaemic phenotype. 
 
7.2. Discussion and Future Perspectives: 
The work detailed in this thesis has focused on the in vivo effects of Bmi-1 deletion 
using a total embryonic knockout mouse model. This has the limitation that the mice 
suffer from deleterious effects in other organs, especially the haematopoietic and 
nervous systems, which leads to them becoming progressively unwell as they age 
towards 3-5 months (van der Lugt et al, 1994). As such it cannot be ruled out that 
some of the effects observed in the liver are secondary to these issues, and it is 
possible that the phenotypes observed in Bmi-1 knockout mice are non-cell 
autonomous. It also creates the possibility of a complex phenotype involving 
competing pathways, resulting from both hepatic deletion of Bmi-1 and secondary 
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effects, which is difficult to unravel. There are a number of approaches that could 
address these issues in the future. The most advantageous would be to use a 
conditional knockout mouse model to facilitate liver specific deletion of Bmi-1, thus 
eliminating the possibility of secondary defects to Bmi-1 deletion in other tissues.  
Conditional Bmi-1 knockout mice have not previously been published, however it 
would be desirable in future to have a strain with a LoxP flanked Bmi-1 allele 
available. These mice could be crossed with mice expressing Cre under the control of 
promoters expressed in specific liver cell populations (e.g. albumin in hepatocytes) to 
allow targeted Bmi-1 deletion. This would allow assessment of whether the 
parenchymal defects observed in the total Bmi-1 knockout mouse directly result from 
the absence of Bmi-1 in the liver. It would also be possible to examine the effects of 
targeted Bmi-1 overexpression in liver in a similar manner, using a Cre/LoxP based 
mouse model (Yadirgi et al, 2011). As an alternative to conditional knockout mice, 
hepatocytes from Bmi-1 knockout livers could be grafted into recipient mice suffering 
from hepatic injury, such as uPA transgenic mice (Braun et al, 2003), which allow 
preferential expansion of transplanted cells. This would allow comparison of the 
proliferative capacity of wild type and Bmi-1 knockout hepatocytes. It would also help 
determine whether the phenotypes observed in Bmi-1 knockout mice, such as the 
reduced polyploidisation, are cell autonomous, although this method does not offer 
many advantages over a conditional Bmi-1 knockout in this respect. 
Alternatively, in vitro studies could provide additional data on the major phenotypic 
effects observed in 8 week old Bmi-1 knockout mice, notably the decreased 
hepatocyte polyploidisation, the small increase in hepatocyte proliferation, and hepatic 
iron overload, and help determine whether they are cell autonomous. Stable shRNA 
mediated Bmi-1 depletion in suitable cell populations would allow a direct assessment 
of whether these phenotypes result directly from Bmi-1 loss. These experiments 
would include assessment of the proliferative ability of primary hepatocytes and 
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cholangiocytes following Bmi-1 knockdown, to determine whether Bmi-1 has a role in 
the proliferation of mature hepatic cell populations. Cultured primary rodent 
hepatocytes can be used to examine the development of polyploidy in vitro (Duncan 
et al, 2010), so Bmi-1 depletion in these cells would determine whether Bmi-1 directly 
affects this process. Although the balance of evidence suggests that the iron overload 
in Bmi-1 knockout mice is secondary to factors such as anaemia, there remains a 
possibility that Bmi-1 loss affects iron homeostasis in hepatocytes. This could be 
investigated by examining iron uptake and storage in Bmi-1 depleted hepatocytes in 
response to iron loaded transferrin (Gao et al, 2009). However, there are caveats to in 
vitro systems, notably that prolonged culture can lead to changes in gene regulation, 
including loss of the H3K27me3 repressive mark (Bracken et al, 2007).  Isolated cells 
are also not necessarily relevant to the behaviour of cells in complex in vivo systems; 
for example HepG2 cells lack HFE expression (Gao et al, 2009), so would not be a 
good model to study iron homeostasis. Finally, the precise function of Mel-18 in 
hepatic cell populations has not been established, with work in cell lines derived from 
other tissues suggesting it may have similar or opposing functions to Bmi-1 in different 
contexts. Depletion of one or both of Bmi-1 and Mel-18 would allow assessment of 
whether their functions are complementary in liver cell populations. We also now have 
the possibility of obtaining liver tissue samples from Mel-18 knockout mice (Akasaka 
et al, 1996). It would be interesting to assess the hepatic phenotype in these to see 
whether they suffer similar defects to Bmi-1 knockout mice, which would suggest that 
the two proteins act in synergy in liver cells. 
This thesis has established that a number of genes/proteins are upregulated at some 
time points following Bmi-1 deletion in mouse livers, including cyclin D1, c-myc, Tfr1 
and Hamp. However, it is not clear whether these are direct targets of Bmi-1, or 
whether their upregulation is secondary to alterations in other pathways. There are 
also likely to be other important Bmi-1 targets in liver which have not yet been 
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characterized. These questions could be assessed in the future using ChIP 
sequencing (ChIP-seq) to map Bmi-1 binding sites in murine liver. This would also 
help address whether the phenotypic abnormalities observed in Bmi-1 knockout 
hepatocytes are cell autonomous. 
7.2.1. Final discussion of Bmi-1 knockout liver phenotypes: 
The hepatic phenotype in the Bmi-1 knockout mice appeared to be less severe than 
that observed in other organs, such as the neural or haematopoietic systems. On the 
other hand, it should be noted that not all Bmi-1 knockout organs show any 
demonstrable phenotype, as lung development and morphology are normal in Bmi-1 
knockout mice (Dovey et al, 2008). The milder phenotypes in Bmi-1 knockout livers in 
comparison to other organs may reflect the fact that the adult liver is generally a 
quiescent organ. The haematopoietic system, for example, constantly relies on self-
renewing haematopoietic stem cells for the generation of new mature blood cells. 
Foetal livers of Bmi-1 knockout mice have normal numbers of haematopoietic stem 
cells (HSCs), however the quantities become markedly reduced in postnatal livers 
(Park et al, 2003). There is little detectable self-renewal of HSCs in Bmi-1 knockout 
mice, so it is unsurprising that the mice suffer progressive haematopoietic defects. 
Cell turnover in the adult liver is much lower than in the haematopoietic system, and 
there is some debate over whether a liver stem cell compartment plays any role in the 
process (see introduction section 1.3.5). It is also clear from the data described in 
Chapter 5 that hepatocyte proliferation is unimpaired in all but the oldest Bmi-1 
knockout mice. Given these factors, it seems likely that if there are any defects in 
stem cell populations in Bmi-1 knockout livers, they would not lead to major 
phenotypic abnormalities under resting conditions. The slow cell turnover in the adult 
liver, coupled with the 12 week lifespan of Bmi-1 knockout mice, also means that 
more severe structural defects may not have time to emerge.  
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One piece of evidence in favour of contribution of portal stem/progenitor cell 
contribution to human liver turnover is the presence of patches of hepatocytes with 
identical mitochondrial mutations, suggesting the cells are clonally derived (Fellous et 
al, 2009a). During the first few months of my PhD, I ascertained that these patches 
are also present in mice (see appendix section A1).  However, attempts to use this 
mitochondrial lineage tracing technique to examine stem cell defects in Bmi-1 
knockout mice were unsuccessful due to a lack of patches, probably due to the 
shortened lifespan of the mice.  
Another point of note is that there appear to be some differences in the phenotypes 
observed in 8 week old and 12 week old Bmi-1 knockout mice. In particular, 8 week 
old mice exhibited an increase in hepatocyte proliferation, while 12 week old mice 
showed a decrease. An increase in expression of the Bmi-1 homologue Mel-18 was 
found in 12 week old Bmi-1 knockout mice relative to wild types, but not in 8 week old 
mice. The 12 week old mice also exhibited more severe iron overload, which was 
coupled with some changes in the expression of genes involved in iron regulatory 
pathways that were not observed at 8 weeks. The predominant difference between 
the knockout mice at 12 weeks of age compared to 8 weeks is their worsening health, 
meaning that all mice were sacrificed by 12 weeks. It is therefore possible that the 
phenotypic differences between the two time points represent the predominance of 
worsening secondary effects due to ill health at 12 week of age. As such, the 8 week 
old mice could be considered more representative of the effects of Bmi-1 deletion in 
liver. However, studies in other organs have shown more severe defects with age, so 
it is possible that some of the additional abnormalities in 12 week old knockout mice 
have physiological relevance. This would become clearer with a liver specific Bmi-1 
knockout mouse. 
It is also notable that the majority of the phenotypic changes observed in Bmi-1 
knockout livers (altered hepatocyte proliferation, polyploidisation, iron overload) affect 
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hepatic parenchymal cells rather than cholangiocytes. This is interesting, given that 
Bmi-1 appeared to be most strongly expressed in cholangiocytes. It is possible that 
Bmi-1 is not required in cholangiocytes under homeostatic conditions, as the 
proliferation rate of cholangiocytes is very low. Alternatively, the loss of Bmi-1 may be 
compensated for by proteins such as Mel-18, which is similarly expressed in 
cholangiocytes. Immunohistochemical analysis showed Bmi-1 expression in some 
hepatocytes at lower levels, so it is possible that the hepatic phenotypes in Bmi-1 
knockout mice directly result from the absence of Bmi-1 in hepatocytes. As mentioned 
previously, the fact that the Bmi-1 knockout is not liver specific again means that 
secondary effects cannot be ruled out. As discussed in the relevant chapters, the 
hepatic iron overload could be secondary to anaemia, while the polyploidisation 
defects could be linked to a reduction in insulin signalling. The creation of a liver 
specific Bmi-1 knockout mouse model would again address these issues. 
7.2.2. Bmi-1 in hepatic stem cell mediated regeneration: 
Much of the previously published work on the liver-specific function of Bmi-1 has 
centred on its role in maintenance of hepatic stem cells in vitro. Chiba et al have 
demonstrated some reduced colony forming potential and bilineage differentiation in 
putative foetal liver stem cell populations following Bmi-1 knockdown, both using 
shRNA (Chiba et al, 2007) and in cells derived directly from Bmi-1 knockout mice 
(Chiba et al, 2010). These effects do not appear as dramatic as in some other organs, 
although they do suggest that Bmi-1 has some function in hepatic stem cell 
maintenance. 
It is established that hepatic stem cells play a role in liver regenerative responses, 
namely the oval cell response which emerges when hepatocyte mediated 
regeneration is impaired. Oval cells are generally believed to be derived from resident 
hepatic stem cells (see introduction section 1.3). Given the in vitro work suggesting 
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that Bmi-1 is important in liver stem cell maintenance, it was considered possible that 
Bmi-1 could play a role in the oval cell response. In support of this, cytokeratin 19 
positive oval cells from two different mouse models displayed strong immunoreactivity 
for Bmi-1. It was therefore hypothesised that the loss of Bmi-1 could result in an 
impaired oval cell response in Bmi-1 knockout mice. One original aim for this thesis 
was to assess this theory by subjecting Bmi-1 knockout mice to protocols which 
induce an oval cell response, namely CDE and DDC diets. Since the commencement 
of this work, Chiba et al have reported an impaired oval cell response in Bmi-1 
knockout mice in the C57BL/6 background (Chiba et al, 2010). Although this was not 
characterised in great detail, the Bmi-1 knockout mice exhibit a significant decrease in 
the numbers of A6 positive oval cells following DDC treatment. This reduction appears 
to be approximately 50% based on cell counting studies, demonstrating that the oval 
cell response is impaired but not abolished. This led the authors to suggest that 
redundancy among other Polycomb group genes may weaken the phenotype. This 
would agree with the similar hepatic expression patterns of Bmi-1 and Mel-18 we 
observed in murine liver. Attempts to assess Mel-18 expression in oval cell reactions 
were unsuccessful, due to poor immunoreactivity of the anti-Mel-18 antibody with the 
archival paraffin blocks, and high background staining. This could be assessed in the 
future on fresh blocks.  
We now have a Home Office project license in place permitting experiments to induce 
liver injury in Bmi-1 knockout mice. This opens up the possibility for future studies into 
the role of Bmi-1 in liver regeneration. Bmi-1 expression was observed in some 
hepatocyte regenerative nodules in human cirrhotic tissue, suggesting that Bmi-1 may 
have a role in hepatocyte mediated regeneration. This could be investigated further by 
subjecting Bmi-1 knockout mice to 2/3 partial hepatectomies, and assessing whether 
the subsequent regenerative process is impaired. We are also aiming to induce the 
oval cell response in Bmi-1 knockout mice on the FVB background using a DDC diet. 
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This will examine whether the reduced oval cell response observed by Chiba et al in 
C57BL/6 Bmi-1 knockout mice is also seen in FVB mice. Depending on the results, 
the characterization of expression changes in other Polycomb genes (especially Mel-
18) and potential Bmi-1 target genes will allow investigation of the mechanistic 
reasons behind an impaired oval cell response (if one is observed), or potential 
compensatory pathways which may prevent Bmi-1 deletion from having a large effect 
on oval cell proliferation (if an impaired oval cell response is not observed). In addition 
to this, the effects of Bmi-1 deletion on cholangiocyte mediated repair could be 
assessed following bile duct ligation. It was not possible to assess the proliferative 
ability of cholangiocytes in resting Bmi-1 knockout livers, due to the very low 
proliferation frequencies observed. Performing bile duct ligations on Bmi-1 knockout 
mice will force cholangiocytes to proliferate (Yoshioka et al, 2005), and hence will 
uncover any defects in the proliferative response of Bmi-1 deficient cholangiocytes. 
Bmi-1-Cre-ER transgenic mice (Sangiorgi & Capecchi, 2008; Sangiorgi & Capecchi, 
2009) also provide a useful model to assess the function of Bmi-1 expressing cells in 
liver regeneration, as they allow stable genetic labelling of cells which express Bmi-1, 
and their progeny. The induction of both hepatocyte and oval cell mediated 
regeneration in these mice would allow direct assessment of the contribution of Bmi-1 
expressing cells to hepatic regeneration. 
7.2.3. Tumourigenesis in Bmi-1 knockout mice: 
Finally, another issue worth considering is the fact that aspects of the hepatocyte 
phenotype in Bmi-1 knockout mice show similarities with tumourigenic environments. 
Bmi-1 knockout livers appear to exhibit reduced hepatocyte polyploidisation, which will 
result in increased numbers of smaller diploid cells. Increased numbers of small 
diploid cells have previously been reported in hyperplastic nodules that characterise 
rat liver carcinogenesis (Schwarze et al, 1984). At 8 weeks of age, Bmi-1 knockout 
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livers also exhibit a small increase in hepatocyte proliferation, coupled with 
upregulation of c-myc mRNA and cyclin D1 protein. C-myc is commonly 
overexpressed in tumours (Adhikary & Eilers, 2005), while transgenic mice 
overexpressing cyclin D1 develop HCC (Deane et al, 2001). Furthermore, iron 
overload has been associated with tumourigenesis, as patients with 
haemochromatosis have a significantly increased risk of developing HCC (Batts, 
2007) (although it should be noted that this is usually following cirrhosis, which was 
not observed in Bmi-1 knockout mice). HCC has also been reported in some other 
hepatic iron loading conditions, including anaemias (Kew, 2009), although it is unclear 
whether lower levels of iron accumulation do actually predispose to HCC. These 
observations hint at the possibility that the environment in Bmi-1 knockout livers could 
be a precursor to the development of hepatic tumours. It is possible that tumours 
would not have time to develop given the short lifespan of the mice.  However, this 
hypothesis would appear contradictory given that most literature suggests Bmi-1 is 
oncogenic and is overexpressed in tumours. Future experiments to subject Bmi-1 
knockout and overexpressing mice to tumour inducing protocols (Alison & Lovell, 
2005) could provide further insight into the role of Bmi-1 in hepatocarcinogenesis.  
7.3. Concluding paragraph: 
Bmi-1 has emerged as a potential molecular target in cancer therapy due to its 
established oncogenic functions, including promoting self-renewal in cancer stem cell 
populations in a variety of tissue types. Targeting Bmi-1 is likely to be possible in 
future through the use of small molecule drugs that reduce its expression, or through 
siRNA mediated approaches (Cao et al, 2011). It is therefore important to have a 
thorough understanding of both the function of Bmi-1 and the consequences of its 
depletion in normal cell populations. There is also a lack of whole human donor livers 
available for transplant. By understanding and harnessing the proliferative potential of 
hepatic stem cells, novel transplantation therapies could be developed (Duncan et al, 
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2009a; Kung & Forbes, 2009). The epigenetic regulation of regenerative responses is 
not well understood, so a better understanding of the role of epigenetic regulators, 
including Polycomb genes such as Bmi-1, could possibly improve cell-based 
treatments or stimulate an endogenous response.  
This thesis has furthered our understanding of the role of Bmi-1 in hepatic cells by 
examining the phenotypic consequences of Bmi-1 deletion on murine liver growth and 
function. The work undertaken has uncovered potential roles for Bmi-1 in hepatocyte 
polyploidisation, proliferation and bodily iron homeostasis which have not previously 
been described in the published literature. In addition, the high levels of Bmi-1 
expression in murine oval cells and some regenerative cells within human cirrhotic 
tissue hint at an important role for Bmi-1 in promoting hepatic tissue regeneration. 
Together, these observations provide scope for a variety of future studies to further 
define the mechanisms underlying the Bmi-1 deletion phenotype and the function of 
Bmi-1 in liver growth and regeneration. 
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Appendix: 
A1. Lineage tracing using mitochondrial DNA mutations: 
Recently established cell lineage tracing techniques using naturally occurring, non-
pathogenic mitochondrial DNA mutations have been to study clonal cell populations 
within human tissue samples, including in hepatic tissue (Fellous et al, 2009b). The 
technique involves using histochemical methods to stain tissue sections for activity of 
the enzyme cytochrome c oxidase (COX), which is encoded by mitochondrial DNA. In 
occasional cells, mutations in COX will accumulate to the extent that the majority of 
mitochondria in the cell contain the same mutation, and the cell will hence stain as 
COX deficient. Mitochondrial DNA sequencing of laser-dissected tissue samples can 
then be used to identify the mutation. This technique identifies patches of COX 
negative cells within various tissues, all of which have the same mutation and are 
hence clonally derived. It can therefore be applied to investigate the location of stem 
cell niches within adult tissues, as it is believed that only stem cells will remain in the 
tissue long enough to accumulate the necessary mutations. In the liver, patches of 
COX negative hepatocytes appear to be connected to portal regions (Fellous et al, 
2009a). This has led the authors to propose the existence of a liver stem/progenitor 
cell niche within the portal region, which may contribute to the turnover of hepatocytes 
in normal liver tissue. This is in agreement with other work which suggests that liver 
stem-cell derived oval cells originate from the canals of Hering, the terminal biliary 
ducts of the liver (Paku et al, 2001), and that Sox9 positive cells within the biliary tree 
can give rise to hepatocytes in normal liver (Furuyama et al, 2011). In vitro work in 
foetal liver derived putative stem/progenitor cells has demonstrated that knockdown of 
Bmi-1 has a negative effect on the colony forming ability and bilineage capacity of 
these cells (Chiba et al, 2007). It was therefore hypothesised that the absence of Bmi-
1 would have an effect on the function adult liver stem cells in vivo, which would in 
turn potentially result in either a reduction or absence of the portally-derived clonal 
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COX deficient patches in Bmi-1 knockout mice. To assess whether the mitochondrial 
lineage tracing technique used in humans could be equally applied to mice, frozen 
liver sections from a 9 month old BL6J mouse were stained for COX activity (Figure 
43). Sections were also counterstained for the nuclear encoded enzyme, succinate 
dehydrogenase (SDH), to allow easier visualisation of COX-negative patches. As in 
humans, small patches of COX negative cells were detected, and many of these 
appeared to originate from portal regions (Figure 43a). To investigate whether the 
patches were either reduced in number or absent completely in Bmi-1 knockout mice, 
thus suggesting defects in the putative portal stem/progenitor cell population, frozen 
sections from 12 week old Bmi-1 wild type and knockout mice were stained for COX 
activity. No COX negative patches were detected in any of the wild type or knockout 
mice examined, so it was not possible to make any comparison between the two 
(Figure 43b,c) (n=5). A potential reason for this is that the mitochondrial mutations 
take a long time to become established, hence they have only been observed in 
human patients above 40 years old (Fellous et al, 2009b). It is therefore likely that 
mice at 12 weeks of age were not old enough to detect any COX negative cells, 
whereas they could be detected at 9 months of age. Due to the fact that the Bmi-1 
knockout mice become unwell as they age, it was not possible to keep the mice 
beyond 12 weeks, and hence this work was not pursued further. 
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Figure 43: Application of mitochondrial lineage tracing techniques to Bmi-1 
knockout mice. 
Frozen liver sections were stained for cytochrome c oxidase (COX, brown stain) and 
counterstained for succinate dehydrogenase (SDH, blue stain). a) COX negative 
patch in 9 month old mouse (red arrow). b,c) Absence of COX negative patches in 12 
week old Bmi-1 wild type (b) and knockout (c) mice. All scale bars 200 µm. 
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A2. Selection of reference gene for Q-RT-PCR experiments: 
The selection of a suitable internal control gene to use to normalise the expression 
data is a necessary step in designing robust Q-RT-PCR experiments. The 
transcription of several commonly used reference genes can be altered dramatically 
by different experimental conditions, for example hypoxia (Caradec et al, 2010), so it 
is important to find a gene that is expressed relatively consistently across all the 
conditions to be studied. Preliminary analysis of cDNA from 12 week old Bmi-1 wild 
type and knock out mouse livers revealed different relative levels of two commonly 
used reference genes; β-actin and glyceraldehyde 3-phosphate dehydrogenase 
(Gapdh). It was therefore decided to determine the most stable reference genes using 
the Normfinder method (Andersen et al, 2004). Briefly, Normfinder uses mathematical 
modelling of gene expression data to estimate the variation of candidate normalisation 
genes, both overall and between different subgroups of samples (in this case, groups 
of Bmi-1 wild type and knockout mice at different ages). Four commonly used 
reference genes in different functional classes were selected for analysis: β-actin, 
Gapdh, β-glucuronidase (Gus), and eukaryotic elongation factor 2 (eEf2). The 
expression of each gene was analysed in pairs of Bmi-1 wild type and knockout mice 
at 3 different time points:  2 sets of newborn, 4 sets of 8 week old and 2 sets of 12 
week old mice. The raw expression data were input into the Normfinder Microsoft 
Excel add-in program (http://www.mdl.dk/publicationsnormfinder.htm) to generate 
values for expression stability, with lower values describing more stable genes. The 
program selected eEf2 as the most stable gene, with a stability value of 0.098. In 
cases where there is no optimal gene for normalisation, it is possible to use a 
normalisation factor based on the average expression of two or more genes to 
improve accuracy. In this case, addition of the gene predicted by Normfinder as the 
second most stable (Gus) slightly improved the stability value to 0.074. It was decided 
that this was not a significant enough improvement to warrant use of a normalisation 
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factor. To provide support for the choice of normalisation factor, the expression data 
for the four chosen candidate genes were also analysed using another program, 
geNorm, which examines pairwise variation between candidate genes 
(Vandesompele et al, 2002). This program also identified eEf2 as the most stable 
reference gene. Therefore, eEf2 expression was run as a reference gene in all 
subsequent Q-RT-PCR experiments. A second gene, β-actin, was also run for all 
subsequent samples to ensure the expression ratio of two genes remained relatively 
constant. In any cases where there was a significant change in the ratio of the two 
genes, up to four additional genes (Gapdh, Gus, Ribosomal protein L27 (Rpl27) and 
Ribosomal 18S) were run to assess which gene showed abnormal expression. In rare 
cases where multiple reference genes showed abnormal expression in a sample, that 
sample was discarded. For all results described in this thesis, eEf2 expression alone 
was considered a suitable normalisation factor, and the addition of another gene did 
not make any alterations to the significance of any results. 
A3. Analysis of hepatocyte nuclear area using touch preparations: 
The measurement of nuclear size in H&E stained sections is imperfect, due to the fact 
that nuclei may not be cut through the same plane and hence may appear to be 
smaller in diameter. To circumvent this problem, hepatocytes were isolated from 
excised mouse livers digested in collagenase by touching a freshly cut surface onto a 
microscope slide. This provided a preparation of whole cells suitable for nuclear size 
analysis and binuclearity counting, which is also imperfect in H&E stained sections. 
The touch preparation slides were stained with methylene blue and haematoxylin, and 
blindly labelled images subjected to analysis using ImageJ software. The image 
analysis procedure is outlined in Figure 44. The threshold feature of ImageJ was used 
to highlight the hepatocyte nuclei in the image. Images were taken using the same 
microscope exposure settings, allowing consistent threshold values to be used for 
analysis of each image, thus removing the need for subjective judgement of threshold 
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settings for each image. The Nucleus Counter of ImageJ was now used to measure 
the average area of marked nuclei. The touch preparations also contained some 
populations of non-parenchymal cells, which were not wanted for analysis. To 
eliminate these, the Nucleus Counter was adjusted to exclude particles below a 
certain size from the average area measurements. However, it was not possible to 
define a single size threshold which completely eliminated all non-parenchymal cells 
without eliminating any of the smallest hepatocytes. Therefore, measurements for 
each image were taken for two different particle minimum sizes: 75 pixels (7.8 µm2), 
which counted all hepatocyte nuclei along with the largest non-parenchymal cells, and 
100 pixels (10.4 µm2), which eliminated all non-parenchymal nuclei and occasionally a 
few of the smallest hepatocytes. The same overall result was observed whichever 
size threshold was used (results using 100 pixel threshold are shown in this thesis). 
The results shown in this thesis are for female mice only to eliminate any possible sex 
specific variations, although males examined did not exhibit any differences. 
 
 
 
Figure 44 (overleaf): Analysis of nuclear area in hepatocyte touch preparations. 
Freshly excised mouse liver sections were touched onto microscope slides and the 
cells stained with methylene blue and haematoxylin. a,b) Touch preparation images 
from 12 week old Bmi-1 wild type (a) and knockout (b) mice. c-f) Analysis of nuclear 
area in touch preparation image using ImageJ. c) Image converted to greyscale. d) 
Nuclei highlighted using threshold feature. e) Thresholded image converted to black 
and white. f) Numbered nuclei, above minimum size threshold, were included in 
counting and average area measurements. All scale bars 50 µm. 
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Figure 44: Analysis of nuclear area in hepatocyte touch preparations. 
See previous page for figure legend. 
 
 
 
 
 
 
